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ABSTRACT 
Rebecca Mae Pollet: Structure and Function Studies of Microbial Conjugative DNA 
Transfer & GI Drug Reactivation Processes 
(Under the direction of Matthew R Redinbo) 
 
Antimicrobial resistance in Staphylococcus aureus presents an increasing threat 
to human health. This resistance is often encoded on mobile plasmids, such as pSK41; 
however, the transfer mechanism of these plasmids is not well understood. In this study, 
we examine key protein features of the relaxase enzyme, NES, which initiates and 
terminates the transfer of the multidrug resistance plasmid pSK41. This work 
establishes that both a novel C-terminal domain and two loops of the NES protein, 
hairpin loops 1 and 2, are essential for proper DNA cleavage and religation by the full 
665-residue NES protein in vitro. Second, we show that NES is able to bind, cleave, and 
religate the oriT sequences of non-conjugative plasmids pSK156 and pCA347. These 
data indicate that the conjugative relaxase in trans mechanism recently described for 
the pWBG749 family of plasmids also applies to the pSK41 family of plasmids, further 
heightening the potential significance of this mechanism in the horizontal transfer of 
staphylococcal plasmids. Finally, we use the knowledge of important NES features to 
design polyamide inhibitors that disrupt key protein-DNA interactions and chelator 
fragments that target a required coordinated metal ion. The efficacy of these inhibitors 
	 iv	
suggests that disrupting NES function may be a viable option for disrupting conjugative 
plasmid transfer. 
β-glucuronidase (GUS) enzymes are responsible for the severe drug toxicity 
associated with the chemotherapy drug irinotecan. Previous characterization of E. coli 
GUS identified inhibitors whose efficacy is dependent on interaction with an active site 
loop termed Loop 1. Analysis of the Human Microbiome Project sequencing data 
establishes a catalog of GUS sequences present in the human gastrointestinal tract. 
Sequences in this catalog are classified according to the presence and size of an active 
site loop and we identify at least one sequence from each class for further 
characterization. Characterization confirms the β-glucuronidase activity of seven new 
enzymes and establishes the ability of six GUS enzymes to process SN-38G. We also 
confirm the importance of pH for optimal enzyme function. This data expands current 
understanding of the β-glucuronidase enzyme family and provides additional GUS 
enzymes against which to optimize inhibitors to prevent SN-38G toxicity. 
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UGT   UDP-glucuronosyltransferase 
UNC   University of North Carolina at Chapel Hill  
UNC-CH  University of North Carolina at Chapel Hill  
UV   ultraviolet 
vol/vol, v/v  volume per volume 
VRSA   vancomycin resistant S. aureus 
vs   versus 
W   tryptophan 
WT   wild type 
x   total protein concentration 
Y, Tyr   tyrosine 
α   alpha 
β   beta 
Δ    deletion 
ΔL1    Hairpin Loop 1 deletion 
ΔL1ΔL2   Hairpin Loop 1 Loop 2 deletion 
ΔL2    Hairpin Loop 2 deletion 
λ   wavelength 
μg   microgram 
μL   microliter 
μM   micromolar 
μm   micrometer
	 1	
 
CHAPTER 1: INTRODUCTION TO CONJUGATIVE PLASMID TRANSFER OF 
pSKS41 IN STAPHYLOCOCCUS AUREUS 
 
Staphylococcus aureus and Antibiotic Resistance 
Staphylococcus aureus is a gram-positive bacterium that is found as a 
commensal in the nose, respiratory tract, gastrointestinal tract, and on the skin of 
humans (1). Despite this potentially beneficial role in the human microbiota, S. 
aureus is best known as a pathogen that causes skin and respiratory infections. 
While these infections are normally treatable, infections resistant to antibiotic 
treatment can enter the bloodstream and cause sepsis and death. Since the 
introduction of penicillin and other antibiotic compounds, resistant strains of S. 
aureus have been appearing in human infections. It took just two years after the 
introduction of methicillin in the clinic for methicillin-resistant Staphylococcus to 
begin to present a barrier to treatment (2). In 2011, methicillin-resistant S. aureus 
(MRSA) caused an estimated 80,461 infections in the United States leading to 
11,285 deaths (2). Staphylococcal bacteria are a leading cause of healthcare-
associated infections leading the Center for Disease Control (CDC) to classify 
MRSA as a serious threat (2).  
In addition to methicillin, S. aureus has been found to be resistant to a wide 
variety of compounds including antiseptics, antibiotics, and disinfectants. Antibiotic 
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resistances found in S. aureus can include oxacillin, erythromycin, levofloxacin, 
clindamycin, mupirocin, doxycycline, gentamicin, trimethoprim-sulfamethoxazole, 
and tetracycline, which when found in the same strain can leave only harsh 
compounds available for treatment (3). It has also been shown that MRSA can 
obtain resistance to vancomycin, the current front-line treatment, leading to 
infections that are resistant to almost all approved antibiotics (4-7). Despite the rise 
of antibiotic resistance in S. aureus and other bacteria, the number of new antibiotics 
approved by the FDA has consistently decreased over the past two decades.  
Even as new antibiotics are introduced, it is expected that resistance will arise 
quickly as seen in the past. Most antibiotics to date have been discovered as or 
derived from small molecules produced by bacteria or plants. In these natural 
environments, these small molecules function as bacteriostatic or bacteriotoxic 
agents in order to regulate the surrounding bacterial community, much like how they 
function as antibiotics relevant to human health. This means the bacteria producing 
the compound or any bacteria that persist in this natural environment must maintain 
a resistance element to avoid toxicity from the compound. In fact, environmental 
bacteria including those preserved for hundreds of years in permafrost, isolated 
caves, and ancient human specimens contain resistance genes (8).  Because 
resistance to a compound similar to any new antibiotics almost certainly already 
exists in nature, it is likely only a matter of time until that resistance element moves 
into pathogenic bacteria.   
Due to both the currently existing antibiotic resistance and the high potential 
for the rise of future resistances, this work set out to better understand the 
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mechanisms by which antibiotic resistance is spread between bacteria. We hope 
that characterization of these processes will lead to drugs that specifically target 
antibiotic resistant bacterial communities or prevent the spread of antibiotic 
resistance within bacterial communities. 
 
Conjugative Plasmid Transfer 
Bacteria become resistant to the effects of antibiotics and other small 
molecules by obtaining genetic elements that encode for proteins that allow the 
bacteria to breakdown or transport the lethal substance out of their cell or encode 
modified targets with reduced antibiotic drug-reactivity. These resistance genetic 
elements can be incorporated into the chromosome of a bacterium or may reside on 
extra-chromosomal elements such as gene cassettes, transposons, bacteriophages, 
and single- or double-stranded DNA plasmids. Bacteria can transfer their genetic 
material, including these resistance elements, through two routes: vertical or 
horizontal gene transfer. Vertical gene transfer takes place between a mother and 
her daughter cells via duplication of the chromosomal and extra-chromosomal 
genetic material and distribution of a complete copy to each daughter cell. Horizontal 
gene transfer (HGT) is the transmission between mature, parent bacteria and 
involves only extra-chromosomal elements. HGT takes many forms including 
scavenging of DNA by naturally competent bacterial cells, bacteriophage facilitated 
transfer, and regulated transfer for single- and double-stranded plasmids. 
Most of the resistance genetic elements in S. aureus are found on double-
stranded DNA (dsDNA) plasmids or are incorporated into the chromosome after 
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movement through a dsDNA plasmid; therefore, this work will focus on the transfer 
mechanism of these plasmids between bacterium. Double-stranded DNA plasmids 
can be beneficial to the larger bacterial community as many of these plasmids are 
readily involved in HGT, allowing an entire population of bacteria to quickly acquire 
antibiotic resistance (9). HGT of dsDNA plasmids is called conjugative plasmid 
transfer (CPT). During CPT, a donor bacterium transfers one strand of a double-
stranded DNA plasmid to a recipient bacterium (Figure 1.1).  
There are several sets of machinery required for this process that may be 
expressed on the plasmid being transferred or on a co-resident plasmid in the donor 
bacterium. This machinery includes the mobility (MOB) set of enzymes that is 
responsible for the replication of the plasmid as well as genes for a type 4 secretion 
system (T4SS) and type 4 coupling protein (T4CP) that facilitate transfer of the 
plasmid (10). The MOB set of proteins forms a large complex called the relaxosome. 
The relaxosome complex includes the highly conserved relaxase (NES in Figure 1.1) 
as well as the replication machinery of the plasmid. The T4SS and T4CP form a 
secretion system through which DNA travels to the recipient cell (blue shaded box in 
Figure 1.1).  
 After relaxosome formation, the relaxase initiates CPT by binding to the origin 
of transfer (oriT) of the plasmid and creating a single-stranded break at the nic site in 
the strand to be transferred (T-strand, red in Figure 1.1) (9, 11). A DNA helicase in 
the relaxosome then separates the T-strand from the parent strand, beginning at the 
nic site. The free T-strand then begins to travel into the recipient cell through the 
T4CP/T4SS complex. The exact mechanisms involved in this process are unclear; 
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some data indicate that the covalently bound relaxase also travels into the recipient 
bacterium where the relaxase can then ligate the T-strand back together (12). A 
DNA polymerase within the donor bacterium replaces the T-strand as it is 
transferred and a DNA polymerase within the recipient bacterium synthesizes a copy 
of the T-strand so that the process culminates with two bacteria each containing a 
full, double-stranded plasmid that can confer antibiotic resistance. 
 
Types of Plasmids 
Plasmids that undergo CPT are divided into three classes based on the 
presence or absence of the MOB, T4CP, and T4SS gene clusters (Figure 1.2). The 
best studied type of plasmid is the conjugative plasmid which encodes all of the 
machinery needed to replicate and transmit itself including the MOB, T4CP, and 
T4SS clusters (Figure 1.2, 10). Mobilizable plasmids do not encode all of the 
machinery needed for their transmission; they express only the MOB proteins 
required for replication but do not encode their own T4SS and therefore must use 
the conjugation machinery expressed by a conjugative plasmid co-resident in the 
same bacterium (10). A small number of mobilizable plasmids encode their own 
T4CP but most utilize the T4CP from the co-resident plasmid expressing the T4SS.  
There is also a third type of plasmid that does not encode its own replication 
or conjugative machinery. Until recently it was assumed these plasmids were 
transferred via mechanisms besides conjugative plasmid transfer such as 
bacteriophage. However, O’Brien et al. showed that these plasmids can partake in 
CPT via a relaxase-in trans conjugative transfer mechanism in which they take 
	 6	
advantage of both the replication (MOB) and conjugation (T4CP/T4SS) machinery of 
a co-resident plasmid (Figure 1.2,13, 14). For this relaxase-in trans transfer, it is 
important that the MOB proteins of a conjugative or mobilizable plasmid co-resident 
in the bacterium match an oriT found on the in trans plasmid. Therefore, 
understanding of MOB proteins is important for characterization of CPT of all three 
plasmid classes.  
The relaxase is the only highly conserved member of the MOB family of 
proteins and is used to identify and classify conjugative and mobilizable plasmids 
(Figure 1.2). A relaxase enzyme is defined by the presence of two motifs (15). The 
first motif is the Y motif which consists of one or more tyrosines that are responsible 
for plasmid nicking and ligation. This conserved tyrosine (Y25 in Figure 1.3) initiates 
a nucleophilic substitution-type (SN2) attack on the scissile phosphate linking two 
nucleotides at the nic site (16). This generates a free 3’ hydroxyl and a 5’ covalent 
phosphotyrosine bond. The reaction is reversible with the 3’ hydroxyl acting as a 
nucleophile to ligate the strand together in the recipient cell. 
The second motif, the HUH motif, consists of a histidine residue, hydrophobic 
residue, and histidine residue and is the mostly highly conserved relaxase motif. 
Often a third histidine is found slightly upstream from the HUH motif and forms a 
triad responsible for coordinating a metal cation in the relaxase active site (H123, 
H131, and H133 in Figure 1.3). This divalent metal ion is required for DNA cleavage, 
and several metals including nickel, manganese, zinc, and copper are sufficient for 
proper function (16-18). As shown in Figure 1.3, the metal coordinates one oxygen 
of the scissile phosphate at which the DNA cleavage will occur (16, 19). 
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 Based on the sequence of their respective relaxase and in particular, the 
sequence in and around the Y and HUH motifs, conjugative and mobilizable 
plasmids have been classified into six families. These families are MOBF, MOBH, 
MOBC, MOBQ, MOBP, and MOBV (Figure 1.2, 20, 21). The relaxases of the MOBH 
and MOBC families have a different architecture and may not contain regions that 
resemble the Y and HUH motifs (15, 22). The MOBF family is the best characterized 
of the six families and contains relaxases with two to three tyrosines in the Y motif 
(15). The MOBQ, MOBP, and MOBV plasmid families encode relaxases containing 
only one tyrosine in the Y motif (15). Because the relaxase is responsible for the 
initiation and termination of CPT, understanding of these proteins could lead to 
development of novel antibiotics targeting resistance-spreading bacterial infections. 
Indeed, it has already been shown that inhibiting the relaxase can disrupt 
propagation of the host plasmid (23).  
 
Introduction to S. aureus plasmid pSK41 
 pSK41 is a 46,445 nucleotide, conjugative, multiresistance plasmid from S. 
aureus (24). Related plasmids were first detected in the mid-1970s; the transfer 
region of pSK41 was analyzed by Firth and colleagues in 1993 and the complete 
sequence of pSK41 was published in 1998 (24, 25). pSK41 is now considered the 
prototype plasmid for this family.    
pSK41 family plasmids have been found to harbor resistance determinants for 
antiseptics, disinfectants, and many antibiotics including tetracycline, gentamicin, 
tobramycin, kanamycin, neomycin, paromomycin, quaternary ammonium 
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compounds, trimethoprim, mupirocin, macrolides, lincosamides, streptogramins, 
bleomycin, and β-lactams (3, 24-26). Of special note is the incorporation of 
vancomycin resistance into pSK41 to form the new plasmid pLW1043 (4). pSK41 
has also been shown to contribute to the spread of antibiotic resistance through 
facilitating the transfer of mobilizable plasmids such as pC221 and pSK639 (27, 28). 
Because pSK41 and related plasmids confer such a wide range of resistances, it is 
an important target for understanding and modulating the spread of antibiotic 
resistance in S. aureus.  
 
Introduction to Nicking Enzyme of Staphylococcus (NES) 
 The relaxase of pSK41 is named nicking enzyme of staphylococci (NES). 
This gene and its oriT target were first identified on the pGO1 plasmid by Climo et al. 
in 1996 (29). The nes gene was confirmed in pSK41 by Berg and colleagues (24). 
NES is a single-tyrosine relaxase in the MOBQ family and is considered the 
prototype relaxase for this family. 
Further characterization of the NES protein was carried out by the Redinbo 
lab in order to characterize the catalytically active tyrosine (residue 25) and nic site 
of the oriT (Figure 1.3,17). Edwards et al. also solved the crystal structure of the N-
terminal relaxase domain of NES bound to its oriT DNA (17). This was the first 
structure of a single tyrosine relaxase bound to its cognate DNA. Previously solved 
crystal structures of relaxases in complex with their oriT DNA showed that the DNA 
bound in a cleft next to a “thumb” motif of the protein that then closed over the DNA 
to hold the DNA in place (30). NES, however, does not contain a thumb motif and 
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instead has two unique features to properly position the oriT DNA (17). The first 
feature is two protein loops (loop 1 and loop 2 in Figure 1.4A) that extend into the 
major and minor groove of the DNA hairpin formed by the oriT DNA. The second 
feature is nucleotide guanine-26 (magenta in Figure 1.4A) of the oriT that is flipped 
in the opposite direction from the surrounding nucleotides and makes significant 
contacts with amino acid side chains of NES.  
Relaxases from the MOBQ, MOBP, and MOBV families including NES are two 
domain proteins with the N-terminal domain containing the relaxase motif. The C-
terminal domain is variable and often functions as a helicase, primase, or DNA-
binding domain that contributes to the DNA replication process (15). Interestingly, 
the NES C-terminal domain shows no similarity to previously characterized C-
terminal domains of relaxases or other relaxosome proteins. The C-terminal domain 
of NES was also crystallized and its structure solved; however, both this C-terminal 
domain structure and the SAXS envelope of the full-length protein did not give any 
suggestion of the potential function of this domain (Figure 1.4B,17).   
Biochemical assays for DNA binding and cleavage conducted with the 
relaxase domain established that the protein loops 1 and 2 are important for proper 
activity and explored the importance of variation and length of the oriT (17). In 
addition, S. aureus conjugation assays showed that both the C-terminal domain and 
loop 1 and loop 2 of the relaxase are essential for proper conjugation of pSK41 (17). 
Therefore, this work characterizes at what point in CPT these protein features play 
an important role in NES function.  
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Figure 1.1. Mechanism of Conjugative Plasmid Transfer 
Conjugative Plasmid Transfer (CPT) is initiated when the relaxase (NES) in the 
relaxosome complex binds to the oriT (blue) on the transfer strand (red, T-strand) in 
order to cleave the plasmids at the nic site (blue dot). The donor cell (blue) and 
recipient cell (red) are then connected via the type 4 secretion system (T4SS) and 
Type 4 coupling protein (T4CP) to allow the relaxase (NES) and T-strand to move 
into the recipient cell. Each of the original strands of the resistance plasmid is 
replicated such that both the donor and recipient cell end with a complete double 
stranded plasmid. 
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Figure 1.2. Classification of Plasmids and MOB Genes 
Bacterial plasmids are classified according to the genes encoded on the plasmid. 
Conjugative plasmids encode resistance elements, mobilization (MOB) genes, a 
type 4 coupling protein (T4CP), and a type 4 secretion system (T4SS). Mobilizable 
plasmids encode only resistance elements and MOB genes while in trans plasmids 
encode on resistance elements. The MOB genes on conjugative and mobilizable 
plasmids are in turn classified as MOBF, MOBH, MOBC, MOBQ, MOBP, AND MOBV 
according to the motifs found in their relaxase gene. 
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Figure 1.3. Proposed Mechanism of DNA Cleavage by NES 
The tyrosine residue of the relaxase (Y25 in NES) initiates a nucleophilic 
substitution-type attack on the scissile phosphate of the nic site of the transfer strand 
of the plasmid to be transferred. In pSK41 this is between a guanine and cytosine 
(nucleotides 28 and 29 in the oligonucleotides used throughout this work). This 
attack creates a free 3’ hydroxyl and the 5’ phosphate becomes covalently attached 
to the tyrosine of the relaxase. The metal coordinated by the HUH motif (H123, 
H131, H133) is shown as Ni2+ here, as has been shown in purified NES; however, 
other divalent metals are likely the predominant cofactor in vivo for NES and other 
relaxases. 
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Figure 1.4. NES Structure from S. aureus pSK41 
A. 2.9 Å crystal structure of the NES relaxase domain (residues 1-195) in complex 
with a 30-nucleotide DNA sequence. PDB ID: 4HT4 
B.  3.0 Å crystal structure of the NES C-terminal domain (residues 254-593). PDB 
ID: 4HTE 
A 
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Figure 1.5. Effect of NES Mutants on Conjugation in S aureus 
Conjugation of pSK41 in S. aureus and the effect of nes deletion (KO) or 
complementation with WT and designed NES loop 1, loop 2, and C-terminal deletion 
(∆C-term) mutants. Originally published in Edwards et al. 2013 (17).	
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CHAPTER 2: PROCESSING OF NONCONJUGATIVE RESISTANCE PLASMIDS 
BY CONJUGATIVE NICKING ENZYME OF STAPHYLOCOCCI1 
 
Introduction 
Antimicrobial resistant strains of Staphylococcus aureus are a growing 
concern for hospital- and community-acquired infections. Most S. aureus bacteria 
examined clinically harbor at least one plasmid that encodes for antimicrobial 
resistance, and many plasmids carry multiple antimicrobial resistance determinants. 
The pSK41 family of plasmids is made up of large, low-copy-number, conjugative 
plasmids for which pSK41 is used as a prototype for characterization (1-4). These 
plasmids carry a variety of antimicrobial resistance determinants, including those 
against aminoglycosides, penicillins, tetracycline, bleomycin, trimethoprim, 
macrolides, lincosamides, mupirocin, antiseptics, and disinfectants (2, 4-9). This 
family of plasmids also played a key role in the rise of vancomycin resistant S. 
aureus (VRSA) (7, 8, 10). In addition to the antimicrobial resistance, they also carry 
transfer (tra) genes encoding the proteins necessary to conduct conjugative plasmid 
transfer that spread these plasmids among S. aureus and other gram-positive 
bacteria (6, 7, 10, 11). 
																																																						
1 This chapter adapted from the previously published work Pollet RM, Ingle JD, Hymes JP, Eakes TC, 
Yui Eto K, Kwong SM, Ramsay JP, Firth N, Redinbo MR. 2016. Processing of Nonconjugative 
Resistance Plasmids by Conjugation Nicking Enzyme of Staphylococci. Journal of Bacteriology 
198:888-897. 
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One of the proteins essential for conjugative plasmid transfer is the relaxase 
enzyme. A relaxase is responsible for initiation and completion of the transfer 
process as it cleaves one strand of the double-stranded plasmid to begin transfer, 
and then ligates that strand back together to complete transfer (8, 12-15). There are 
two classes of relaxases: multi-tyrosine relaxases that use a “thumb” motif to 
position the plasmid DNA for processing, and single-tyrosine relaxases which lack 
this thumb motif (9, 16). The relaxase of pSK41 is termed NES, nicking enzyme in S. 
aureus, and is a single-tyrosine relaxase (1-6, 8, 9).  NES contains a relaxase N-
terminal 220 residues and a C-terminal 350 residues necessary for in vivo function 
but via an uncertain mechanism (5, 7, 8, 10). Here we determine in which steps of 
conjugation the C-terminal domain plays an important role. 
The crystal structure of the relaxase domain of NES was the first of a single-
tyrosine relaxase bound to its target DNA, allowing for more detailed 
characterization of the protein-DNA interactions than previously possible (6-8, 11). 
This structure revealed two sets of important protein-DNA interactions. The first is 
that the “thumb” used by multi-tyrosine relaxases to position the DNA appears to be 
replaced by 12 protein-DNA contacts including a buried nucleotide 3 bases 
upstream of the nic site that places the DNA in the correct position to be nicked by 
the single, catalytically active tyrosine. The second set of protein-DNA interactions 
unique to the NES-DNA complex is composed of two protein loops, termed Hairpin 
Loop 1 and 2, that surround the DNA hairpin formed upstream of the nic site (Figure 
2.1A and B). NES Hairpin Loop 1, shown in yellow in Figure 2.1A and B, forms two 
base specific contacts with the minor groove of the oriT DNA and one contact to the 
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phosphate backbone. NES Hairpin Loop 2, green in Figure 2.1A and B, contacts the 
DNA more extensively, with six base specific interactions and four phosphate 
contacts in the major groove of the DNA hairpin. Edwards et al. previously showed in 
vitro that these loops disrupt DNA cleavage by the relaxase domain alone and in 
vivo that full-length NES protein lacking these loops was not able to facilitate plasmid 
transfer (7, 8, 10, 14). However, this important protein-DNA interaction had not been 
characterized in vitro in the context of the full-length 665-residue NES protein and 
we set out to determine in which steps of conjugation this interaction plays a role. 
pSK41-like conjugative plasmids have been shown to mobilize several 
smaller co-resident plasmids such as pC221 and pSK639, which encode their own 
mob genes (9, 12, 13, 15, 16). Recently, O’Brien et al. showed that another 
staphylococcal conjugative plasmid pWBG749, which is unrelated to pSK41, can 
facilitate the mobilization of other plasmids that lack mob genes (17). They 
demonstrated that this transfer is facilitated by origin-of-transfer sequences on the 
non-conjugative plasmids that mimic the pWBG749 origin-of-transfer sequence, 
suggesting a conjugative relaxase-in trans mechanism (18). We have identified 
sequences similar to the pSK41 origin of transfer on numerous non-conjugative 
staphylococcal resistance plasmids (Appendices 1 and 2), raising the possibility that 
pSK41 family plasmids might likewise facilitate mobilization of other plasmids by an 
analogous relaxase-in trans mechanism mediated by NES. To investigate this 
possibility, we have characterized the pSK41 oriT mimic sequences from two 
divergent non-conjugative plasmids. The first plasmid, pSK156, was isolated from a 
clinical strain in 1951 and is the earliest known multidrug efflux-
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(19). The second plasmid, pCA347, was first sequenced in 2013 after isolation from 
a USA600 methicillin-resistant strain of S. aureus and encodes resistance to 
penicillin and heavy metals (20). Importantly, the variation in the origin-of-transfer 
sequence of pSK41 and the mimics of pSK156 and pCA347 is in the hairpin region 
of the DNA (Figure 2.4A). Based on these observations we sought to explore the 
ability of NES to bind to and process putative oriT regions from pSK156 and pCA347 
and the ability of pSK41 to facilitate transfer of plasmids containing these putative 
oriT regions in order to examine the potential for mobilization of plasmids containing 
pSK41 oriT mimics in staphylococci. 
 
Materials and Methods 
Cloning, Expression and Purification of the Relaxase Domain of NES 
The relaxase domain of NES was previously cloned into the cysteine 
protease domain (CPD) fusion protein expression system developed by Shen et al. 
and optimized by this lab (7, 21). Sequence confirmed constructs were transformed 
into Escherichia coli BL21 (DE3) AI cells and grown in 1.5 L of lysogeny broth (LB), 
in the presence of ampicillin, at 37 °C, with shaking, to an optical density of 0.6–0.8. 
An L-Arabinose solution was added to the growth at a final concentration of 0.2% 
(vol/vol), and the temperature was reduced to 18 °C for 30 min. Protein expression 
was induced with 100 μM isopropyl-β-D-thiogalactopyranoside (IPTG) and cells 
were allowed to grow for 16 h. The resulting growths were spun at 4,500 × g for 30 
min at 4 °C and pellets were stored at −80 °C. Individual pellets were resuspended 
in Buffer A [500 mM NaCl, 25 mM imidazole, 20 mM potassium phosphate buffer, 
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pH 7.4, and 0.02% (vol/vol) sodium azide] along with protease inhibitor tablets 
(Roche), DNase, and lysozyme. The slurry was lysed using a Fisher Scientific Sonic 
Dismembrator. The lysed cells were then spun at 18,500 × g for 1 h. The 
supernatant was filtered and flowed over a 5 mL HisTrap column (GE Healthcare). 
The column and bound protein was then washed with Buffer A followed by 
incubation with 1 CV of 2 mM inositol hexakisphosphate (InsP6) for 3 hours at 4 °C. 
The cleaved protein was washed off the column with Buffer A and flowed directly 
onto a Superdex 200 column (GE Healthcare) preequilibrated in sizing buffer [300 
mM NaCl, 50 mM Tris buffer, pH 7.4, and 0.02% (vol/vol) sodium azide]. Fractions 
containing protein as assessed by UV absorbance were analyzed via SDS-PAGE 
and fractions containing >95% pure protein were combined and stored at -80 °C. 
Cloning, Expression and Purification of Full-Length NES  
Wild-type full-length NES was previously cloned into the cysteine protease 
domain (CPD) fusion protein expression system developed by Shen et al. and 
optimized by this lab (7, 21). Loop deletion mutants were made through site directed 
mutagenesis to remove Hairpin Loop 1 (residues 77 to 82) and Hairpin Loop 2 
(residues 150 to 157) and replace each with a linker composed of one glycine and 
one serine. Cleavage inactive mutants used in binding studies were made by 
replacing the tyrosine at amino acid position 25 with a phenylalanine. The resulting 
plasmids were transformed into Escherichia coli BL21 (DE3) AI cells and grown in 
1.5 L of lysogeny broth (LB) in the presence of 0.1 mg/ml ampicillin at 37°C with 
shaking. At an optical density of 0.6-0.8, an L-Arabinose solution was added at a 
final concentration of 0.2% (vol/vol) and the temperature reduced to 18°C. After 30 
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minutes, protein expression was induced with 100 μM isopropyl-β-D-
thiogalactopyranoside (IPTG) and cells were allowed to grow for 16 hours. The cells 
were pelleted and stored at -80°C. Individual cell pellets were resuspended in Buffer 
A [500 mM NaCl, 20 mM KH2PO4 pH 7.4, 25 mM Imidazole, 0.02% (v/v) sodium 
azide] along with protease inhibitor tablets (Roche), DNase, and lysozyme. The 
mixture was sonicated and then clarified via centrifugation. The supernatant was 
filtered and loaded onto a 5 mL HisTrap column (GE Healthcare). The CPD 
expression system contains a His6 tag in addition to the CPD tag, which has self-
cleavage abilities in the presence of inositol hexakisphosphate (InsP6). Therefore, 
after the His-CPD-NES fusion protein was bound to the column via the His6 tag, the 
column was washed with 2 column volumes (CV) Buffer A and then incubated with 2 
mM InsP6 for 3 hours at 4°C. The NES protein was then eluted off the column in 
Buffer A while the His6 and CPD tags remained bound to the column. The NES 
protein was then passed over a Superdex 200 column (GE Healthcare) pre-
equilibrated in sizing buffer [25 mM HEPES pH 7.4, 300 mM NaCl, 0.02% (v/v) 
sodium azide].  Purity of each fraction was assessed by SDS-PAGE gel and 
fractions containing >95% pure protein were combined and concentrated to 
approximately 1.2 mg/ml. 
DNA Binding Studies  
5’-end 6-FAM labeled DNA oligos were ordered from Integrated DNA 
Technologies, resuspended in annealing buffer (10 mM Tris pH 7.5, 50 mM NaCl, 
0.05 mM EDTA), and hairpin was formed by heating the oligo to 98°C for one minute 
and then cooling the solution by 3°C per second. The dissociation constant of 
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binding was calculated using fluorescence anisotropy as described in Edwards et al. 
(7). Briefly, protein was serially diluted into a buffer of 100 mM NaCl, 0.1 mg/ml BSA, 
5 mM Magnesium Acetate, 25 mM Tris Acetate, pH 7.5 to give 40 μL at final protein 
concentrations ranging from 0 to 0.5 μM.  Assays were conducted in a 384-well 
black assay plate (Costar) allowing for 16 concentrations of protein. 10 μL of the 
DNA probe was added to the 40 μL protein solution resulting in a final concentration 
of DNA of 50 nM in a total volume of 50 μL in each well. Fluorescence anisotropy of 
the fluorescein-labeled DNA was observed via excitation at 485 nm and emission at 
520 nm using a PHERAstar plate reader (BMG Labtech). Measurements were made 
in triplicate and reported values are the average of three separate triplicate runs. 
Data were plotted as average fluorescence anisotropy as a function of protein 
concentration using Graphpad PRISM v6.05 (Graphpad, 2014). The following 
equation was employed to fit the data and to calculate the KD for the substrate: 
 
where is average fluorescence anisotropy signal; T, total DNA concentration (set to 
50 nM); x, total protein concentration; K, KD; min, average fluorescence anisotropy 
signal of no protein control; and max, average fluorescence anisotropy signal of 
sample at saturating concentration of protein. A single binding site was assumed 
and standard error is reported for each measurement. The reported values are an 
average of at least 5 independent experiments. 
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DNA Cleavage Assays  
The same 5’-end 6-FAM labeled DNA oligos used for the DNA binding studies 
were used to measure equilibrium DNA cleavage via polyacrylamide gel 
electrophoresis (PAGE) gels. Each 10 μL reaction contained 1.52 μM NES protein 
(relaxase or full-length constructs), 1 μM DNA substrate, and EMSA buffer (50 mM 
NaCl, 20 mM Tris, pH 7.4, 0.02% (vol/vol) sodium azide). The reaction was 
incubated at 37°C for 1 hour and quenched by the addition of 2X running buffer 
(0.01% xylene cyanol, 0.01% Bromophenol Blue, 85% formamide, 20 mM EDTA, 2X 
TAE, 0.2% SDS). The resulting 20 μL reactions were run through a denaturing 16% 
polyacrylamide gel [35 mL 16% acrylamide gel stock (8 M urea, 16% 
polyacrylamide/bisacrylamide, 1X TBE), 300 μL 10% ammonium persulfate (APS), 
33 μL tetramethylethylenediamine (TEMED)] in 1X TBE running buffer to separate 
cleaved product DNA from the substrate. Using the fluorescein tag, oligos were 
visualized using a VersaDoc Imaging System, 4400 MP (BioRad) and the 
QuantityOne software (BioRad). ImageJ 1.45s software was used to quantify band 
intensities and the percent cleavage product formation was calculated as a 
percentage of the product band intensity divided by the product plus the substrate 
band intensities. The average of at least six individual cleavage experiments are 
presented. 
DNA Strand Transfer Assays 
DNA strand transfer assays were performed similarly to DNA cleavage 
assays except two pieces of DNA were used. The first piece of DNA was an 
unlabeled substrate of the same sequence and length as the oligos used in the DNA 
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binding and cleavage studies (red DNA in Figure 2.3B). The second piece of DNA 
was a 5’-end 6-FAM labeled DNA oligo of the same sequence as the unlabeled 
substrate, but ending at the NES cleavage site (black DNA in Figure 2.3B). Each 10 
μL reaction contained 1.52 μM NES protein (relaxase or full-length constructs), 1 μM 
unlabeled DNA substrate, 1 μM labeled DNA substrate, and EMSA buffer. The 
reaction was incubated, run, and analyzed as in the DNA cleavage assays. Percent 
strand transfer was calculated as a percentage of the product band intensity divided 
by the product plus the labeled substrate band intensities. The unlabeled DNA 
substrate was not visualized or quantified. The average of at least six individual 
cleavage experiments are presented. 
Structure Modeling  
The NES relaxase domain-DNA complex structure reported previously 
(Edwards et al.; RCSB accession code 4HT4) was employed for Figures 2.1A-B and 
2.4B-C. (7). For Figures 2.4D and E in which pSK156 and pCA347 were modeled in 
place of the original pSK41 DNA, Coot was used to mutate each DNA residue, and 
the final figures were rendered in PyMol (22, 23).  
Plasmid Sequence Analysis  
The plasmid database compiled and analyzed for pWBG749 family oriT 
sequences by O’Brien et al. was analyzed for oriT sequences similar to that of 
pSK41 (18). The online interface of BLASTN was used to search these plasmids for 
the sequence ATAAGTGCGCCCTTACGGGATTTAAC from the pSK41 oriT and 
each sequence with a match was manually inspected for an adjacent DNA hairpin 
sequence (24). Plasmids were then grouped according to varying sequences found 
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in the DNA hairpin. Plasmids determined to carry potential pSK41 oriT-mimics were 
then searched for the NES relaxase gene (Accession Code: NC_005024.1, 
nucleotides 8115 to 10112) to determine if the plasmid is a conjugative plasmid. 
Bacterial Strains, Plasmids, Growth and Assay Conditions  
Strains and plasmids used are listed in Table 2.1. E. coli and S. aureus were 
cultured at 37°C on LB agar or in liquid LB medium with aeration (200 rpm). When 
required, growth medium was supplemented with antibiotics at the following 
concentrations: ampicillin (Ap) 100 μg/mL; chloramphenicol (Cm) 10 μg/mL; 
gentamicin (Gm) 20 μg/mL; novobiocin (Nb) 5 μg/mL; streptomycin (Sm) 50 μg/mL.  
DNA fragments encompassing oriT regions were synthesised as GeneArt 
Strings (Figure 2.6; Life Technologies) and cloned into HindIII and/or BamHI sites of 
the pSK1-based S. aureus/E. coli shuttle vector pSK5632. The insert integrity was 
verified by sequencing. pSK5632 constructs were introduced into the restriction-
deficient S. aureus strain RN4220 by electroporation. pSK41 was introduced into 
each resulting strain by conjugation with strain SK5428 and resulting CmR/GmR-
transconjugants were used as donors in mobilization experiments. Mobilization 
assays were conducted in BHI liquid medium (Sigma Aldrich) containing 40% (final) 
polyethylene glycol (PEG) as described previously (O’Brien et al., 2015). The 
WBG4515 strain was used as a recipient and Sm/Nb was used to select against 
donors. Transconjugants were isolated on media additionally carrying either Gm (for 
pSK41) or Cm (for pSK5632).  
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Results 
Role of the C-terminal Domain of NES 
 As discussed in Chapter 1, the C-terminal domain of NES is essential for 
function in vivo; Edwards et al. showed that a NES mutant lacking its C-terminal 
domain was not able to successfully facilitate conjugation of pSK41 (25). We set out 
to characterize the role of the C-terminal domain in vitro to determine in which step 
of conjugation it plays a significant role. To do so we compared the activity of the 
relaxase domain (1-220) of NES and the full-length (1-665) NES in both cleavage 
and strand transfer assays. In each case we also tested a range of oligonucleotide 
lengths as this has been previously shown to effect NES activity but it is unclear 
which lengths are biologically relevant (25). The oligonucleotides used are shown in 
Figure 2.1C. 
 In the cleavage assay, NES 1-220 and NES 1-665 showed differential activity 
(p<0.005) against OriTHP30 and OriTHP35 (Figure 2.2A). NES 1-665 was able to 
process OriTHP30 at a higher rate than NES 1-200; however, NES 1-220 was able 
to process OriTHP35 at a higher rate. In contrast, NES 1-220 and NES 1-665 did not 
show differential activity against OriTHP40 and OriTHP45 leading us to conclude 
that the C-terminal domain does not play a major role in the cleavage activity of 
NES. 
 As shown in Figure 2.2B, NES 1-220 and NES 1-665 did not show differential 
strand transfer activity against OriTHP30, OriTHP35, or OriTHP40. Interestingly, 
NES 1-220 showed significantly higher activity against OriTHP45 than NES 1-665. 
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We conclude that the C-terminal domain is important for proper regulation of the 
strand transfer activity of NES.  
Characterization of NES Hairpin Loop 1 and 2 
The crystal structure of the relaxase domain of NES in complex with pSK41 
oriT DNA hairpin, reported previously by Edwards et al., revealed two features 
unique to this class of relaxase: two protein loops, termed Hairpin Loop 1 and 2 
(Figure 2.1A and B), that clamp around the hairpin duplex of the oriT DNA (7). These 
contacts are unique to this class of relaxase compared to those observed with the 
longer, multi-tyrosine relaxases like F TraI, and they have yet to be characterized in 
the context of the full-length protein. Hence, we sought to determine the impact 
deleting these unique loops would have on NES functions in vitro. Hairpin Loop 1 
deletion (ΔL1), Hairpin Loop 2 deletion (ΔL2), or double-deletion (ΔL1ΔL2) forms of 
full-length NES protein were created using site-directed mutagenesis in which the 
loops were replaced with Gly-Ser linkers. The proteins were expressed 
recombinantly in E. coli and purified to homogeneity. DNA binding, cleavage, and 
strand transfer assays were conducted using DNA oligonucleotides similar to that 
employed in the complex presented in the crystal structure and possessing the same 
sequence as the origin of transfer (oriT) of NES conjugated plasmid pSK41 (Figure 
2.1C).  
For DNA binding studies, these variant proteins contained an active site Tyr-
25-Phe mutation. Previous evidence suggested NES relaxase activity is dependent 
on oligonucleotide length (Figure 2.2, 7) so varying lengths of the oriT were used to 
verify this trend and named as in Figure 2.1C. Longer oligonucleotides should better 
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mimic in vivo plasmid transfer. As shown in Figure 2.3A, the ΔL1 form of full-length 
NES exhibited increased DNA binding (p<0.005) compared to wild-type NES on the 
OriTHP35 and OriTHP40 oligonucleotides. ΔL2 NES did not demonstrate 
significantly different DNA binding on any oligo.  In contrast, ΔL1ΔL2 NES showed 
significantly increased DNA binding (p=0.0002) on the shortest oligo tested, 
OriTHP30, but decreased binding (p<0.005) on OriTHP35. For the longest 
oligonucleotide tested, OriTHP45, no difference in binding was observed for any 
variant proteins compared to wild-type NES.  Thus, we conclude that eliminating 
Hairpin Loops 1 or 2 from full-length NES can alter DNA binding in vitro in an 
oligonucleotide length-dependent manner.  
DNA cleavage and strand transfer assays were conducted as described in 
Figure 2.3B. The cleavage assay mimics the cleavage of the plasmid oriT to produce 
the single strand transferred during conjugation. On OriTHP30, only ΔL1 NES 
exhibited a significant (p<0.0001) difference in DNA cleavage, in this case a 
reduction, relative to wild-type NES (Figure 2.3C). On the longer OriTHP35, 
OriTHP40 and OriTHP45 oligos, all three variant proteins (ΔL1, ΔL2, ΔL1ΔL2) 
demonstrated statistically significant (p<0.0001) increases in levels of DNA cleavage 
relative to wild-type NES.  For these longer oligos, wild-type cleavage was observed 
at ~4%, while the variant proteins exhibited 2- to 7-fold increases in cleavage.  We 
conclude that eliminating the DNA hairpin-associating loops from NES increases 
DNA cleavage by the enzyme.  
A more dramatic effect was observed in examining DNA strand transfer by 
the variant full-length forms of NES.  The strand transfer assay measured the 
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ligation of a portion of DNA covalently linked to NES following cleavage to a new 
piece of DNA containing the hairpin characteristic of the oriT (Figure 2.3B). This 
mimics the ligation step of conjugation that ends plasmid transfer. For OriTHP30, all 
NES variants (ΔL1, ΔL2, and ΔL1ΔL2) showed 5- to 15-fold increases in DNA strand 
transfer relative to wild-type NES (Figure 2.3D).  For OriTHPs 35, 40 and 45, the 
increases were even larger – 25% to nearly 50% of the substrate oligos provided to 
the NES variants were processed to strand transfer, while ~5% of the oligos formed 
strand transfer products with wild-type NES.  Thus, eliminating the DNA hairpin 
contacting loops of NES produces significant and dramatic increases in the level of 
DNA strand transfer in vitro compared to wild-type NES. It can be concluded that the 
Hairpin Loop 1 and Loop 2 regions of NES play an important role, particularly on 
longer DNA substrates more relevant to transfer in vivo, in limiting the level of DNA 
religation during conjugation. 
Modeling of NES Bound to pSK156 and pCA347 
We next sought to determine if related DNA sequences from other plasmids 
might serve as substrates for pSK41 NES.  We examined the S. aureus plasmids of 
known sequence and selected two with sequences identical to the pSK41 oriT 
cleavage site. These two plasmids, pSK156 and pCA347, exhibited the same 
sequence as pSK41 in the 20 nucleotide region from the predicted hairpin through 
the nic site, but deviated somewhat from the DNA hairpin region of the pSK41 oriT 
(Figure 2.4A).  We predicted based on modeling that pSK156 and pCA347 might 
each form 8 base pair DNA hairpins with a one-nucleotide bulge; by contrast, pSK41 
is known from crystal structure to form a 7 base pair DNA hairpin with no bulge 
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(Figure 2.4A and B).  Interestingly, within the predicted DNA hairpins of pSK156 and 
pCA347, nucleotides at the base of the DNA hairpin (G3, C17 and G18) are conserved 
with the sequence of pSK41 (Figure 2.4A, C, D and E).   Furthermore, we noted that 
the 8 base pair hairpins predicted for pSK156 and pCA347 are nearly identical in 
sequence to each other (Figure 2.4A, D and E). 
We next modeled the pSK156 and pCA347 DNA sequences into the pSK41 
NES relaxase domain-DNA hairpin complex crystal structure. For reference, Figure 
2.4B shows the NES relaxase domain in complex with the pSK41 DNA hairpin, 
highlighting the interactions between the protein and DNA; the boxed region 
contains all the protein contacts with the DNA hairpin and will remain the focus of the 
pSK156 and pCA347 models. As shown in Figure 2.4C, NES makes base specific 
contacts with the pSK41 DNA hairpin at C4 via N154, T16 via R78, C17 via G153 and 
N154, G18 via R151, and C19 via Y156.  All but one contact to pSK156 and two 
contacts to pCA347, along with six phosphate contacts, are maintained in the 
models despite the changes in the DNA sequences between these plasmids and 
pSK41 (Figures 2.4D and E). Because C17 and G18 are conserved in both pSK156 
and pCA347, the contacts via G153, N154, and R151 are maintained. The cytosine 
at position 19 in pSK41 is replaced by a thymine in pSK156 and pCA347; however, 
the para-oxygen of thymine appears capable of receiving a hydrogen bond from 
Y156 of NES.  Position 16 of pSK156 and pCA347 contains an adenine rather than 
the thymine found in pSK41. The ring nitrogen of adenine appears capable in our 
models of receiving the same hydrogen bond from R78 as the oxygen of thymine; 
however, while the thymine oxygen can form two hydrogen bonds, the adenine 
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nitrogen can form only one. Thus, in spite of sequence differences between pSK41 
and these other two S. aureus plasmids, contacts between NES and the predicted 
oriTs of all three plasmids are largely maintained.  
  An additional contact is predicted to be lost between NES and pCA347. While 
a cytosine is conserved in the same positions in pSK41 (position -4) and pSK156 
(position -2), it is a thymine in pCA347 (T2; Figure 2.4E). In pSK41 and pSK156 the 
amine group of C4 donates a hydrogen bond to the oxygen of N154; however, the 
para-oxygen of thymine cannot form the same interaction. It is possible that the 
asparagine side chain could rotate to allow the thymine oxygen to receive a 
hydrogen bond from the N154 side chain amine.  In doing so, though, this side chain 
would lose an interaction with C17.  Despite this potential change, five base-specific 
contacts and six phosphate contacts are maintained in our models between NES 
and the sequences of plasmids pSK156 and pCA347 in this region.  Thus, we 
hypothesize that NES is capable of binding to and utilizing these potential oriT 
regions of pSK156 and pCA347 as substrates.   
Characterization of NES Processing of pSK156 and pCA347 
We next analyzed the ability of pSK41 NES to process the potential oriT 
regions of pSK156 and pCA347 by measuring the protein’s ability to employ these 
DNAs for binding, cleavage and strand transfer. For DNA binding studies, wild-type 
full-length NES with an active site Y25F mutation was employed along with 
OriTHP40-like forms of the pSK41, pSK156, and pCA347 (Figure 2.4A). The 
OriTHP40-like form alone was analyzed as longer oligonucleotides have been 
shown to be important for the regulatory function of the C-terminal domain (Figure 
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2.2, 7) but significant differences between OriTHP40 and 45 were not seen in 
assays with the NES loop deletion protein mutants. NES bound the oriT mimic 
regions of pSK156 and pCA347 but less well compared to its binding of the pSK41 
oriT (Figure 2.5A). The KD of NES binding to pSK41 is 19.3 ± 3 nM; in contrast, NES 
binds to pSK156 and pCA347 3- and 9-fold weaker, with KDs of 55.8 ± 9 nM and 175 
± 30 nM, respectively. While the loss of one or two hydrogen bonds is not sufficient 
to explain this decrease in binding affinity, it is interesting that the changes in binding 
affinity reflect the degree of change in sequence and interactions seen in our 
models.  
DNA cleavage and strand transfer assays with full-length wild-type pSK41 
NES and the OriTHP40-like regions of pSK156 and pCA347 were conducted as 
described in Figure 2.3B.  For DNA cleavage, pSK156 exhibited the same level of 
activity as pSK41, while pCA347 showed significantly decreased cleavage by NES 
(p<0.0001, Figure 2.5B).  However, as the cleavage process is dependent on NES 
first binding the DNA, this reduction in cleavage may result from the decrease in 
binding seen in Figure 2.5A for pCA347. For DNA strand transfer, both pSK156 and 
pCA347 showed significantly increased DNA strand transfer, with 3- and 7-fold 
increases in strand transfer for pSK156 and pCA347, respectively, relative to pSK41 
(Figure 2.5C). Taken together, these DNA binding, cleavage, and strand transfer 
data reveal that NES is capable of processing pSK156 and pCA347 oriT-like sites 
but does so at lower efficiency than at its cognate site. 
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Relaxase-in trans Mobilization by pSK41 In Vivo 
To investigate the ability of pSK41 to facilitate relaxase-in trans mobilization, 
the oriT-like sites corresponding to pSK156 and pCA347, and the pSK41 oriT 
sequence itself were synthesized and cloned into the non-mobilizable shuttle vector 
pSK5632 (26) to generate the plasmids pSK6881, pSK6879 and pSK6877, 
respectively; the DNA fragments cloned are shown in Figure 2.6. These new plasmid 
constructs and pSK5632 were electroporated into S. aureus strain RN4220 and 
pSK41 was subsequently introduced via conjugation. These strains were then used 
as donors in mobilization assays with the recipient strain S. aureus WBG4515. As 
shown in Table 2.2, pSK41 was found to mobilize pSK6877, containing its own 
cognate oriT sequence, at a frequency of 2.9 x 10-5, approximately five-fold lower 
than pSK41 itself transferred in the same assay (1.4 x 10-4). However, despite 
repeated efforts, mobilization of the plasmids containing the pSK156 or pCA347 oriT 
mimics was never detected. These results demonstrate that pSK41-encoded NES 
can mediate in trans mobilization of a plasmid containing a copy of its own oriT site, 
but suggest its activity on the variant oriT-like sites from pSK156 and pCA347 is 
inadequate to facilitate plasmid transfer in vivo.  As discussed below, an accessory 
protein may be required to complete relaxase-in trans transfer in vivo. 
 
Discussion 
Transfer of conjugative and mobilizable plasmids is a major route by which 
antimicrobial resistance propagates, but the lack of details about the mechanism of 
this process impedes efforts to slow or prevent the spread of such resistance. We 
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focus on the mechanism of action of the NES relaxase enzyme encoded by pSK41 
and related plasmids from staphylococci. NES is a two domain protein where the C-
terminal domain is distinct from that which is normally paired with a relaxase domain. 
Rather than possessing a function important to the conjugation process such as a 
helicase, NES does not seem to possess any catalytic activity but was previously 
shown to be essential for successful conjugation (25). Here we show that the C-
terminal domain is important for the strand-transfer (ligation) function but not 
cleavage activity of NES (Figure 2.2). It is likely that the increase in DNA strand 
transfer causes DNA to be ligated before transfer is complete. It has been suggested 
that the ligation action of single-tyrosine relaxases such as NES requires homo-
dimerization, which could be mediated by the C-terminal domain. Alternatively, 
although we have not measured the DNA binding ability of the C-terminal domain, it 
could play a role in DNA sequence discrimination to ensure ligation only occurs to 
the 3’ end of the T-strand rather than any DNA blunt end it encounters. 
Formation of a DNA hairpin in the pSK41 oriT and the importance of the 
associated NES Hairpin Loop 1 and 2 had been suggested previously (7). We 
demonstrate here that NES Hairpin Loops 1 and 2 are important for proper DNA 
cleavage and strand transfer (Figure 2.3C and D) but not for DNA binding (Figure 
2.3A). The large increase in DNA strand transfer causing DNA to be ligated before 
transfer is complete is likely the biggest contributor to the large reduction of plasmid 
transfer seen when either Hairpin Loop 1 or Loop 2 are eliminated from the encoded 
NES enzyme (7). It is also likely that accessory proteins in the pSK41 relaxosome 
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complex with NES through interactions with the NES Hairpin Loop 1 and 2, 
amplifying the effect of loss of these protein features. 
Because relaxases are essential for transfer, share many common features, 
and are unique to the conjugative plasmid system, they represent a novel 
therapeutic target for decreasing the spread of antimicrobial resistance to allow 
current antimicrobial compounds to maintain efficacy. As explored previously and 
continued in Chapter 3, there are two potential sites of disruption common to 
relaxases: the metal binding site and specific protein-DNA interactions (7, 27). 
These results validate the NES Hairpin Loop 1 and 2 DNA interactions as a target 
site for such therapeutics. By disrupting the specific protein-DNA interactions in the 
NES Hairpin Loops, a molecule such as a sequence-specific polyamide could 
specifically disrupt cleavage and religation during pSK41 conjugation (7). As there 
seems to be some sequence conservation at the base of the DNA hairpin, this 
inhibitor molecule could target mobilizable plasmids in addition to the conjugative 
plasmid. Interestingly, there is a biological example of relaxase interference from 
Staphylococcus epidermidis strains carrying a CRISPR spacer that matches the nes 
gene of pSK41 and limits conjugative transfer (28). Targeted disruption of 
conjugation after initiation of the process and formation of the mating pore could 
cause cell death specifically in conjugative plasmid containing bacteria. This 
targeted approach to bactericidal compounds is desirable as we learn more about 
the importance of the human skin microbiome (29). 
Despite the importance of the protein-DNA interactions at the DNA hairpin, 
we show that there is some flexibility in the DNA hairpin sequence allowing 
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sequences from pSK156 and pCA347 to be processed by NES. The origin-of-
transfer-mimic sequences of pSK156 and pCA347 maintain all but one or two 
protein-DNA contacts, respectively, and are able to be bound, cleaved, and ligated 
by NES, although with altered efficiency. We were therefore somewhat surprised to 
find that plasmid constructs containing pCA347 or pSK156 oriT mimics could not be 
mobilized from cells harboring pSK41 co-resident, in contrast to a pSK41 oriT 
construct. However, the analogous relaxase-in trans mobilization phenomena 
recently described for the distinct pWBG749-like conjugative plasmids provide a 
precedent that likely explains this apparent paradox. Namely, pWBG749 oriT-like 
sequences exist as sub-types differentiated by sequence divergence in an inverted 
repeat (IR2) located adjacent to the nic site-containing core sequence (18). This 
results in specificity between various mobilizable plasmids and particular pWBG749-
like conjugative plasmids. Thus, pWBG749 can mobilize plasmids with a pWBG749-
like oriT of sub-type OT49 but not those carrying an OT45 sub-type, which instead 
can be mobilized by pWBG749-like conjugative plasmids that possess a cognate 
OT45 sub-type oriT (18). Despite this, pWBG749 was able to stimulate 
recombination between OT49- and OT45-type oriT sequences carried on the same 
mobilizable plasmid, indicating that the pWBG749 relaxosome could recognize the 
OT45-type oriT even though it can’t mediate transfer of that sub-type (18). By 
analogy, it would seem plausible that the pSK156 and pCA347 oriT-mimics 
examined here represent sub-types of pSK41-like oriTs that can be recognized by 
NES but cannot be mobilized by the pSK41 relaxosome. In the case of the 
pWBG749 system, it has been shown that specificity for IR2 sub-types is dictated by 
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a small putative DNA-binding accessory protein, SmpO, encoded adjacent to the 
oriT on pWBG749, rather than the relaxase SmpP (18), The involvement of 
accessory proteins in the pSK41 relaxosome is yet to be established. 
Importantly, the scenario proposed above implies the existence of pSK41-like 
conjugative plasmids with variant oriT sequences that would be capable of 
mobilizing plasmids such as pSK156, pCA347 and other plasmids listed in Appendix 
2. Although no such variant pSK41-like plasmids have been detected to date, the 
presence of variant pSK41-like oriT mimic sequences on one fifth of all sequenced 
staphylococcal plasmids (not including pSK41-like plasmids themselves) makes the 
whereabouts of such a reservoir an important question, since it is clearly influencing 
the evolution of plasmids in clinical staphylococci.  
Interestingly, the origin-of-transfer-mimic sequence found in pCA347 is 
identical to a sequence found in pWBG757, a plasmid that could not be mobilized 
with pWB749 in the studies by O’Brien and colleagues (17). Comparative data such 
as this may allow us to classify mobilizable plasmids into families related to 
relaxase(s) used for trans-mobilization. The origin-of-transfer-mimic sequence of 
pSK156 is also found in plasmid pWB747, which could be mobilized by pWBG749, 
suggesting pWBG747 harbors two distinct origin-of-transfer sequences to maximize 
its ability to be transferred (17, 18).  
 We searched the sequenced staphylococcal plasmids for other pSK41 oriT-like 
sequences and found 85 sequences from 83 different plasmids, including 14 pSK41-
family conjugative plasmids (Appendix 1). This represents 23.6% of Staphylococcus 
plasmids which is significantly lower than the 53% of plasmids O’Brien et al. 
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identified as harboring the pWBG749 oriT-like sequence (18). However, the set 
identified here includes 26 plasmids that do not have a pWBG749 oriT sequence, 
suggesting NES is an important factor in the relaxase-in trans conjugation 
mechanism.  
 Analysis of all 85 sequences shows that oriT sequences identical to that of 
pSK41 are only evident on plasmids which encode their own NES protein. On other 
plasmids, the pCA347 and pSK156 hairpin sequences with their one-nucleotide 
difference are by far the most common oriT mimic, representing 73% of the 
sequences (Appendix 2). The other two major pSK41 oriT-mimic types are 
significantly different in sequence but are still predicted to form a DNA hairpin which 
will allow for most of the NES protein-DNA interactions seen with the pSK41 oriT to 
be maintained, again suggesting that these specific protein-DNA interactions may be 
a potential therapeutic target. It is likely that that NES proteins are capable of acting 
on a wide range of non-conjugative staphylococcal plasmids that contain an oriT 
mimic sequence, ranging from the oldest known multidrug resistance plasmid 
pSK156 to prevalent contemporary plasmids such as pMW2 and pUSA300HOUMR. 
The results described here imply that the recently described relaxase in-trans 
mechanism of mobilization extends beyond pWBG749-like conjugative plasmids to 
the clinically more prevalent pSK41-like plasmids, thereby further increasing the 
proportion of staphylococcal plasmids that are potentially mobilizable. These 
observations lend further weight to the recent proposal that relaxase-in trans 
mobilization represents a significant driver of horizontal transfer in Staphylococci 
(18).  
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Figure 2.1. Structure of NES Relaxase Domain and pSK41 oriT 
A. Structure of the NES relaxase domain in complex with DNA from the pSK41 
origin of transfer (4HT4, 13). The NES Hairpin Loop 1 is shown in yellow and NES 
Hairpin Loop 2 in green. 
B. Hairpin Loop 1 (yellow) of NES binds in the minor groove of the DNA hairpin 
formed by the pSK41 origin of transfer while Hairpin Loop 2 (green) binds to the 
major groove. 
C. Schematic of the pSK41 oriT and the oligonucleotides used in these studies. 
When only black portion is used, the oligo is referred to as OriTHP30. When the 
sequence is extended to include the orange portion it is referred to as OriTHP35, the 
teal as OriTHP40, and the purple as OriTHP45. 
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Figure 2.2. Cleavage and Strand Transfer by Relaxase Domain and Full-length 
NES. 
A. Effect of oligonucleotide length on cleavage by NES 1-220 (relaxase domain) 
and NES 1-665 (full-length) protein.  
B. Effect of oligonucleotide length on strand transfer by NES 1-220 (relaxase 
domain) and NES 1-665 (full-length) protein.  
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Figure 2.3. Functional Analysis of NES Loop Deletion Mutants 
A. KD ± standard deviation of DNA binding measured by fluorescence anisotropy for 
the indicated pSK41 oligonucleotides and NES mutants. 
B. Schematic of the DNA cleavage and strand transfer assays. DNA cleavage 
assays involve only the red DNA substrate labeled with a 5’ 6-FAM. DNA strand 
transfer assays involved both the red and black DNA substrate with the red 
substrate being unlabeled and the black substrate being 5’ 6-FAM labeled. 
C.  Functional analysis of cleavage activity of NES mutants on varying pSK41 
oligonucleotides. Wild-type data is the same as that presented in Figure 2.2A. 
D. Functional analysis of strand transfer activity of NES mutants on varying pSK41 
oligonucleotides to mimic religation during conjugative plasmid transfer. Wild-type 
data is the same as that presented in Figure 2.2B. 
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Figure 2.4. Modeled Structure of the pSK41, pSK156, and pCA347 oriTs 
A. Schematic of the pSK41, pSK156, and pCA347 oligonucleotides used in these 
studies. Colored nucleotides indicate a difference in sequences from the pSK41 oriT. 
B. The relaxase domain of NES in complex with the pSK41 oriT. The box shows the 
region focused on for Figure 2.4C, D and E. 
C. Contacts between the NES relaxase domain Hairpin Loop 1 and 2 amino acids 
and the pSK41 oriT nucleotide. 
D. Contacts between the NES relaxase domain Hairpin Loop 1 and 2 amino acids 
and the modeled pSK156 oriT nucleotide. Green nucleotides differ from the pSK41 
oriT.  
E. Contacts between the NES relaxase domain Hairpin Loop 1 and 2 amino acids 
and the modeled pCA347 oriT nucleotide. Gold nucleotides differ from the pSK41 
oriT.  
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Figure 2.5. NES Processing of pSK41, pSK156, and pCA347 oriT 
Oligonucleotides 
A. KD ± standard deviation of DNA binding measured by fluorescence anisotropy for 
the pSK41, pSK156, and pCA347 oriTs. The pSK41 data is the WT NES data as 
presented in Figure 2.3A.  
B. Cleavage activity of the pSK41-encoded NES protein on the pSK41, pSK156, and 
pCA347 oriTs.  
C. Strand transfer activity of the pSK41-encoded NES protein on the pSK41, 
pSK156, and pCA347 oriTs.  
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pSK41	oriT-string	
	
cccaagcttAGCACGCGAACGGAACGTTCGCATAAGTGCGCCCTTACGGGATTTAACTAGAT
TATAACGGTAAAACTTGAATCTGTCAAACGAAggatccgc 
 
pSK156	oriT-string	
	
gatcggatccTTTTTCTTTCGACGCCGTATCGTCGATGTAATTCAAAAAAGTTATGGGCTAT
AAATCTACATCACTTTTTCAAGAATGTAGTAGCAATATTCAACGCAAATTAATTTTTATAAC
TGCTCGGAATATCTCAAGCCGTTTCTTTAATTTTGAAATAAAAAAAATCGACGAAGGTCGAT
TACGTTTTTGTACACGTCGATTTATCCGACGTATAAGTGCGCCCTTACGGGATTTAACTAGA
TTATAACGACGAATTTTAGACCTGTAAAGCAATggtaccaagcttggatccgatc 
	
pCA347	oriT-string	
	
gatcggatccTTTTTCTTTCGACGCCGTATCGTCGATGTAATTCAAAAAAGTTATGGGCTAT
AAATCTACATCACTTTTTCAAGAATGTAGTAGCAATATTCAACGCAAATTAATTTTTATAAC
TGCTCGGAATATCTCAAGCCGTTTCTTTAATTTTGAAATAAAAAAATCGACGAAGGTCGATT
ACGTTTTTGCACATGTCGATTTATCCGACGTATAAGTGCGCCCTTACGGGATTTAACTAGAT
TATAACGACGAATTTTAGACCTGTAAAGCAATggtaccaagcttggatccgatc 
	
	
Figure 2.6. Nucleotide Sequences for in vivo Transfer Assays  
Nucleotide sequences of the GeneArt Strings (Invitrogen) encompassing the oriT 
regions of plasmids pSK41 (GenBank Acc. AF051917, nt 10189-10273), pSK156 
(GenBank Acc. GQ900448, nt 13396-13126) and pCA347 (GenBank Acc. 
CP006045, nt 3825-4094). Sequences in lower case were added to the DNA 
fragments to facilitate cloning and the BamHI and HindIII restriction sites used are 
underlined. Sequence in bold correlates to the oligonucleotide oriTs shown in Fig. 
2.4A.	
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Table 2.1. Bacterial Strains and Plasmids Used in This Study 
 
Strain or 
plasmid 
Descriptiona Reference or 
source 
   
Escherichia coli  
DH5a F- endA hsdR17 supE44 thi-1 l- recA1 gyrA96 relA1 f80 
dlacZDM15 
Bethesda Research 
Laboratories 
BL21(DE3) F- ompT hsdSB (rB- mB-) dcm gal l(DE3) Novagen 
   
Staphylococcus aureus  
RN4220 Restriction-deficient derivative of NCTC8325-4 Kreiswirth et al., 1983 
SK5428 SK982 harboring pSK41 Lyon et al., 1984 
WBG541 SmR/NbR derivative of NCTC8325-4 Townsend et al., 1983 
WBG4515 FsR/RfR derivative of NCTC8325-4 Townsend et al., 1983 
   
Plasmids   
pSK41 GmR, TbR, KmR, NmR, tra+, conjugative multiresistance 
plasmid 
Berg et al., 1998 
pSK5632 pSK1-based S. aureus (CmR)/E. coli (ApR) shuttle vector Grkovic et al., 2003 
pSK6877 pSK41 oriT-string cloned into HindIII and BamHI of 
pSK5632 
This study 
pSK6879 pCA347 oriT-string cloned into BamHI of pSK5632 This study 
pSK6881 pSK156 oriT-string cloned into BamHI of pSK5632 This study 
 
a SmR, streptomycin resistance; NbR, novobiocin resistance; FsR, fusidic acid resistance; RfR, rifampin 
resistance; GmR, gentamycin resistance; TbR, tobramycin resistance; KmR, kanamycin resistance; 
NmR, neomycin resistance; CmR, chloramphenicol resistance; ApR, ampicillin resistance; tra+ 
conjugative transfer genes. 
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Table 2.2. Relaxase-in trans Mobilization of Plasmids Containing oriT Sites 
	
	 	 Transfer	frequency
*	
Plasmid	 oriT	site	 pSK41	 	 pSK5632	derivative	
pSK5632	 none	 9.9	x	10-5	 	 Not	detected	
pSK6877	 pSK41	 1.4	x	10-4	 	 2.9	x	10-5	
pSK6879	 pCA347	 6.6	x	10-5	 	 Not	detected	
pSK6881	 pSK156	 8.7	x	10-5	 	 Not	detected	
*	Transfer	frequencies	are	presented	as	per-donor	frequencies	and	are	the	average	of	three	experiments.	
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CHAPTER 3: INHIBITION OF NICKING ENZYME IN STAPHYLOCOCCI (NES) 
 
Introduction 
	 Conjugative plasmid transfer (CPT) is the predominant mechanism through 
which antibiotic resistance spreads in human pathogens (1). There is a great need to 
understand the mechanism of CPT in different bacterial and plasmid systems and 
use that knowledge to design ways to specifically target resistant bacteria or prevent 
the future spread of that resistance. As the initiator of CPT and a highly conserved 
element, the relaxase is an attractive target for such work (1). Indeed, inhibitors for 
relaxase proteins have been previously characterized, although they have not shown 
the desired efficacy in vivo (2).  
The enzyme of interest is NES, the relaxase on the plasmid pSK41. We hope 
that by targeting the relaxase, we might design inhibitors that have one of two 
effects. First, by inhibiting the relaxase and disrupting CPT, the inhibitor might have 
a specific antibiotic effect against bacteria containing the relaxase-encoding plasmid. 
CPT is a tightly regulated process that involves opening a pore (the type 4 secretion 
system discussed in Chapter 1) between two bacterial cells as well as modulating 
the form of resistance-encoding DNA (double-stranded plasmid to single-stranded T-
strand back to a double-stranded plasmid as described in Chapter 1). Thus, 
disruption of this process and specifically, DNA processing is likely to trigger key 
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regulatory mechanisms such as those responding to increased amounts of free DNA 
ends and may lead to cell death. Second, if the inhibitor does not have an antibiotic 
effect, by disrupting CPT, we might eliminate plasmid-encoded resistances from that 
bacterial population. Since many humans are permanently colonized with S. aureus, 
eliminating resistances from their infections and/or colonizing microbes would 
decrease the likelihood of future resistant infections and transfer of resistance to 
other colonizers (3). The benefit to this mechanism is that bacteria are unlikely to 
develop resistance to such treatments quickly.  
NES is a single-tyrosine relaxase that uses several key features to bind and 
cleave the DNA found in the origin-of-transfer (oriT) of pSK41. The first feature is 
two protein loops, Hairpin Loop 1 and 2, that form contacts with the DNA hairpin 
formed upstream of the nic site in the oriT. The role of these protein loops in NES 
function is analyzed in Chapter 2 and they are shown to be essential for proper 
cleavage and ligation of DNA. Therefore, we set out to characterize pyrrole-
imidazole (Py-Im) polyamides inhibitors which can be designed to bind GC-rich 
sequences with high affinity in order to disrupt protein-DNA interactions in this region 
(4, 5). 
Another important region for NES function is the HUH-motif that binds a 
divalent metal ion and is important for coordination of the phosphate backbone of the 
oriT DNA prior to cleavage (Chapter 1). Edwards et al. showed that without a metal 
bound in this position, NES is unable to cleave DNA, suggesting that a small 
molecule that could specifically disrupt this metal coordination would inhibit NES 
function and CPT (6). The Cohen laboratory at University of California, San Diego, 
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has compiled a chelator fragment library (CFL) based on a variety of metal binding 
groups in order to facilitate fragment-based drug design (FBDD) against 
metalloenzymes such as NES (7). This approach is ideal for this system as we have 
not been able to develop a high-throughput screening (HTS) assay for relaxase 
activity and FBDD is a more efficient exploration of chemically diverse space that 
can lead to higher ligand efficiencies than traditional HTS methods (7). The refined 
library CFL-1.1 contains 96 metal chelators with two to four donor atoms for metal 
binding including picolinic acids, hydroxyquinolones, pyrimidines, hydroxypyrones, 
hydroxypyridinones, salicylic acids, hydroxamic acids, and sulfonamides (Figure 3.3, 
7, 8). We set out to characterize these compounds and their derivatives for the 
ability to disrupt the metal coordination of the HUH-motif of NES in order to disrupt 
NES function and therefore conjugative plasmid transfer.  
 
Materials and Methods2 
Polyamide Synthesis 
Polyamides were synthesized using microwave-assisted solid-phase 
synthesis on oxime resin as reported previously (9). Following cleavage from oxime 
resin, compounds were purified by preparative HPLC. The identity and purity of each 
polyamide were confirmed by MALDI-TOF and analytical HPLC analysis. Match 
Polyamide 1 ImβImPy-(R)α-NH2γ-PyβImPy-(+): MS (MALDI-TOF) calculated for 
																																																						
2 The Polyamide Synthesis, DNA Duplex Melting Temperature Analysis, and Polyamide Inhibition 
sections were previously published as a portion of the manuscript Edwards JS, Betts L, Frazier ML, 
Pollet RM, Kwong SM, Walton WG, Ballentine WK, Huang JJ, Habibi S, Del Campo M, Meier JL, 
Dervan PB, Firth N, Redinbo MR. 2013. Molecular basis of antibiotic multiresistance transfer in 
Staphylococcus aureus. Proceedings of the National Academy of Sciences of the United States of 
America 110:2804–2809. 
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C50H70N21O19 [M+H]+ 1108.6, found 1108.9. Mismatch Polyamide 2 ImImImPy-
(R)α-NH2γ-PyPyPyPy-(+): MS (MALDI-TOF) calculated for C56H72N23O9 [M+H]+ 
1210.6, found 1209.9. Polyamides were suspended in 100% DMSO at 10 mM and 
stored at -80°C. 
DNA Duplex Melting Temperature Analysis  
Melting temperature analysis was performed on a Varian Cary 100 
spectrophotometer equipped with a thermo-controlled cell holder possessing a cell 
path length of 1 cm. An aqueous solution of 10 mM sodium cacodylate, 10 mM KCl, 
10 mM MgCl2, and 5 mM CaCl2 at pH 7.0 was used as an analysis buffer. 
Oligonucleotides (0.1-mM stock solutions dissolved in 10 mM Tris·Cl, 0.1 mM EDTA, 
pH 8.0) were purchased from Integrated DNA Technologies. DNA duplexes and 
hairpin polyamides (1 or 2) were mixed to a final concentration of 1 μM and 1.2 μM, 
respectively, for each experiment. Before analysis, samples were heated to 90 °C 
and cooled to a starting temperature of 25 °C with a heating rate of 5 °C/min for 
each ramp. Denaturation profiles were recorded at λ = 260 nm from 25 °C to 90 °C 
with a heating rate of 0.5 °C/min. The reported melting temperatures were defined 
as the maximum of the first derivative of the denaturation profile and represent the 
average of two independent measurements. All melting temperature shifts (ΔTm) are 
calculated relative to a standardized naked control oligonucleotide. 
Polyamide Inhibition  
DNA cleavage assays were conducted in vitro with either the relaxase domain 
of NES (1–220) or the full-length (1-665) enzyme as described in Chapter 2. For 
polyamide inhibition, 2.5 μL of 20 μM OriTHP37 DNA substrate was incubated with 
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2.5 μL of polyamide at 20x the reaction concentration or 100% DMSO for 15 min. 
Each reaction contained 1 μL of the incubated DNA mixture in place of the 1 μL of 
DNA alone previously used. 
Chelator Fragment Library Synthesis  
 Most of the fragments in the CFL-1.1 were obtained from commercial sources 
(Sigma Aldrich, Acros). The remaining compounds (B10, D1, D2, D3, D5, D8, D9, 
D10, D11, D12, E3, E4, E5, E7, E8, E9, E10, E11, E12, and G6) were prepared as 
described in Agrawal et al. and Jacobsen et al. (7, 8). The 4HPT1 derivative library 
was synthesized as described in Agrawal et al. and Garner et al. using a microwave-
assisted synthetic procedure (7, 10). Each compound was suspended in 100% 
DMSO to a concentration of 50 mM (5mM for C10 and H1) and stored at 4°C. 
Chelator Fragment Library Inhibition  
DNA cleavage assays were conducted with full-length NES similarly as 
described in Chapter 2. Briefly, 1 μL 15.2 μM NES protein and 1 μL chelator at 10x 
the final chelator concentration or 100% DMSO were incubated in 7 μL EMSA buffer 
at room temperature for 15 minutes. 1 μL of 10 μM 5’-FAM labeled DNA substrate 
(OriTHP37- 5’-ACGCGAACGGAACGTTCGCATAAGTGCGCCCTTACGG-3’) was 
then added and the resulting reaction incubated at 37°C for 1 hour and quenched by 
the addition of 2X running buffer (0.01% xylene cyanol, 0.01% Bromophenol Blue, 
85% formamide, 20 mM EDTA, 2X TAE, 0.2% SDS). The resulting 20 μL reactions 
were run through a denaturing 16% polyacrylamide gel. 
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Results 
Polyamide Inhibition3 
The dependence of conjugative plasmid transfer of pSK41 on intact protein 
Loops 1 and 2 suggests the potential for inhibiting relaxase function and limiting the 
spread of antibiotic resistance genes through disruption of those NES-DNA 
interactions. This led us to investigate inhibition of NES by Py-Im polyamides, a 
class of sequence-specific minor-groove-binding compounds that can be 
programmed to bind GC-rich sequences with high affinity (Figure 3.1A, 11). Match 
polyamide 1 was designed to bind selectively to the 5’- GCGAA-3’ sequence 
contacted by the essential Loop 1 of NES (see Chapter 2, Figure 3.1A). As a control 
the activity of this compound was compared to a mismatch polyamide 2, which 
shows lower affinity for the 5’-GCGAA-3’ sequence (Figure 3.1A and B). The DNA 
cleavage activity of the relaxase 1-220 region of NES was eliminated by match 
polyamide 1 at 50 μM (Figure 3.2A). Interestingly, 2.5 to 50 μM concentrations of the 
mismatch control polyamide 2 caused a significant increase in product formation by 
the relaxase (Figure 3.2A). This result is similar to those obtained when the Loop 1 
and 2 regions of the relaxase were deleted (6). Taken together, these data indicate 
that, for the isolated relaxase domain, disrupting the protein-DNA interactions 
around the DNA hairpin can significantly shift the enzyme’s cleavage-religation 
equilibrium. This effect, however, is not seen when intact, 1-665 NES is used. 
																																																						
3 The Polyamide Inhibition section was previously published as a portion of the manuscript Edwards 
JS, Betts L, Frazier ML, Pollet RM, Kwong SM, Walton WG, Ballentine WK, Huang JJ, Habibi S, Del 
Campo M, Meier JL, Dervan PB, Firth N, Redinbo MR. 2013. Molecular basis of antibiotic 
multiresistance transfer in Staphylococcus aureus. Proceedings of the National Academy of Sciences 
of the United States of America 110:2804–2809. 
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With full-length 1-665 NES, mismatch polyamide 2 showed no significant 
effect, while the match polyamide 1 significantly reduced DNA cleavage activity at 25 
μM and eliminated activity at 50 μM (Figure 3.2B). The difference between the 
relaxase and full-length results is likely a result of the C-terminal domain regulation 
as explored in Chapter 2. A closer examination of NES inhibition by concentrations 
of match polyamide 1 between 5 and 50 μM produced inhibition curves and IC50 
values of 18 and 21 μM for the full-length and relaxase regions of NES, respectively 
(Figure 3.2C). Thus, full-length NES is inhibited by a polyamide targeted to the 
hairpin minor groove DNA sequence and is resistant to the effects of the non-
specific polyamide. Taken together, these results confirm that full-length NES acts in 
a manner distinct from the isolated relaxase with respect to catalytic activity, as well 
as confirming the importance of the DNA hairpin-NES Loop 1 interaction explored in 
Chapter 2. The data also suggest that with further development, small molecules 
capable of inhibiting NES-DNA interactions could disrupt NES function to prevent 
antibiotic resistance transfer.  
Fragment-Based Chelator Inhibition 
Chelator Fragment Library-1.1 
Previous data both with NES and other relaxases have shown that the metal 
coordinated by the HUH motif is essential for relaxase nicking (6, 12, 13). Therefore, 
we set out to identify chelator based inhibitors of NES from the Chelator Fragment 
Library-1.1 (CFL-1.1) introduced in Agrawal et al. and refined in Jacobsen et al (7, 
8). The Cohen lab provided CFL-1.1, a 96 compound library that was screened at 
100 μM for effects on NES cleavage to identify the most promising candidates 
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(Figure 3.3, 3.4). Previous screens with this library have been conducted at 1 mM 
but even with the more stringent requirement of 60% inhibition at 100 μM, we 
identified 17 hits for a 17.7% hit rate. 
Compounds in this library are arranged into lettered sets which share the 
same core structure, usually an aromatic ring component (Figure 3.3). At 100 μM, 
the A compounds, picolinic acids, showed varying efficacy ranging from no 
significant effect (A2, A3, A4, A6, A7, A9, A11, A12) to 100% inhibition (A8, Figure 
3.4A). Compounds A1 (71% inhibition), A5 (61% inhibition), A8 (100% inhibition), 
and A10 (62% inhibition) were chosen for further characterization. The B 
compounds, quinolones, also showed varying efficacy ranging from no significant 
effect (B5, B8, B9, B11) to a 75% reduction in activity (B12, Figure 3.4B). 
Compounds B2 (73% inhibition), B10 (66% inhibition), and B12 (75% inhibition) were 
chosen for further characterization. While two C compounds, pyrimidines, showed 
statistically significant decreases in NES activity, only one compound showed 
efficacy above the 60% inhibition threshold for future analysis (Figure 3.4C). Inhibitor 
C5 showed a 79% reduction in enzyme activity and moved forward for further 
characterization. None of the D compounds, hydroxypyrones, exhibited efficacy 
above the 60% inhibition threshold; the most potent compound, D2, showed on a 
52% reduction in enzyme activity (Figure 3.4D). The E compounds, 
hydroxypyridinones, showed varying efficacy ranging from no effect (E1, E3, E4, E5, 
E6, E8, E9, E10) to an 87% reduction in activity (E7, Figure 3.4E). Compounds E2 
(85% inhibition), E7 (87% inhibition), E11 (60% inhibition), and E12 (82% inhibition) 
were selected for further characterization. The F compounds, salicylic acids, showed 
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very poor efficacy with only F9 showing a decrease in activity greater than the 
DMSO control (p=0.0061) and none showing a reduction in activity of 60% or greater 
(Figure 3.4F). The G compounds, miscellaneous structures, were the most effective 
class with G3 showing 100% inhibition, G6 and G7 showing 93% and 91% inhibition 
respectively, and G10 showing a 65% reduction in activity (Figure 3.4G). Finally, the 
H compounds, also miscellaneous, showed poor activity with only H1 (62% 
inhibition) showing statistically significant reduction in NES activity beyond the 
effects of DMSO (p=0.0095, Figure 3.4H).  
The compounds chosen for future study were screened at 0.1, 1, 10 and 100 
μM. Compounds A1, A5, A8, and A10 are shown in Figure 3.5A. Only Inhibitor A8 
showed efficacy at 10 μM with a 48% reduction in activity that was not statistically 
significant compared to DMSO treatment. Compounds B2, B10, B12, and C5 did not 
show efficacy at 10 μM or lower concentrations (Figure 3.5B). B10 did show a slight 
decrease in activity but did not reach significance. Inhibitor E2 exhibited a 77% 
reduction in activity at 10 μM as well as small but significant effects at 1 and 0.1 μM 
(Figure 3.5C). This prompted further characterization of this backbone via 
derivatization. Despite E7’s 87% reduction in NES activity at 100 μM, it showed only 
a 57% reduction at 10 μM and no significant effect at 0.1 and 1 μM (Figure 3.5C). 
However, because of its backbone similarity to E2 and efficacy at 10 μM, we chose 
to move forward with derivatization of this compound as well. E11 and E12 did not 
show efficacy in reducing enzyme activity at 10 μM and therefore were not 
considered for further characterization (Figure 3.5C). Compounds G3, G6, and G7 
were the most promising compounds screened; they showed a 93%, 79% and 80% 
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reduction in activity, respectively (Figure 3.5D). G3 and G6 showed modest but 
significant effects at 1 μM and only G7 exhibited an effect, although not significant, 
at 0.1 μM. Despite these results, G3, G6, and G7 were not considered for further 
derivatization as previous work has shown them to be a general chelator of metals 
from all protein. Therefore, without attaching an additional fragment to target the 
molecule to NES, treatment with these compounds would cause major side effects 
both for the S. aureus being treated as well as the infected host. Compounds G10 
and H1 did not exhibit significant inhibitory effects at 10 μM and therefore were not 
considered for further characterization.  
HPT1 Library 
Derivatives of E7 make up the HPT1 library shown in Figure 3.6. To test for 
increased efficacy, these 7 compounds were screened in NES cleavage assays at 
0.1, 1, 10, and 100 μM. The 4HPT1.C7 compound showed increased efficacy at 100 
μM where it eliminated NES cleavage activity (Figure 3.6B). However, while NES 
cleavage activity was significantly reduced at 0.1, 1, and 10 μM, it did not show a 
dose dependent reduction suggesting 4HPT1.C7 is not an effective inhibitor. 
4HPT1.F11 was more effective in decreasing NES cleavage activity at 100 μM than 
the parent E7 compound; however, it did not show any effect on activity at 10 μM 
and caused an increase in activity at 0.1 and 1 μM. Larger derivatives 4HPT1.C10, 
4HPT1.E6, 4HPT1.F1, 4HPT1.F3, and 4HPT1.F9 showed decreased efficacy at 100 
μM as compared to E7, with 4HPT1.F1 having no effect on NES cleavage (Figure 
3.6B and C). We conclude that derivatization of E7 will not increase the efficacy of 
inhibitors against NES activity. 
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DMD Library 
The DMD library is composed of derivatives of the E2 compound with the 
structures and names as shown in Figure 3.7A. We screened these 5 derivatives at 
0.1, 1, 10, 50, and 100 μM for increased efficacy as compared to the parent E2 
compound. All compounds in the DMD library eliminated NES activity at 100 μM and 
were moderately more effective at 50 μM, although the reduction in activity beyond 
that of E2 did not reach significance (Figure 3.7B). All of the DMD compounds 
maintained efficacy at 10 μM but only DMD-11 was more effective than E2, although 
again not reaching significance (Figure 3.7B). At 0.1 and 1 μM, none of the DMD 
library compounds showed a significant reduction in activity. However, the modest 
reduction in activity caused by DMD-14 was significant when compared to E2 and 
DMD-13 showed a significant increase in activity. The efficacy of these CFL 
compounds, especially DMD-11, supports previous data about the importance of the 
bound metal to relaxase function and is proof of principle that a chelating inhibitor is 
an effective modulator of relaxase activity. With further development such chelator 
fragments paired with other inhibitory or targeting fragments could be capable of 
selectivity inhibiting NES function to prevent antibiotic resistance transfer.  
 
Discussion 
Antibiotic resistance is largely spread among bacterial populations by 
conjugative plasmid transfer (14, 15). This transfer is facilitated by the relaxase 
enzyme which is often, but not always, encoded on the plasmid to be transferred. 
We focused on the NES relaxase enzyme encoded on the plasmid pSK41. Previous 
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characterization of this enzyme identified several regions essential for proper 
function of NES (Chapter 2, 6).  
One essential region is two protein loops (Loop 1 and Loop 2) that bind to the 
minor and major groove, respectively, of the hairpin formed by the pSK41 oriT DNA. 
We establish that disruption of the minor groove contacts with a polyamide inhibits 
NES activity in vitro (Figure 3.2). Minor-groove-targeted Py-Im match polyamide 1, 
designed to bind to the GC-rich DNA minor groove of the NES substrate hairpin, 
demonstrated IC50 values of 18 and 21 μM against the full-length and relaxase 
domain of NES, respectively, with respect to DNA cleavage. While it is possible that 
optimization of polyamide architecture and functionalization will yield organism-
specific uptake in S. aureus, these compounds may be able to bind similar DNA 
sites throughout the genome resulting in off-target effects. Indeed, we found that the 
minimum inhibitory concentration (MIC) of match polyamide 1 is 16 μM for cultured 
S. aureus.   
A second region essential for NES function is the HUH-motif and the bound 
divalent metal. We show that small molecule chelators successfully inhibit NES 
cleavage activity in vitro (Figure 3.4-3.7). Using CFL-1.1 we found 17 small 
molecules that show a 60% or greater reduction in NES activity at 100 μM (Figure 
3.4). Of these 17 hits, six compounds (A8, E2, E7, G3, G6, G7) also showed 
significant effects at 10 μM and were considered for further optimization. Due to their 
similarity, E2 and E7 were derivatized and screened for increased efficacy. E7 
derivatives did not show increased, dose-dependent efficacy. In addition, E7 and 
related compounds have been found to be potent inhibitors of other 
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metalloenzymes, suggesting it would have many off target effects in vivo (7, 8, 10). 
The best E2 derivative compound, DMD-11, has an estimated IC50 of 10 μM with 
respect to DNA cleavage. Further derivatization and screens for selectivity are 
needed to improve and verify the efficacy of this compound class. Despite concerns 
with other compounds tested against NES, compounds from CFL-1.1 have been 
shown to have high selectivity for their target proteins suggesting it is possible to 
develop E2 into a NES selective molecule (16).  
One path for optimization via fragment based drug design is to join a chelator 
fragment with an additional inhibitory element. Another essential region for DNA 
binding by NES is the guanine-26 nucleotide base that is buried in a cavity where it 
makes two hydrogen-bonding contacts with NES residues. This cavity is 
approximately 10 Å from the metal bound at the HUH-motif; thus, we hypothesize 
that a purine nucleotide or mimic linked to an optimized chelator fragment would 
yield a selective and efficient inhibitor of NES activity. A co-crystal structure or 
docking model of NES bound to E2 or DMD-11 would assist both with optimization of 
the metal binding group as well as designing the linker to a purine mimic. Thus far, 
crystal trials of the relaxase domain in complex with a shorter oriT DNA 
oligonucleotide and chelator fragment hits have yielded crystals with poor diffraction, 
the best diffraction being to 8 Å.  
Taken together, the data presented in this chapter confirm that inhibition of 
NES activity is possible via several different protein sites. Indeed, targeting NES 
activity as a means to limit DNA transfer has been seen in Staphylococcus 
epidermis strain RP62a which contains a functional CRISPR spacer targeting the 
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nes gene (17). This, in combination with the in vivo conjugative transfer data with 
mutant forms of NES presented in Chapter 1 and Edwards et al., suggests that both 
the polyamide and chelator inhibitors would serve as inhibitors of DNA transfer via 
their impact on NES function.  
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Figure 3.1. Polyamide Structure 
A. Structures of the Match Polyamide 1 and Mismatch Polyamide 2 
B. DNA thermal melting with polyamides. Shown is melting temperature (Tm) of the 
DNA duplex alone and with the Match and Mismatch Polyamides (1 and 2, 
respectively). The change in Tm is also indicated. One strand of the duplex oligo is 
shown, with the target sequence depicted in blue. 
This data was originally published in Edwards et al. (6)  
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Figure 3.2 Polyamide Impact on NES Activity  
A. Inhibition of NES relaxase in vitro with Match Polyamide 1 (black) and Mismatch 
Polyamide 2 (grey). Polyamides were dissolved in 5% DMSO. 
B. Inhibition of Full-length NES in vitro with Match Polyamide 1 (black) and Mismatch 
Polyamide 2 (grey). Polyamides were dissolved in 5% DMSO. 
C. Eighteen- and 21-μM IC50 values of the Match Polyamide 1 for the full-length and 
relaxase forms of NES, respectively. 
This data was originally published in Edwards et al. (6)
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Figure 3.3. Chelator Fragment Library- 1.1 (CFL-1.1) 
Structures of all fragments in CFL-1.1. Each row corresponds to a metal binding group class: picolinic acids (A), 
quinolones (B), pyrimidines (C), hydroxypyrones (D), hydroxypyridinones (E), and salicylic acids (F). Compounds in 
row G and H are miscellaneous.  
A1	 A2	 A3	 A4	 A5	 A6	 A7	 A8	 A9	 A10	 A11	 A12	
B1	 B2	 B3	 B4	 B5	 B6	 B7	 B8	 B9	 B10	 B11	 B12	
C1	 C2	 C3	 C4	 C5	 C6	 C7	 C8	 C9	 C10	 C11	 C12	
D1	 D2	 D3	 D4	 D5	 D6	 D7	 D8	 D9	 D10	 D11	 D12	
E1	 E2	 E3	 E4	 E5	 E6	 E7	 E8	 E9	 E10	 E11	 E12	
F1	 F2	 F3	 F4	 F5	 F6	 F7	 F8	 F9	 F10	 F11	 F12	
G1	 G2	 G3	 G4	 G5	
G6	 G7	 G8	
G9	 G10	 G11	 G12	
H1	 H2	 H3	 H4	 H5	 H6	 H7	 H8	 H9	 H10	 H11	 H12	
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Figure 3.4. 100µM Screen of CFL-1.1 
A. Effect of compounds A1-A12 on NES cleavage product formation. 
B. Effect of compounds B1-B12 on NES cleavage product formation. 
C. Effect of compounds C1-C12 on NES cleavage product formation. 
D. Effect of compounds D1-D12 on NES cleavage product formation. 
E. Effect of compounds E1-E12 on NES cleavage product formation. 
F. Effect of compounds F1-F12 on NES cleavage product formation. 
G. Effect of compounds G1-G12 on NES cleavage product formation. 
H. Effect of compounds H1-H12 on NES cleavage product formation. 
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Figure 3.5. Chelator Impact on NES Cleavage Product Formation 
A. Effect of compounds A1, A5, A8, and A10 at 0.1, 1, 10, and 100 µM on NES 
cleavage product formation. 0 µM data is DMSO control and p-values are calculated 
against this control. 
B. Effect of compounds B2, B10, B12, and C5 at 0.1, 1, 10, and 100 µM on NES 
cleavage product formation. 0 µM data is DMSO control and p-values are calculated 
against this control. 
C. Effect of compounds E2, E7, E11, and E12 at 0.1, 1, 10, and 100 µM on NES 
cleavage product formation. 0 µM data is DMSO control and p-values are calculated 
against this control. 
D. Effect of compounds G3, G6, G7, G10, and H1 at 0.1, 1, 10, and 100 µM on NES 
cleavage product formation. 0 µM data is DMSO control and p-values are calculated 
against this control. 
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Figure 3.6. HPT1 E7 Derivative Library 
A. Structures of E7 derivatives for the HPT1 Library 
B. Effect of compounds 4HPT1.C7, 4HPT1.C10, and 4HPT1.E6 at 0.1, 1, 10, and 
100 µM on NES cleavage product formation. Indicated p-values are calculated with 
reference to the E7 reaction. 
C. Effect of compounds 4HPT1.F1, 4HPT1.F3, 4HPT1.F9, 4HPT1.F11 at 0.1, 1, 10, 
and 100 µM on NES cleavage product formation. Indicated p-values are calculated 
with reference to the E7 reaction. 
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Figure 3.7. HPT1 E2 Derivative Library 
A. Structures of E2 derivatives for the DMD Library 
B. Effect of compounds DMD-10, DMD-11, DMD-13, DMD-14, and DMD-15 at 0.1, 
1, 10, and 100 µM on NES cleavage product formation. Indicated p-values are 
calculated with reference to the E2 reaction. 
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS FOR 
CHARACTERIZATION OF pSK41 AND ITS RELAXASE, NES 
 
Conclusions 
 The Redinbo lab has had a long-lasting interest in conjugative plasmid 
transfer (CPT) and the previous three chapters present work characterizing the 
plasmid pSK41 and its relaxase, NES. Specifically, initial characterization conducted 
with the relaxase domain of NES by Jon Edwards has been extended to 
characterization of the full-length protein. As discussed in Chapter 2, the C-terminal 
domain of NES functions as a regulator of the relaxase domain as opposed to the 
independent function of most relaxase-associated C-terminal domains.  In addition, 
NES protein Hairpin Loops 1 and 2 are established as important features for proper 
DNA cleavage and religation, but not DNA binding. Having confirmed the importance 
of this protein-DNA interaction, the importance of the DNA sequence that these 
protein loops contact was then analyzed and it was noted that NES is able to 
process variant hairpins found in the oriTs of the plasmids pSK156 and pCA347 in 
vitro. While this relaxase-in trans mechanism had previously been shown for the 
pWBG749 family of plasmids in S. aureus, this work suggests that other plasmid 
families including pSK41 likely utilize the same system to facilitate conjugation of 
plasmids that were previously considered non-conjugative. Chapter 3 takes 
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advantage of protein regions that were noted as important in Chapter 1 and 2 in 
order to design inhibitors of NES activity. We hope this work will lead to drugs that 
will decrease the spread of antibiotic resistance in S. aureus communities. These 
experiments have also spurred several additional questions about how NES 
facilitates conjugative plasmid transfer not only of pSK41, but also of pSK156 and 
pCA347. These additional hypotheses are explored below. 
Future Directions 
Formation of the DNA Hairpin 
 Chapter 2 establishes that the protein-DNA contacts formed to the DNA 
hairpin just upstream of the nic site of the oriT are important for proper DNA 
cleavage and religation (strand transfer) by NES (Figure 2.3). However, it has not 
been established when during CPT the inverted repeats of the oriT form this DNA 
hairpin in vivo. While this is difficult to directly measure in vivo, NES activity in vitro 
on DNA with and without the hairpin would further establish when the hairpin is 
essential and therefore, when it is likely to form. An ideal experiment would be to 
compare binding, cleavage, and strand transfer rates between identical linear and 
annealed, hairpin forms of the oriT sequence. Because hairpin formation is favorable 
when the DNA is not in its double-stranded form, it may be difficult to obtain a clean 
linear portion so an alternative approach is to test oligonucleotides with a disrupted 
DNA hairpin (altered bases in the inverted repeats), no hairpin (a short 
oligonucleotide that starts directly after the hairpin), and with only the second 
inverted repeat closest to the nic site (Table 4.1). Edwards et al. showed that 
oligonucleotides with shortened or eliminated first inverted repeats (the inverted 
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repeat furthest from the nic site) were not able to out-compete binding of the full oriT 
sequence to the relaxase domain of NES (1). However, an oligonucleotide with a 
scrambled first inverted repeat was able to bind to the relaxase domain, even in the 
presence of the wild-type oriT oligonucleotides. If a similar trend holds true in direct 
binding experiments with the full-length NES protein, it would suggest that hairpin 
formation is not required for binding of NES and initiation of CPT but that it is 
important that the full length of both inverted repeats be exposed in a single-
stranded form.  
Similar cleavage and strand transfer experiments will characterize the 
importance of hairpin formation in those steps of CPT as well. Preliminary cleavage 
studies of oligonucleotides with a disrupted DNA hairpin (altered bases in the 
inverted repeats), no hairpin (a short oligonucleotide that starts directly after the 
hairpin), and with only the second inverted repeat (half hairpin) suggest that NES is 
able to cleave these oligonucleotides but with increased rates as seen in the loop-
deletion mutations of the NES enzyme (Figure 4.1). However, cleavage rates are 
necessarily dependent on binding so it is also important to know binding affinities for 
each oligonucleotide before drawing conclusions. A full analysis of binding, 
cleavage, and strand transfer will help form a model for hairpin formation upon which 
further experiments can build. As we learn more about pSK41 and CPT, it will also 
be important to consider how other MOB proteins might influence hairpin formation. 
Characterization of the pSK41 Relaxosome 
 Chapter 2 demonstrates that in vitro NES is able to bind, cleave, and ligate 
oriT DNA from plasmids pSK156 and pCA347 (Figure 2.5). However, in in vivo 
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conjugation assays, NES and the other MOB genes encoded on pSK41 were not 
able to facilitate transfer of plasmids containing the pSK156 or pCA347 oriT 
(Chapter 2 Table 2.2). We hypothesize that this is because an accessory protein is 
required that differentiates between different sub-types in the pSK41 family and this 
accessory protein encoded on pSK41 is incongruent with the pSK156 and pCA347 
oriTs. This relaxase-in trans conjugation system was first shown for the plasmid 
pWBG749 and O’Brien et al. showed that a small putative DNA-binding accessory 
protein, SmpO, is responsible for differentiating sub-types of plasmids containing 
pWBG749-like oriT sequences (2, 3). NES is the only protein in the pSK41 
relaxosome that has been characterized so it is difficult to hypothesize what this 
accessory protein might be for the pSK41 system. Homolog models and preliminary 
work by the Redinbo lab have identified pSK41 proteins Orf86 and Orf90 as putative 
DNA binding proteins so they are candidates for this accessory protein but there are 
likely other candidates in the Orf and Tra regions of pSK41. Systematic 
characterization of the MOB genes of pSK41 will not only aid in identifying this 
accessory protein, but will also reveal additional information about the conjugation 
process.  
Optimization of Chelator Fragment Inhibitors 
 Data presented in Chapter 3 characterizes preliminary NES inhibitors from a 
chelator fragment library and proposed optimization of these inhibitors via 
attachment of a guanine-mimic to block binding of the uniquely positioned nucleotide 
Gua-26 in the pSK41 oriT. Edwards et al. showed that oriT DNA with an abasic site 
at position 26 was cleaved at an increased rate by the NES relaxase domain and the 
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structure revealed the pocket in which this nucleotide specifically binds (Figure 4.2, 
1). Further basic characterization of this DNA-protein interaction in the context of the 
full-length protein will provide insight on how to optimize a small molecule to bind in 
this pocket. Binding, cleavage, and strand transfer assays with DNA containing an 
abasic site in place of Gua-26 with the full-length NES protein will serve as a proof of 
principle that disruption of this interaction will have a significant effect on NES 
function. If we are able to identify a small molecule that targets this position, the 
effects will likely mimic the NES activity seen with the abasic site DNA. The chelating 
inhibitors could even be tested in this system to further explore the combination 
approach before synthesis of new small molecules. 
 There are also several mutations that would produce clashes between the 
newly introduced side chain and the guanine nucleotide. M3W, G90L, and N93M 
mutations will introduce larger side chains that will likely disrupt the binding pocket 
into which the guanine nucleotide normally sites. The clashed formed by M3W is 
shown in Figure 4.3. This will again serve as a proof of principle that disruption of 
proper guanine binding will have a significant effect on NES function. In addition, it 
will provide information on the flexibility of this binding site and parts of the binding 
pocket that it will be beneficial to disrupt.  
 An effective inhibitor of the Gua-26 binding pocket will need to have a high 
binding affinity in order to bind prior to DNA binding or outcompete the Gua-26 
nucleotide. As shown in Figure 4.2, there are several contacts formed between NES 
and the Gua-26 nucleotide. While most of the contacts are to backbone oxygens, the 
impact of the hydrogen bond to N129 could be explored by mutation to leucine or 
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alanine. Unfortunately, most of the other surrounding amino acid side chains are not 
amendable to forming hydrogen bonds so most optimization will depend on 
optimizing backbone contacts.   
 An additional consideration for the chelator fragment library is specificity of 
the chelators for different metals. While we have confirmed the metal bound in our 
purified NES enzyme is nickel, it is unclear if this is physiologically relevant or a 
consequence of purification on a nickel column (1). Therefore, chelators that are 
effective against a nickel-bound NES in vitro may show differential effectiveness in 
vivo.  It is possible to chelate out the nickel bound to NES with EDTA; therefore, it 
should be possible to replace this nickel with other metals that facilitate NES activity 
such as manganese and copper in order to analyze the effect of the chelators 
against varying metal cofactors (1).  
Variation in NES Genes 
 Although pSK41 is the prototype plasmids for the MOBQ class and NES is the 
best characterized single-tyrosine relaxase, there are several other plasmids that 
contain an NES gene and some variation is seen in this gene across plasmids. For 
example, the conjugative transfer regions of the pGO1 and pSK41 plasmids are 
considered to be essentially identical; however, there is a 24-nucleotide segment in 
the nes gene that differs between the two plasmids (4). This results in an 8 amino 
acid sequence that is different between the NES enzymes expressed by each 
plasmid and could have significant implications on the function of the enzyme. It has 
been suggested that the nic site of pGO1 and pSK41 differs by one nucleotide 
position despite the oriT being the same sequence. Perhaps this 8 amino acid 
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difference between the NES enzymes could explain this difference and 
characterization of that change would further understanding of NES DNA binding 
function. 
 Additionally, several plasmids that contain a nes gene have frame-shift 
mutations in the gene that result in a truncated enzyme. Truncations have been 
seen that result in 303, 482, or 555 amino acid proteins rather than the 665 residue 
full-length enzyme characterized here. It is unclear if these truncated enzymes are 
functional and able to facilitate CPT. Notably, the frame shift mutation resulting in a 
303-residue enzyme is found on the pUSA03 plasmid in the MRSA-USA300 strain. 
This is the C-terminal mutant that was not able to facilitate transfer of pSK41 in vivo 
in Edwards et al. but it is possible that other changes in the pUSA03 plasmid allow 
the shorter enzyme to be sufficient for transfer (Chapter 1 Figure 1.5) (1). 
 Conjugative plasmids that encode nes genes or plasmids that move via a 
relaxase in-trans mechanism represent a large reservoir of antibiotic resistance 
genes. Understanding of this highly conserved enzyme that is responsible for 
initiation via DNA cleavage and termination via DNA ligation is key to understanding 
the mechanism of conjugative plasmid transfer and developing therapeutics to limit 
spread of genes encoding for antibiotic resistance. While work in this thesis has 
expanded understanding of the function and potential for inhibition of NES, there are 
also many questions left to answer about this enzyme across plasmids and many 
ways to optimize inhibition.  
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Table 4.1. Altered Hairpin Oligonucleotides 
	
Oligo Name Sequence (Hairpin Underlined) 
OriTHP40  ACGCGAACGGAACGTTCGCATAAGTGCGCCCTTACGGGAT 
Disrupted Hairpin ACATAGGTAAAAATGGATAATAAGTGCGCCCTTACGGGAT 
No Hairpin                    ATAAGTGCGCCCTTACGGGAT 
Half Hairpin           AACGTTCGCATAAGTGCGCCCTTACGGGAT 
	
	
	
	
	
	
Figure 4.1. NES Cleavage of Altered Hairpin Oligonucleotides 
NES cleavage activity on oligonucleotides containing the wild-type sequence 
(OriTHP40), a disrupted hairpin, beginning after the hairpin (no hairpin), or half of the 
hairpin sequence from the oriT of pSK41. 
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Figure 4.2. Gua-26 Binding Pocket 
Guanine-26 (magenta) in the pSK41 oriT is coordinated by the NES protein 
backbone and the asparagine-129 side chain (green). PDB ID: 4HT4 
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Figure 4.3. M3W Mutation Effects 
Guanine-26 (magenta) in the pSK41 oriT clashes (red) with the M3W mutation 
(white) of the NES relaxase domain (cyan). PDB ID: 4HT4 
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CHAPTER 5: INTRODUCTION TO β-GLUCURONIDASE- MICROBIAL ENZYME 
RESPONSIBLE FOR GI DRUG REACTIVATION 
 
Microbiome 
 It has long been appreciated that many bacteria make the human body their 
home. Recent technological advances have greatly expanded our appreciation of 
the vast number and types of bacteria that are found on and in the human body and 
given rise to the human microbiome field of study. The term microbiota refers to the 
symbiotic bacteria that live in and on the human bodies. A recent estimate calculated 
that each of person maintains approximately equal numbers of human and bacterial 
cells with the bacterial cells concentrated largely on the skin and on the mucus 
membranes of the mouth and gastrointestinal tract (GI) (1). The microbiome is the 
collection of genomes associated with the microbiota. Because of the large 
variability between bacterial genomes and quick reproduction time of bacteria, the 
microbiome contains many more unique genes and evolves much more quickly than 
the human genome.  While bacteria have been studied for hundreds of years, only 
recently has it become feasible to sequence and compile large numbers of bacterial 
genomes in order to explore the variations between strains and genes that are non-
essential or do not impart a strong phenotype.  
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To better understand this vast bacterial population, the National Institutes of 
Health (NIH) began the Human Microbiome Project (HMP) to establish resources 
that would enable research to characterize the human microbiome and its role in 
human health and disease (2). This included collecting and sequencing microbial 
samples from healthy individuals across several different body sites including nasal 
passages, oral cavity, skin, gastrointestinal tract, and urogenital tract (2). In addition 
to the whole-genome sequencing metagenomics studies conducted with these 
microbial samples, the HMP is also working to culture bacteria from these samples 
in order to establish 3,000 reference strains with complete genome sequences.   
Completion of the HMP and the on-going efforts of other microbiome 
sequencing initiatives such as the American Gut Project have highlighted the 
complexity and diversity of the human microbiota. Samples vary widely between 
individuals, likely reflecting the highly variable environments in which we live, genetic 
differences, and various foods and drugs that we consume (2). Samples also show 
significant diversity when the same individual is sampled over time (3). Only healthy 
individuals were sampled for the HMP in hopes of establishing a common, healthy 
baseline to which the microbiota associated with disease could be compared. 
Subsequent comparisons have suggested links between microbiota dysbiosis and 
autism spectrum disorders, metabolic disorders, irritable bowel syndrome, diabetes, 
and cardiovascular disease (4-6). These associations emphasize the importance of 
maintaining a healthy microbiota and limiting the use of broad-spectrum antibiotics, 
especially in early childhood, as this significantly alters the diversity of the GI 
microbiota (7, 8). More recent studies have focused on determining the mechanism 
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by which changes in the microbiota lead to disease, examining both which individual 
bacteria are responsible for the effect as well as characterizing molecular processes 
those bacteria facilitate by narrowing in on a particular gene or gene cluster. This 
has allowed for an increased appreciation of the interactions between mammalian 
tissues and the microbiota (9).  
 
Glycoside Hydrolases 
 One microbial enzyme class that is of particular interest is glycoside 
hydrolases. Glycoside hydrolases are expressed by both prokaryotic and eukaryotic 
cells and are responsible for hydrolyzing the glycosidic bond between carbohydrate 
sugars or between a sugar and a non-carbohydrate moiety.  
The average human diet contains a vast array of both simple and complex 
carbohydrates that include glycosidic sugars. Glycosidic sugars come in a variety of 
discrete but related structures and can also be derivatized with the attachment of a 
functional group such as sulfate. These varying sugars can be arranged through a 
variety of different bonds in an almost endless library of carbohydrate molecules that 
must be broken down in order to be used for both human and bacterial energy 
production. The 135 families of glycoside hydrolases are the primary enzymes 
responsible for degradation of these large carbohydrate molecules. Many of these 
enzymes have strict specificity for one glycosidic sugar (e.g. glucuronate vs 
galactose) as well as the bond linking the sugar to the next molecule (e.g. alpha- vs 
beta-linkage); therefore, it is not surprising that both mammals and bacteria express 
a wide range of glycoside hydrolase enzymes (10, 11). 
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β-Glucuronidase4 
β-Glucuronidase, or GUS, enzymes are members of the glycoside hydrolase 
family 2 (GH2). These enzymes are found in plants, animals, and bacteria in order to 
cleave a beta-linked glucuronide moiety from a larger compound. As with other 
glycoside hydrolase enzymes, the hydrolysis of the glycosidic bond by GUS 
enzymes is catalyzed by two amino acid residues, usually glutamic acids. The 
proposed mechanism for the E. coli GUS is shown in Figure 5.1. This proposed 
mechanism is based on similarity to the lysozyme and β-galactosidase mechanisms 
that have been more extensively studied (12). 
The human GUS enzyme is found in lysosomes where it hydrolyzes 
glucuronic acid from the non-reducing end of glycosaminoglycans such as 
chondroitin sulfate and hyaluronic acid (13). The structure of human GUS was 
reported in 1996 and characterized at high resolution in 2013 (13, 14). This is an 
essential enzyme in humans and deficiencies resulting from a mutation in the gene 
lead to a build-up of non-hydrolyzed glycosaminoglycans referred to as Sly 
syndrome (15).  
Microbial GUS enzymes allow the encoding microbes to scavenge for a 
carbon-based energy source. There are a wide variety of compounds containing 
glucuronide moieties that enter the GI including glycosaminoglycans and small 
molecules that are conjugated to a single glucuronide sugar through phase II drug 
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metabolism in the liver; however, it is still unclear what the native substrate is for 
these enzymes. Microbial GUS activity was first characterized in E. coli and E. coli 
GUS (EcGUS) is often used as a reporter gene to monitor gene expression in plant, 
mammalian, and even bacterial cells via a robust, colorimetric assay (16, 17).  
EcGUS is only essential for E. coli bacteria when glucuronic acid is the only 
available carbon source (17). The structure of EcGUS was determined in 2010 by 
the Redinbo lab and showed a functional tetramer that has been confirmed by gel 
filtration chromatography and multi-angle light scattering (Figure 5.2) (18, 19). In 
order to expand the understanding of microbial enzymes, the GUS enzymes from 
Streptococcus agalactiae (SaGUS) and Clostridium perfringens (CpGUS) have also 
been characterized (19). Structures of SaGUS and CpGUS exhibit overall structures 
similar to the EcGUS and human GUS structures reported previously (Figure 5.2) 
(13, 14, 18).  
Using the EcGUS, SaGUS, and CpGUS crystal structures as a guide, we 
were able to define functionally relevant sequence motifs. GUS enzymes align ether-
linked glucuronides for hydrolysis using hydrophobic, hydrogen bonding, and 
electrostatic interactions with the glucuronic acid sugar moiety. The asparagine and 
lysine residues that contact the carboxylic acid group unique to glucuronic acid 
relative to galactose are particularly critical and we have denoted this as the N-K 
motif (N566/567/563, K568/569/565 in Figure 5.3A). This motif is completely 
conserved even in more distantly related GUS enzymes from Archaeal and 
Thermotoga sources, as well as Bacteroides species and a gene obtained from an 
uncultured sample whose gene product, H11G11, was demonstrated to have GUS 
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activity (Figure 5.3B) (20). This motif was previously noted when Matsumura and 
Ellington evolved glucuronidase activity from galactosidase enzymes (21). In 
addition to the N-K motif, a tyrosine residue located ~4 Å from the glucuronic acid 
binding site appears to ensure by steric occlusion that only beta-linked substrates 
are processed by the two catalytic glutamic acid residues of GUS enzymes; an 
alpha-linkage would clash with the aromatic ring at this position (Y468 in Figure 
5.3A).  
Using the N-K motif as a marker for GUS enzymes within the GH2 family, we 
were able to identify a previously solved structure of a Bacteroides fragilis enzyme 
(RCSB: 3CMG) as a GUS enzyme rather than its originally annotated beta-
galactosidase label (Figure 5.2). As shown in Figure 5.3B, this B. fragilis GUS 
(BfGUS) maintains the N-K motif. Indeed, EcGUS, SaGUS, CpGUS, and BfGUS 
were shown to have activity against the glucuronidated substrate p-nitrophenyl 
glucuronide (PNPG) (Table 5.1). Thus, we propose that the N-K and Y motifs should 
join the catalytic glutamic acid residues as structural features considered essential 
for GUS activity and defining GUS sequences.  
The EcGUS, SaGUS, and CpGUS enzymes have a unique motif relative to 
the human GUS structure: they contain a “bacterial loop” that folds over the active 
site (Figure 5.4A). By contrast, human GUS lacks this loop. The bacterial loops are 
highly divergent in sequence, sharing only 11-36% identity between EcGUS, 
CpGUS, and SaGUS (Figure 5.4B). In human GUS, this region is replaced by a 
single residue, P415. Sequence analysis of bacterial loops in a set of microbial GUS 
enzymes from the NCBI database reveals that some of the enzymes contain the 
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loop and some do not (Figure 5.4B). BfGUS seems to be an intermediate between a 
full bacteria loop like that seen in EcGUS, SaGUS, and CpGUS and no loop as in 
human GUS. 
These observations support the conclusion that the GI microbiome maintains 
an array of enzyme orthologs capable of scavenging glucuronic acid from a range of 
chemically distinct substrates. Diverse endobiotic, food, and xenobiotic glucuronides 
are expected to be regularly delivered to the GI tract, and thus the microbial species 
therein are poised to utilize these diverse sources of carbon. The addition of BfGUS 
to the array of characterized GUS enzymes has emphasized the limited scope of the 
current understanding of the sequence and structure of GUS enzymes. The 
following chapters begin to expand current understanding of the GUS enzyme family 
by defining a catalog of GUS sequences found in the human microbiome and 
characterizing some of those unique enzymes. 
 
Irinotecan5 
 Irinotecan (CPT-11) is a potent anticancer drug used to treat solid tumors and 
other malignancies (22-24). It is an essential component of FOLFIRI (where IRI 
indicates irinotecan), which is widely used for late-stage colorectal cancer (25, 26), 
and FOLFIRINOX, which was recently recommended as the first-line regimen for 
pancreatic cancer (27). According to the Food and Drug Administration package 
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insert for irinotecan, up to 88% of patients experience diarrhea and 31% show grade 
3-4 diarrhea, which requires significant medical intervention including dose 
reductions or treatment termination (28-30). 
 As shown in Figure 5.5, irinotecan is a prodrug that is activated by human 
carboxylestrases in the liver during phase I drug metabolism (30, 31). This active 
metabolite, SN-38, is a topoisomerase I poison and leads to irreversible double-
strand breaks in the DNA of targeted cells (32). SN-38 is further processed by UDP-
glucuronosyltransferases (UGT), in particular UGT1A1, to become the inactivated 
glucuronide conjugate SN-38G, which is sent to the GI tract for elimination (28-30). 
In the GI tract, bacterial GUS enzymes remove the glucuronic acid and thus 
reactivate the topoisomerase I poison SN-38, which causes GI damage and the 
diarrhea that is dose-limiting for irinotecan (33-36).  
 Several strategies have been tested to decrease the toxicity caused by 
irinotecan. Reduction in irinotecan dosing and administration of anti-motility 
medication such as loperamide are the most basic approaches for patients 
experiencing severe diarrhea (37). Antibiotics to target the host microbiota have 
been administered prior to irinotecan treatment; however, as discussed above, the 
microbiota plays an important role in many biological functions and disruption of 
those functions has significant effects, including increasing the risk of pathogenic 
infection in these cancer patients who are often already immune-compromised (31).  
Attempts to produce SN-38 analogues that cannot be glucuronidated have been 
pursued, but results in the clinic have been slow to materialize. Low-potency GUS 
inhibitors have also been explored and one tested in rats in 2004 showed limited 
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efficacy in reducing the GI toxicity associated with irinotecan.	Therefore, the Redinbo 
lab set out to design high-potency inhibitors targeted to bacteria GUS enzymes in 
order to alleviate this irinotecan-induced diarrhea. 	
 
GUS Inhibitors 
 In 2010, Wallace et al. presented four potent and novel inhibitors of bacterial 
GUS enzymes identified by a 10,000-compound high-throughput screen using 
EcGUS and showed that they significantly reduced the GI damage caused by 
irinotecan in mice (Inhibitors 1-4 in Table 5.2) (38, 39). An additional four novel 
inhibitors were explored by Roberts et al. in 2013 (Inhibitors 5-8 in Table 5.2). These 
inhibitors are non-toxic to both bacterial and mammalian cells and are selective for 
bacterial GUS enzymes containing the bacterial loop by more than 1,000-fold over 
the human enzyme orthologue (18, 40). We pinpointed the basis for the selectivity to 
a loop present in bacterial GUS enzymes that is missing from the human enzyme 
ortholog; the inhibitors bind to this loop, making them ineffective against mammalian 
GUS enzymes (18). In an attempt to optimize the efficacy of Inhibitor 1, compounds 
R1 and R3 were designed using knowledge gained through EcGUS-inhibitor 
structures.    
These compounds were also tested against SaGUS, CpGUS, and BfGUS. All 
characterized compounds inhibit EcGUS with Ki values below 2 µM. However, the 
compounds exhibit markedly different effects toward CpGUS and SaGUS with some 
compounds showing efficacy against both enzymes in addition to EcGUS and other 
compounds showing much weaker or no efficacy against the new enzymes despite 
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the presence of the bacterial loop (Table 5.2). The smaller bacterial loop of BfGUS is 
not sufficient for the activity of these compounds and BfGUS is not subject to 
inhibition at up to 100 µM inhibitor concentrations (Table 5.2). This result is 
reminiscent of the no loop, mammalian GUS enzyme from Bos taurus (bovine, 
BtGUS), which was also not subject to inhibition (Table 5.2). These results confirm, 
as seen in crystal structures, that a full bacterial loop is essential for efficacy of these 
inhibitors in addition for their selectivity relative to the mammalian enzymes. Despite 
the ineffectiveness against a subset of bacterial enzymes such as BfGUS, Inhibitors 
1, 5, and R1 have been shown to be effective in reducing CPT-11 induced diarrhea 
in mice; the decrease in diarrhea in mice following Inhibitor 1 treatment is shown in 
Figure 5.6A. 
There were concerns that these inhibitors of microbial GUS activity would 
affect irinotecan pharmacokinetics and therefore decrease efficacy in patients. To 
address this, the Redinbo lab measured circulating plasma levels of CPT-11 
(irinotecan) with and without Inhibitor 1 treatment. As shown in Figure 5.6B, Inhibitor 
1 was effective at reducing the percentage of mice with CPT-11 induced diarrhea, 
but the circulating levels of CPT-11, SN-38, and SN-38G were not affected by 
Inhibitor 1 treatment. This suggests that SN-38 formed from SN-38G cleavage by 
bacterial GUS enzymes is not reabsorbed into the plasma and therefore, inhibitor 
treatment does not significantly disrupt the circulating plasma levels of this drug and 
should not impact tumor response to CPT-11.  
  With these very promising results, the Redinbo lab plans to continue to 
optimize these inhibitors. However, to ensure we are targeting the GUS enzymes 
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primarily responsible for SN-38G processing and optimizing the inhibitors against 
those enzymes, we need to understand what GUS enzymes are present in the GI 
and which interact with SN-38G. The following chapters contain the initial steps to 
catalog and characterize GUS enzymes from the human microbiome. These results 
will be coupled with microbiome sequencing studies in mice to inform future work to 
optimize GUS inhibitors. 
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Table 5.1. Catalytic Activity of GUS 
Data are presented as the average over >3 experiments ± SEM for Escherichia coli 
(EcGUS), Clostridium perfringens (CpGUS), Streptococcus agalactiae (SaGUS), 
and Bacteroides fragilis (BfGUS) β-Glucuronidases. kcat, catalytic rate; KM, Michaelis 
constant;  kcat/KM, catalytic efficiency. Originally published in Wallace et al. (2015) 
(19) 
 
Enzyme kcat (s-1) KM (mM) kcat/KM (s-1mM-1) 
EcGUS 120 ± 12 0.13 ± 0.01 920 ± 160 
SaGUS 80 ± 2 0.36 ± 0.03 222 ± 24 
CpGUS 2.6 ± 0.6 1.1 ± 0.2 2.4 ± 1 
BfGUS 18 ± 1 1.9 ± 0.3 9.5 ± 2 
 
Table 5.2. In vitro GUS Inhibition, Ki (μM) 
Enzyme inhibition properties of small molecule inhibitors against representative GUS 
enzymes. Grey data from Roberts et al. (2013), Wallace et al. (2010) (18, 40). Black 
data from Wallace et al. (2015) (19) ni: no inhibition. Data are presented as the 
average over >3 experiments ± SEM for Escherichia coli (EcGUS), Clostridium 
perfringens (CpGUS), Streptococcus agalactiae (SaGUS), Bacteroides fragilis 
(BfGUS), and Bos taurus (bovine, BtGUS) β-Glucuronidases.  
 
Inhibitor CpGUS SaGUS EcGUS BfGUS BtGUS (mammalian) 
1 0.97 ± 0.1 1.4 ± 0.4 0.16 ± 0.01
 ni ni 
R1 ni ni 1.9 ± 0.5 ni  
R3 ni ni 0.61 ± 0.2 ni  
2 1.1 ± 0.5 3.0 ± 1 0.21 ± 0.03 ni ni 
3 7.8 ± 0.9 11 ± 3 0.68 ± 0.08 ni ni 
4 24 ± 3 36 ± 5 1.4 ± 0.2 ni ni 
5 0.54 ± 0.2 0.81 ± 0.2 0.22 ± 0.04
 ni ni 
6 6.1 ± 2 2.8 ± 0.3 0.67 ± 0.03 ni ni 
7 ni ni 1.9 ± 0.02 ni ni 
8 ni ni 0.96 ± 0.03 ni ni 
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Figure 5.1. Enzymatic Mechanism of E. coli GUS 
Glutamic acid residues 413 and 504 are hypothesized to serve as the key catalytic 
residues in order to process a generic glucuronide-linked substrate. 
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Figure 5.2. Structure of Microbial GUS Enzymes 
Crystal structures of bacterial GUS enzymes from Clostridium perfringens (yellow, 
CpGUS, PDB ID:4JKM), Streptococcus agalactiae (magenta, SaGUS, PDB ID:4JKL), 
Escherichia coli (purple, EcGUS, PDB ID:3K46), and Bacteroides fragilis (green, 
BfGUS, RCSB:3CMG). 
 
 
 
C.	perfringens S.	agalactiae 
E.	coli B.	fragilis 
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A 
EcGUS   558-QGILRVGGNKK-568 
HsGUS       QSPTRVLGNKK 
ArchIa     QNHWRTMLNRK 
TherTn     QNVRRPILNHK 
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SaGUS   555-LMILRVQGNHK-565 
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Figure 5.3. N-K and Y Motif 
A. Superposition of the active sites of CpGUS (yellow), SaGUS (magenta), and EcGUS 
green) in complex with the glucuronic acid mimic glucaro-∂-lactam, showing the binding 
of the ligand’s carboxylate moiety (left) and indicating that the proximity of the 
conserved tyrosine indicated (YI468/464) favors the alignment of a β linkage (right) for 
catalysis. The labels for the two catalytic glutamic acid residues of each enzyme are 
boxed. 
B. The Asn (N) and Lys (K) residues create the N-K loop conserved in β-glucuronidases 
(GUS). GUS enzymes listed those characterized by the Redinbo lab (CpGUS, SaGUS, 
EcGUS, and BfGUS) as well as those from mammalian (Homo sapiens, HsGUS), 
Archaeal (ArchIa), Thermatogae (ThermTn), and other sources. The enzymes for which 
a crystal structure is available are underlined. ArchIa, Archaea Ignisphaera aggregans, 
WP_013302863; TherTn, Thermotogae Thermotoga naphthophila, ADA67771; BactNk, 
Bacteroidetes Niastella koreensis, AEV98753; H11G11, 745-residue protein from 
uncultured bacterium.  
Originally published in Wallace et al. (2015) (19) 
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Bacterial	Loop 
	
CpGUS     PAVGLHLNFMATGFG-------GDAPKRDTWK----EIGTKE 
SaGUS     PAVGLFQNFNASLD-----LSP---KDNGTWS----LMQTKA 
EcGUS     AAVGFNLSLGIG-------FE-AGNKPKELYSEEAVNGETQQ 
PROT      AAVGLWDMMISGGGIAGAGAGAGGAEKLKFFDNEDVKNATQQ 
ACTIN     PAVGLNWSMAGG-------IL--DSDGGETFEDGHVDASTQA 
FUNGI     PAVGLAYSIGAG-------V-SSE-DSPQTFTPEGINNNTRE 
HsGUS     PGVGIALPQF-------------------------FNNVSLQ 
ArchIa    PICLSG---MPS--------------N-DDARKWCSNPIIIE 
TherTn    PHVGITRYH--------------------------YNPETQK 
DICTY     PAVGLNLWNRD----------------EKVFTKGRVDEKTLE 
BactNk    PIYQHI---------------------------QFADSAVRA 
ACIDO     PLWQRI---------------------------SFDKSDVYD 
BfGUS     PFVGPGGYADKG---------------------FVDQASFRE 
H11G11    PYISRHM------------------------------PGGRE 
B 
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Figure 5.4. Presence of the Bacterial Loop in Representative GUS Enzymes 
A. The representative bacterial loop containing GUS enzyme EcGUS (red) and smaller 
bacterial loop containing GUS enzymes BfGUS (yellow) superimposed on the structure 
of human GUS (purple) reveals the lack of a bacterial loop in the mammalian enzyme 
and the size difference between loops of EcGUS and BfGUS. 
B. The bacterial loop, boxed, is maintained in several GUS enzymes including those 
from several fungi, but is missing from other enzymes including some from bacterial 
sources such as H11G11. Enzymes such as BfGUS and DICTY have a smaller 
bacterial loop than that of SaGUS, CpGUS, and EcGUS. The enzymes for which a 
crystal structure is available are underlined. PROT, Proteobacteria Vibrio harveyi, 
WP_005434141; ACTIN, Actinobacteria Corynebacterium massiliense, 
WP_022863751; FUNGI, Eukaryota Aspergillus niger, CAK36851; ArchIa, Archaea 
Ignisphaera aggregans, WP_013302863; TherTn, Thermotogae Thermotoga 
naphthophila, ADA67771; DICTY, Dictyoglomi Dictyoglomus turgidum, ACK42813; 
BactNk, Bacteroidetes Niastella koreensis, AEV98753; ACIDO, Acidobacteriua 
Terriglobus roseus, WP_01478374;H11G11, 745-residue protein from uncultured 
Adapted from figure originally published in Wallace et al. (2015) (19) 
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Figure 5.5. Metabolic Pathway of CPT-11 
Irinotecan (CPT-11) is administered via I.V. injection to patients and then goes 
through the following metabolic pathways to reach the tumor and eventually be 
eliminated from the body. However, GI microbial GUS enzymes interfere with this 
elimination process causing GI damage and severe diarrhea in patients. The 
Redinbo lab works to discover potent inhibitors to these GUS enzymes in order to 
eliminate the GI damage and diarrhea caused by reactivated SN-38. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
		 116	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
		 117	
 
Figure 5.6. Microbial GUS Inhibitors in Mice Treated with CPT-11 
A. CPT-11 (irinotecan) produced delayed diarrhea in 25%, 60%, and 100% of mice 
in 8, 9, and 10 days, respectively. Oral delivery of Inhibitor 1 eliminates the 
appearance of diarrhea on day 8 and reduces the number of mice that experience 
diarrhea on days 9 and 10. 
B. The circulating plasma levels of CPT-11 (irinotecan), its active metabolite SN-38, 
or its inactive glucuronide conjugate SN-38-G are unaffected by the oral delivery of 
the microbial GUS Inhibitor 1 (Inh1). 
Adapted from figure originally published in Wallace et al. (2015) (19) 
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CHAPTER 6: DEFINING THE β-GLUCURONIDASE ENZYME FAMILY IN THE 
HUMAN GASTROINTESTINAL TRACT 
 
 
Introduction 
 The human gastrointestinal (GI) microbiota is a vast ecosystem of bacteria 
that are constantly interacting with each other, the human body, and many of the 
substances that enter the human body. The GI microbiota has been shown to 
interact with a wide range of small molecules, both produced by the human body 
and from outside the body. For instance, conjugated bile acids that are produced in 
the human liver can be de-conjugated by the GI microbiota which can lead to 
bacterial overgrowth and inflammation (1). In addition, a large part of food digestion 
and absorption takes place in the GI and the microbiota play a key role in breaking 
down the polysaccharides that humans lack the enzymes to process (2). The 
microbiota can also activate pro-drugs as seen with sulfasalazine, inactivate drug 
molecules such as in the processing of digoxin by E. lenta, or bind drugs, preventing 
the drug from reaching its intended target as seen in L-DOPA treatment (3). We are 
interested in such microbiota-drug interactions, especially microbiota processing of 
drugs that have been inactivated in the liver and are then excreted via the intestine.   
The chemotherapy drug irinotecan (CPT-11) is a prodrug that is activated 
through phase I drug metabolism to the compound SN-38 (4, 5). SN-38 inhibits 
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topoisomerase I and is used as a treatment of solid tumors including colorectal and 
pancreatic cancer (6). SN-38 then returns to the liver where a glucuronide sugar is 
attached by the UGT enzymes of phase II drug metabolism (4, 7, 8). The SN-38-
glucuronide (SN-38G) compound is more soluble and enters the intestines in order 
to be excreted from the body. β-glucuronidase (GUS) enzymes expressed by the GI 
microbiota can cleave the glucuronide sugar off SN-38G resulting in active SN-38. 
SN-38 causes cell death of the intestinal epithelium leading to delayed-onset 
diarrhea that often leads to patients receiving lower doses of irinotecan or being 
taken off this effective chemotherapy completely (9-12). In 2010 the Redinbo lab 
showed that inhibitors designed against the purified E. coli GUS reduce the number 
of bloody diarrheal events in mice co-treated with irinotecan and inhibitor (13).  
Since 2010 the Redinbo lab has characterized the GUS enzyme from E. coli 
(EcGUS), Streptococcus agalactiae (SaGUS), Clostridium perfringens (CpGUS), 
and Bacteroides fragilis (BfGUS) and eight small molecule inhibitors (14, 15). This 
initial characterization included solving the structures of EcGUS, SaGUS, and 
CpGUS and characterization of a previously solved structure (PDB ID: 3CMG) as a 
β-glucuronidase (BfGUS) (14). This allowed us to identify key conserved residues in 
the active site including two catalytic glutamic acids, an NxKG motif that interacts 
with the carboxylic acid group of glucuronic acid, an asparagine residue next to the 
first catalytic glutamic acid, and a tyrosine defined as part of the Y loop in Wallace et 
al. (14). Despite previous characterization of these enzymes, little evidence exists 
about the abundance of these enzymes or even the associated bacteria in the 
human GI. In order to understand which bacteria in the human GI express GUS and 
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the relative abundances of GUS genes, we set out to analyze the Human 
Microbiome Project (HMP) sequencing repository for GUS genes. 
The HMP sequencing repository is part of the NIH-funded Human Microbiome 
Project Consortium that set out to develop resources and methods to manage high-
throughput metagenomics data in order to characterize the microbial communities 
obtained from sampling a large number of healthy individuals across a wide range of 
body sites (16). There are over 11,000 samples from 300 healthy adults across 18 
specific body sites (16). We chose to analyze sequences obtained from stool 
samples for which 139 individuals were sampled. To facilitate analysis, the 
metagenomics sequencing data from these samples has undergone gene prediction 
and annotation. Therefore, we were able to use the HMGI- Gene Indices and 
HMGC- Clustered Gene Indices catalogs to search for GUS genes. As shown in 
Figure 6.1, we screened genes from stool samples in these catalogs for the key 
active site residues we had previously characterized in order to identify genes 
encoding for GUS enzymes. We then classified those identified GUS sequences 
according to a highly variable loop region just outside of the active site. The Redinbo 
lab previously identified the bacterial loop found in EcGUS, SaGUS, and CpGUS as 
a novel feature that allowed for the discovery of small molecule inhibitors that are 
selective for these bacterial GUS enzymes over the human ortholog (13, 14). We 
have re-named the bacterial loop Loop 1 as we identified a second loop, Loop 2, that 
is predicted to occupy a similar position at the entrance of the active site of these 
enzymes. We classified each of the identified GUS sequences based on the size 
and type of active site loop they contain. There are six loop classes: no loop, Loop 1, 
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Mini Loop 1, Loop 2, Mini Loop 2, and Mini Loop 1 Mini Loop 2. Previously 
characterized enzymes EcGUS, SaGUS, and CpGUS fall into the Loop 1 class while 
BfGUS is a Mini Loop 1 enzyme. This analysis showed that the human GI microbiota 
expresses many GUS enzymes with a much wider sequence diversity that has 
previously been explored.  
 
Materials and Methods 
Human Microbiome Project (HMP) data 
Protein sequences for stool samples from the HMP Clustered genes- HMGC 
(http://hmpdacc.org/HMGC) and Gene Indices – HMGI (http://hmpdacc.org/HMGI/) 
were downloaded as FASTA files and used as a database for subsequent NCBI 
BLASTp searches. Microbial assemblies, annotations and reads for stool samples 
were obtained from http://hmpdacc.org/HMASM/ and used for abundance 
calculations. 
HMP β-glucuronidase Identification 
In order to identify β-glucuronidases (GUS) in the HMP stool proteins, we 
used Escherichia coli β-glucuronidase (NCBI Accession: NP_416134.1), Clostridium 
perfringens β-glucuronidase (NCBI Accession: WP_003467686.1), Streptococcus 
agalactiae β-glucuronidase (NCBI Accession: WP_000966715.1) and Bacteroides 
fragilis (NCBI Accession: 3CMG) in a pair-wise alignment approach. Briefly, each 
HMP stool protein was aligned to the above proteins using NCBI BLASTp. We 
considered alignments with an E-value < 0.05 and percent identity ≥25 to be valid 
hits. Only those valid hits were then checked for the presence of NxKG motif, 
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catalytic E residues and N and Y motifs corresponding to GUS positions shown in 
Table 6.1. We classified HMP proteins that satisfied all the above conditions as β-
glucuronidase. 
HMP β-glucuronidase Loop Classification 
HMP GUS proteins identified above were subjected to a multiple sequence 
alignment (MSA) using Clustal Omega along with selected model GUS sequences 
(E. coli (NCBI Accession: NP_416134.1), Streptococcus agalactiae (NCBI 
Accession: WP_000966715.1), Clostridium perfringens (NCBI Accession: 
WP_003467686.1), Homo sapiens (NCBI Accession: NP_000172.2), H11G11-BG 
from uncultured bacterium (NCBI Accession: CBJ55484.1) and Bacteroides fragilis 
(NCBI Accession: 3CMG)).  
The MSA alignment was examined for the presence of two loop regions. The 
first (loop 1) corresponds to E. coli GUS positions 356 to 380 and the second (loop 
2) corresponds to E. coli GUS positions 416 to 419. HMP GUS proteins were then 
categorized into six categories based on the number of residues present in those 
two regions after excluding gap characters as shown in Table 6.2. 
Gene Abundance Calculations 
The trimmed and duplicate-marked reads for each stool sample were aligned 
to its own assembly using bowtie2 (v.2.2.5) (17). Alignments were stored in bam files 
and gene specific counts were obtained by running the program featurecount from 
the subread package (v.1.4.6-p2-Linux-x86_64) on each bam file (18). To account 
for differences in read numbers between samples, we normalized and log 
transformed the counts as shown below: 
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where RC is the read count for a gene in a particular sample, n is the total number of 
reads in that sample, the sum of x is the total number of reads in all samples and N 
is the total number of samples. 
 
Results 
HMGC- Clustered Gene Indices GUS Enzymes 
 The HMGC- Clustered Gene Indices is a non-redundant catalog of bacterial 
genes found during the Human Microbiome Project sequencing initiative grouped by 
body site. Genes from the HMP gene indices (HMGI discussed below) were 
compared at a 95% identity cut-off and redundant sequences were removed. The 
translated protein sequences from this database were compared to previously 
characterized GUS proteins to identify sequences possessing the conserved NxKG 
motif, catalytic E residues and N and Y motifs discussed in Chapter 5 and shown in 
Table 6.1. This analysis identified 293 unique GUS sequences, most of which have 
never been characterized as GUS enzymes (Figure 6.2A).  
This non-redundant set of sequences gave us a manageable dataset in order 
to characterize important features of this enzyme class. One feature this dataset 
uncovered is a wide range in protein sequence length. As shown in Figure 6.2B, 
about one third of these GUS sequences are longer than the four previously 
characterized GUS enzymes. This is interesting as we previously established that 
both EcGUS and BfGUS form tetramers in solution but models of the structures of 
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these longer sequences suggest that this extra length may interfere with that 
tetramer formation (14). We are currently working to determine which bacterial 
species each of these GUS sequences was sequenced from in order to establish a 
database that will allow for easy prediction of the GUS composition of a bacterial 
community characterized only by 16S rRNA sequencing.   
HMGI- Gene Indices GUS Enzymes 
 Stool samples were taken from 139 individuals and the genes found via whole 
genome sequencing of bacteria in those samples are found in the HMGI- Gene 
Indices database of the Human Microbiome Project (HMP). Each protein in these 
sequences was aligned to the previously characterized GUS proteins (EcGUS, 
SaGUS, CpGUS, and BfGUS) and analyzed for the presence of NxKG motif, 
catalytic E residues and N and Y motifs as shown in Table 6.1. This resulted in the 
identification of 3,013 GUS proteins as shown in Figure 6.3A. This dataset 
represents the first compilation of the GUS proteins found in the human 
gastrointestinal microbiome from sequencing data.  
 This dataset allowed us to analyze details about the number and type of GUS 
proteins each individual possessed. As shown in Figure 6.3B, there is a wide range 
of the number of GUS enzymes found in the stool samples of each individual with 
the minimum number being 4 and the maximum number being 40. This mimics the 
high diversity seen in other characterizations of the human GI microbiome.  
Establishment of GUS Loop Characterizations 
   As described in Chapter 5, we have previously established that a flexible loop 
outside of the GUS active site is important for selective inhibition of these enzymes; 
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this loop was previously termed the bacterial loop but will now be referred to as Loop 
1. Using alignments of the 293 GUS sequences identified from the HMGC database 
we were able to identify 3 distinct categories of enzymes with respect to Loop 1. The 
first category is made up of GUS enzymes that contain no loop in this region and 
resemble the tight turn seen in the Homo sapiens GUS enzyme (H_sapiens, 
P_merdae, H11G11-BG, B_uniformis, and B_dorei sequences in Figure 6.4A). The 
second category is made up of enzymes that contain a full loop of 15 or more 
residues in this region that resembles that previously characterized in EcGUS, 
CpGUS, and SaGUS (Loop 1 or L1 category, red sequences in Figure 6.4A). The 
third category is made up of enzymes that fall in between the first two categories and 
have a smaller loop between 10 and 15 residues (B_fragilis, green in Figure 6.4A). 
We have termed this Mini Loop 1 (mL1) due to its smaller size. This characterization 
left 75.8% of the sequences in the no loop category, prompting us to look more 
closely at the active site of this category. Approximately 35 residues downstream 
from Loop 1, we identified an additional loop region that is predicted to also extend 
over the active site in a similar manner to Loop 1. We termed this additional loop 
region Loop 2. Just as in the Loop 1 region, we found enzymes with a full loop of 12 
residues or more (Loop 2 or L2 category, B_uniformis in Figure 6.4A) as well as 
enzymes with a shorter loop of 9 to 11 residues (mini Loop 2 or mL2 category, 
P_merdae in Figure 6.4A).  Interestingly, enzymes that contain a mini Loop 1 may 
also contain a mini Loop 2 (mini Loop 1 mini Loop 2 or mL1mL2 category, B_ovatus 
in Figure 6.4A) but the full Loop 1 or Loop 2 were not seen in combination together 
or with a mini loop in the opposing position. We hypothesize that a large flexible 
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region in both the Loop 1 and Loop 2 positions is not favorable due to the many 
clashes that would occur as the two loops moved. The two loops in combination 
might also hinder function of the enzyme by blocking access of a substrate trying to 
enter the active site or preventing the products from diffusing out of the active site. 
There were also enzymes that did not contain a loop in either of these positions (no 
Loop or nL category, B_dorei in Figure 6.4A) which results in bacterial enzymes that 
are similar to the Homo sapiens and other mammalian GUS enzymes that have 
been characterized. The full alignment of these enzymes is shown in Appendix 3.   
 Using the criteria set out above and in Table 6.2, the HMGC (293 sequences) 
and HMGI (3013 sequences) datasets were classified into these six loop 
classifications (Figure 6.4 B and C). The distribution across loop classes was similar 
for each dataset. Because the HMGI dataset includes information on GUS content in 
each individual, we moved forward with analysis of the HMGI GUS dataset. Of the 
3013 sequences identified as GUS sequences, 144 did not have sufficient coverage 
in the area of the loops in order to determine their loop classification. Forty-eight 
percent of individuals in the database possessed at least one of these sequences 
(Figure 6.5A). The 144 unclassified sequences represent 3.8% of all identified GUS 
sequences. Previously characterized EcGUS, CpGUS, and SaGUS fall into the L1 
class. 67% of individuals sampled possessed at least one L1 GUS sequence with an 
average 1.8 ± 1 L1 GUS sequences per individual (Figure 6.5B). The L1 class 
contains 165 sequences which is 5.5% of all identified GUS sequences. The 
previously characterized BfGUS is a mL1 enzyme. 98% of individuals possessed at 
least one mL1 GUS sequence with an average 4.5 ± 2.2 GUS sequences per 
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individual (Figure 6.5C). The 615 mL1 GUS sequences represent 20.4% of all 
identified GUS sequences. Three hundred and fifty-one identified sequences were 
classified as L2 GUS sequences which is 11.6% of all identified sequences. 91% of 
individuals had at least one L2 GUS sequence with an average 2.7 ± 1.5 GUS 
sequences per individual (Figure 6.5D). The mL2 class represents 6.9% of all 
identified GUS sequences with 208 sequences identified from the HMGI database. 
80% of all individuals possessed at least one mL2 GUS sequences with an average 
1.9 ± 0.8 mL2 GUS sequences per individual (Figure 6.5E). The mL1mL2 class is 
the least well represented in this sample with just 28% of individuals having at least 
one mL1mL2 GUS sequence and an average of 1.1 ± 0.2 mL1mL2 GUS sequences 
per individual (Figure 6.5F). From the HMGI database, we identified only 36 
mL1mL2 GUS sequences which represents just 1.2% of all identified GUS 
sequences. Finally, the no loop class represents the largest percentage (49.6%) of 
the identified GUS sequences with 1494 GUS sequences. All individuals possessed 
a nL GUS sequence. There was an average of 11 ± 5 nL GUS sequences per 
individual (Figure 6.5G).  
GUS-Containing Bacteria 
 As mentioned above, we are interested in establishing which bacteria are 
likely to possess each identified GUS sequence. For each of the 139 individuals 
sampled, we identified the most abundant sequence (via read counts) in each loop 
class and matched the sequence to a deposited reference genome in NCBI. This 
allowed us to identify the organism from which the sequence likely originated and 
therefore the phyla distribution of GUS sequence containing bacteria for each loop 
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class. Because the 3013 GUS sequences is a redundant set of sequences found 
across the 139 individuals, several of the most abundant sequences in each loop 
class were the same across individuals. For each loop class we present the top 5 
most common abundant sequences with the number of individuals for which each 
was the most abundant sequence of that loop class in the count column. The 
majority of L1 GUS sequences could not be matched to a deposited reference 
genome. Of the sequences that were identified, 42 matched to bacteria from the 
Firmicutes phylum and one was from the Proteobacteria phylum. The most common 
sequences in the L1 class were from Faecalibacterium prausnitzii and Eubacterium 
eligens. These GUS sequences were chosen to be expressed, purified, and 
characterized in the lab as described in Chapter 7. The mL1 class of sequences was 
found predominately in bacteria from the Bacterodetes phylum with a small number 
from the Firmicutes phyla. Although Bacteroides fragilis was not an abundant 
sequence seen in this analysis, we chose to move forward with characterization with 
BfGUS that has already expressed in the Redinbo lab. All identified L2 GUS 
sequences are from the Bacteroidetes phyla. The most common sequences were 
associated with multiple species (MSP) of Bacteroidetes and Bacteroides uniformis. 
The sequence associated with Bacteroides uniformis was chosen for 
characterization in the lab. The mL2 GUS sequences were also predominately found 
in bacteria from the Bacteroidetes phylum. Uniquely, there were also sequences 
found in bacteria of the Verrucomicrobia phylum. The most common sequence was 
from Parabacteroides merdae and was chosen for further characterization. The 
sequences in the mL1mL2 class that were able to be matched to reference genomes 
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were found exclusively in bacteria from the Bacteroidetes phyla. Two different 
sequences, each seen in 12 individuals, were associated with Bacteroides ovatus 
and one of these sequences was chosen for further characterization. Finally, 65.7% 
of matched sequences from the nL class were found in bacteria from the 
Bacteroidetes phylum. The remaining 34.3% of matched sequences were from the 
Firmicutes phylum. The most common sequences were found in Bacteroides 
uniformis and Bacteroides dorei. The sequence from Bacteroides dorei was chosen 
for further characterization in the Redinbo lab. This analysis of the Human 
Microbiome Project stool sample sequencing database provides the first in-depth 
look at the GUS sequences contained in the human microbiome. This dataset gives 
us a better appreciation of the variation in GUS sequence and has allowed us to 
choose representative proteins to further characterize the function of this enzyme 
class as discussed in Chapter 7. 
 
Discussion 
 Bacterial GUS enzymes have been established as the cause of drug toxicity 
of glucuronidated compounds such as irinotecan and NSAIDs. However, previous 
efforts to compile a catalog of GUS sequences found in the human GI microbiota 
have depended on the automated annotation of genes which we have previously 
shown is imprecise and often confuses β-glucuronidase and β-galactosidase 
enzymes (14). Instead we chose to classify genes as a GUS based on the presence 
of key, conserved active site residues in a one-to-one sequence alignment with the 
previously discussed, well-characterized bacterial GUS enzymes. This resulted in a 
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much more complete catalog of 293 non-redundant GUS sequences identified from 
the HMP Clustered Gene Indices Database. Identifying GUS sequences from the 
HMP Gene Indices Database also allowed us to examine the variability in GUS 
sequences across 139 individuals. Although the vast variability of the microbiota 
from person to person has been shown in analyses of other microbiome 
characteristics, this is the first evidence to suggest that the number and type of GUS 
enzymes expressed by each individual is highly variable. This may contribute to the 
varying severity of drug toxicity seen with drugs such as irinotecan.  
 This new dataset of GUS sequences allowed us to identify features of this 
enzyme class that have not previously been explored. For instance, almost one third 
of these GUS sequences are longer than previously characterized bacterial 
enzymes. The extra length forms an uncharacterized C-terminal domain that likely 
disrupts tetramer formation and may alter the function of these enzymes. In addition, 
we were able to expand understanding of the previously identified bacterial loop at 
the entrance of the active site. In addition to this bacterial loop, now termed Loop 1, 
we identified a second loop region (Loop 2) that is predicted to extend over the 
entrance of the active site similar to Loop 1. By analyzing the absence or length of 
the loop in both the Loop 1 and Loop 2 regions, we were able to break the larger 
GUS sequence datasets into six categories for further characterization. The loop 
classes are Loop 1 (L1), Mini Loop 1 (mL1), Loop 2 (L2), Mini Loop 2 (mL2), Mini 
Loop 1 Mini Loop 2 (mL1mL2), and no Loop (nL) with loop lengths as defined in 
Table 6.2. Because these loops sit at the entrance of the active site, we hypothesize 
that the presence and size of the loop may impact the size of substrate the enzyme 
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is able to process. We have also previously shown that Loop 1 is important for the 
selectivity of GUS inhibitors over H. sapiens GUS while Mini Loop 1 is not sufficient 
to facilitate efficacy of the inhibitors (13, 14). Therefore, we are interested in the type 
of GUS sequences found in each individual. Indeed, we found variability in the 
presence of some loop classes as well as the number of sequences in each class 
that individuals have. Most individuals possessed a few different sequences in the 
L1, mL1 L2, and mL2 classes suggesting that these enzymes are a regular member 
of the GI community; however, the activity of various sequences within each class 
may be redundant such that each individual needs only one sequence of each type. 
All individuals possessed at least one nL GUS and the average nL GUS sequence 
content was 11 ± 5 nL GUS sequences. This suggests that each nL GUS enzyme 
may be selective for a specific substrate so that each individual maintains several nL 
GUS enzymes in order to process varying but related substrates. Alternatively, only 
28% of individuals contained a mL1mL2 GUS sequence and most of those 
individuals contained only one mL1mL2 sequence. While all individuals sampled 
were considered healthy, we do not have details about significant variations in their 
diet or genetics that might cause significant changes in the glucuronidated 
compounds present in their GI that are degraded by mL1mL2 GUS enzymes. 
Despite this interesting distribution of total number of GUS sequences and number 
of sequences in each loop class, this data does not take into account the abundance 
or expression of these sequences. It is well known that some bacteria are much 
more abundant in the microbiota and it is also possible that some bacteria contain 
more than one GUS sequence, either of different sequence, different class, or 
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duplication of a gene. Future analysis will account for abundance of each gene by 
using normalized read counts.     
  We are also interested in which bacteria express each of the identified GUS 
sequences. We were able to match the most abundant sequence of each loop class 
from each of the 139 individuals to deposited reference genomes in order to assign 
the taxonomy of the expressing bacteria. Looking at the phyla level yielded 
interesting trends in distribution of GUS sequences of each loop class. All loop 
classes except for L1 were dominated by bacteria of the Bacteroidetes phylum. It 
seems likely that the L2 and mL1mL2 GUS sequences are found exclusively in the 
Bacteroidetes phylum. The mL2 class contained the only identified GUS sequences 
from the Verrucomicrobia phylum. The mL1 and nL classes include sequences from 
the Firmicutes phylum in addition to Bacteroidetes but sequences from Firmicutes 
seem to be less common.  The L1 class presented a unique taxonomic distribution; 
although over half of the sequences could not be matched to a deposited reference 
genome, the remaining sequences were exclusively from the Firmicutes and 
Proteobacteria phyla. This is the only class that included a sequence from the 
Proteobacteria phylum. While previous characterization has focused on L1 class 
enzymes from the Firmicutes (SaGUS, CpGUS) and Proteobacteria (EcGUS) phyla, 
this new dataset shows that there is a wide range of GUS sequence as well as 
bacterial diversity that remains to be characterized in order to better understand the 
GUS family of enzymes. Indeed, we have chosen sequences from each of the loop 
classes in order to characterize the structure and function of these novel GUS 
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enzymes. An exploration of the function of these enzymes is presented in Chapter 7 
of this thesis.  
This exploration of the HMP sequence repository establishes the first catalog 
of GUS sequences based on homology to characterized bacterial enzymes. This 
new information about the diversity of sequences included in this enzyme class will 
lead to better understanding of the function of these enzymes in the human GI 
microbiota and their impact on human health. 
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Bacterium NxKG motif  
positions 
Catalytic E 
residues 
positions 
N and Y motifs 
positions 
Escherichia coli 566, 568, 569 413, 504 412, 468 
Clostridium 
perfringens 
567, 569, 570 412, 505 411, 468 
Streptococcus 
agalactiae 
563, 565, 566 408, 501 407, 464 
Bacteroides fragilis 547, 549, 550 395, 476 394, 445 
	
Table 6.1. Key active site residues used for β-glucuronidase Identification. 
 
 
 
 
 
 
 
 
 
Category Residues in Loop 1 
region- EcGUS 356-380 
Residues in Loop 2 
region- EcGUS 416-419 
No Loop (nL) < 10 < 9 
Loop 1 (L1) > 15 < 9 
Mini Loop 1 (mL1) ≤ 15 and ≥ 10 < 9 
Loop 2 (L2) < 10 ≥ 12 
Mini Loop 2 (mL2) < 10 ≥ 9 and < 12 
MiniLoop 1 + 
MiniLoop 2 (mL1mL2) 
≤ 15 and ≥ 10 ≥ 9 and < 12 
 
Table 6.2. Criteria used for β-glucuronidase Loop Classification 
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Stool Samples 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. Workflow for Identification and Classification of Novel GUS 
Sequences 
Protein sequences for stool samples from the HMP Clustered Genes (HMGC) or the 
HMP Gene Indices (HMGI) were aligned to previously characterized GUS 
sequences in order to identify sequences containing the key active site residues. 
These novel GUS sequences were then classified according to the loop features 
they contain.  
 
 
	
Novel 
GUS Sequences 
NxKG	motif	
	
N	and	Y	Motifs 
Catalytic	E	
Residues 
No Loop  Loop 1  Loop 2  Mini Loop 1 Mini Loop 2 Mini Loop 1  
Mini Loop 2 
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Figure 6.2. Identification of Novel GUS Sequences from HMGC- HMP Clustered 
Gene Indices Database  
A. 293 Non-Redundant Novel GUS Sequences were identified from the HMGC 
database.  
B. Distribution of protein sequence length of the 293 Novel GUS Sequences. 
A. 
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Figure 6.3. Identification of Novel GUS Sequences from HMGI- HMP Gene 
Indices Database  
A. 3013 GUS Sequences were identified from the HMGI database. N is the total 
number of GUS sequences in each individual. 139 individuals were sampled. 
B. Number of GUS Sequences found in each individual in the HMGI database.  
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H_sapiens          RYGIVVIDECPGVGLALPQF---------------F-----NNVSLHHHMQVMEEV 411 
F_prausnitzii      EEGFLIIDEVPAVGFMQSTANFLAANQGNGRQQGFFEK-ETTPALLKNHKAALTDM 400 
E_coli             EHGIVVIDETAAVGFNLSLGIGF--EAGN-KPKELYSEEAVNGETQQAHLQAIKEL 395 
S_agalactiae       RMGVLVIDEVPAVGLFQNFNASL--DLSP----KDNGT-WNLMQTKAAHEQAIQEL 390 
C_perfringens      REGIVVIDETPAVGLHLNFMAT---GFGG-DAP-KRDT-WKEIGTKEAHERILREL 394 
E_eligens          EEGIVVIDETTAVGVNLQFGGGA--NFGG-ERIGTFDK-EHGVQTQEHHKDVIRDL 407 
P_merdae           ELGILVWEEIPWCRGG-----------------------LGGDVYKKQARRMLANM 394 
H11G11-BG          ECGMAVWAEIPYISRH-------------------------MPGGRENTVSQMKEL 358 
B_fragilis         KHGIVTWAEIPFVGPGGYADKGF----------------VDQASFRENGKQQLIEL 377 
B_ovatus           ENGIILWTEIPMCGPGGQAFTGF----------------VDTEGYKDNARLAVKEL 379 
B_uniformis        KLGMLAWEEIPIIDIV-----------------------PNTPGYGDNCERNLREM 383 
B_dorei            ELGLIVWSEICVVNEV-----------------------RKNTAFAHNCKEMLKEM 385 
 
 
 
 
H_sapiens          VRRDKNHPAVVMWSVANEPASHLE--------------SAGYYLKMVIAHTKSLDP 452 
F_prausnitzii      IDRDKNHPSVIAWSLLNEPQCTSA--------------GTEEYFKPLFELARRLDP 442 
E_coli             IARDKNHPSVVMWSIANEPDTRPQ--------------GAREYFAPLAEATRKLDP 436 
S_agalactiae       VKRDKNHPSVVMWVVANEPASHEA--------------GAHDYFEPLVKLYKDLDP 434 
C_perfringens      VSRDKNHPCVVMWSVANEPDSDSE--------------GAKEYFEPLIKLTKELDP 436 
E_eligens          ISRDKNHACVVMWSIANEPDSAAE--------------GAYDYFKPLYDLARELDP 449 
P_merdae           IVQHHNHPAVIIWGLGNENDWPNDFNTFDKS-------AIRAFMKELHDMAHRLDD 442 
H11G11-BG          IYQNINHPSIIVWGLSNEITMNGASD----S-------SLIENHRMLNDLVHKIDP 402 
B_fragilis         IRQHYNHPSICFWGLFNELKEV-------GD-------NPVEYVKELNALAKQEDP 418 
B_ovatus           VYQKFNHPSICFWGICNEILVSDGKRFVEYD-------NPIPFIKELNGIYKSIDS 427 
B_uniformis        IRQHYNHPSIITWGYMNEILLVTQRKYKTEAELKPVLERTLALANRLERVLKEEDS 438 
B_dorei            ILQNYNHPSVVLWGAMNELWDYHKQ--------------AIALARELEALKKELDP 426 
A. 
	
Loop	1	Region	
Loop	2	Region	
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Figure 6.4. Classification of Novel GUS Sequences by Loop 
A. Example of multiple sequence alignment used to assign loop category according 
to the specifications set out in Table 6.2. The bacterium from which each sequence 
was taken is color-coded for the assigned loop class. Purple- no loop, red-Loop 1, 
royal blue- Loop 2, green- Mini Loop 1, light blue- Mini Loop 2, magenta- Mini Loop 1 
Mini Loop 2.  
B. Distribution of sequences in each loop class of the 293 Non-redundant Novel 
GUS Sequences found in the HMGC database. 
C.  Distribution of sequences in each loop class of the 3013 GUS Sequences found 
in the HMGI database. 
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Figure 6.5. Number of GUS Sequences of Each Loop Class Found per 
Individual 
A. Number of no coverage (nc) GUS Genes per individual. 
B. Number of Loop 1 (L1) GUS Genes per individual. 
C.  Number of Mini Loop 1 (mL1) GUS Genes per individual. 
D. Number of Loop 2 (L2) GUS Genes per individual. 
E. Number of Mini Loop 2 (mL2) GUS Genes per individual. 
F. Number of Mini Loop 1 Mini Loop 2 (mL1mL2) GUS Genes per individual. 
G. Number of No Loop (nL) GUS Genes per individual.  
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Name Phylum Count 
Faecalibacterium prausnitzii Firmicutes 13 
Eubacterium eligens CAG:72 Firmicutes 11 
Eubacterium sp. CAG:76 Firmicutes 7 
Eubacterium sp. CAG:38 Firmicutes 5 
Eubacterium eligens Firmicutes 4 
Uncultured bacterium (fragment) Unknown 4 
 
 
Name Phylum Count 
Bacteroides vulgatus Bacteroidetes 11 
Bacteroides vulgatus Bacteroidetes 11 
Parabacteroides merdae Bacteroidetes 9 
Bacteroides sp. CAG:98 Bacteroidetes 8 
Bacteroides dorei Bacteroidetes 7 
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Name Phylum Count 
Bacteroides MSP Bacteroidetes 15 
Bacteroides uniformis 
CAG:3 
Bacteroidetes 11 
Bacteroides vulgatus Bacteroidetes 9 
Bacteroides sp. 3_1_23 Bacteroidetes 9 
Bacteroides uniformis Bacteroidetes 8 
 
 
Name Phylum Count 
Parabacteroides merdae Bacteroidetes 38 
Bacteroides MSP Bacteroidetes 33 
Akkermansia sp. CAG:344 Verrucomicrobia 10 
Bacteroides cellulosilyticus 
CAG:158 
Bacteroidetes 10 
Bacteroides cellulosilyticus Bacteroidetes 6 
 
 
 
 
115
11
L2	GUS	Sequences
Bacteroidetes Unknown
37
11
1
mL2	GUS	Sequences
Bacteroidetes Verrucomicrobia Unknown
C. 
D. 
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Name Phylum Count 
Bacteroides ovatus Bacteroidetes 12 
Bacteroides ovatus Bacteroidetes 12 
Bacteroides 754 Bacteroidetes 4 
Bacteroides MSP Bacteroidetes 2 
 
 
Name Phylum Count 
Bacteroides uniformis Bacteroidetes 24 
Bacteroides dorei Bacteroidetes 19 
Bacteroides vulgatus Bacteroidetes 9 
Parabacteroides 
merdae 
Bacteroidetes 8 
Bacteroides 
massiliensis 
Bacteroidetes 7 
 
 
Figure 6.6. Predicted Bacteria Containing GUS Sequence of Each Loop Class  
For each of individual, the most abundant GUS sequence in each loop class was 
matched to a deposited reference genome using BLASTp. The matched organism, 
phylum of that organism, and number of individuals for which each sequence was 
the most abundant sequence of that loop class (count) is presented for the top five 
most common sequences for the Loop 1 (A), mini Loop 1 (B), Loop 2 (C), mini Loop 
2 (D), mini Loop 1 mini Loop 2 (E), and no loop (F) classes. Bolded sequences were 
chosen for further characterization.  
30
1
mL1mL2	GUS	Sequences
Bacteroidetes Unknown
88
46
11
nL GUS	Sequences
Bacteroidetes Firmicutes Unknown
E. 
F. 
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CHAPTER 7: FUNCTIONAL CHARACTERIZATION OF β-GLUCURONIDASE 
ENZYMES IDENTIFIED IN THE HUMAN GASTROINTESTINAL TRACT 
 
Introduction 
 Changes in the human gut microbiota have been linked to many disorders 
including obesity, inflammatory bowel disease, and intensity of Clostridium difficile 
infection (1, 2). The activity of specific microbes in the gut has also been linked to 
the development of heart disease and varied response to drug therapy (3, 4). One 
drug that has varying effects because of the microbes in the intestine is the 
chemotherapy irinotecan (CPT-11). The active form of irinotecan, SN-38, is 
inactivated in the liver during Phase II drug metabolism by the addition of a 
glucuronide sugar to form SN-38-glucuronide (SN-38G) (5-7). SN-38G is then 
excreted from the body through the intestines. However, the β-glucuronidase (GUS) 
enzymes expressed by many microbes in the intestine can cleave the glucuronide 
sugar off SN-38G, resulting in active SN-38 that kills the intestinal epithelium and 
leads to dose-limiting diarrhea (8-11).  
 To better understand the activity of the GUS enzymes responsible for this 
drug toxicity, the Redinbo lab characterized the GUS enzyme from E. coli (EcGUS) 
and identified small molecule inhibitors that have been shown to be effective in 
decreasing the side effects of irinotecan in mice (12, 13). Acknowledging that the 
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microbiota is made up of a wide range of bacteria, we also characterized the GUS 
enzymes from Streptococcus agalactiae (SaGUS), Clostridium perfringens 
(CpGUS), and Bacteroides fragilis (BfGUS) (14). Characterization of these enzymes 
with inhibitors revealed a flexible loop outside the active site referred to as Loop 1 
(L1) that is essential for the efficacy of selective GUS inhibitors. The structures of 
these four enzymes revealed key features of GUS enzymes including conserved 
residues in the active site (14).  
 These key GUS features were used to compile a catalog of all GUS 
sequences found in the Human Microbiome Project (HMP) sequencing repository as 
described in Chapter 6. We identified 3,013 GUS sequences from the stool samples 
of 139 individuals which we were then able to break down into classes according to 
the presence, size, and location of a flexible loop outside the active site. As 
mentioned above, such a loop (L1) had previously been characterized but analysis 
of this GUS sequence catalog revealed a second loop (Loop 2, L2) found just 
downstream in the GUS sequence and predicted to occupy a similar position to L1. 
These loops can be completely absent or can be smaller in size (mini) than the 
previously characterized L1 found in EcGUS, SaGUS, and CpGUS. This gave us six 
loop classes: Loop 1 (L1), mini Loop 1 (mL1), Loop 2 (L2), mini Loop 2 (mL2), mini 
Loop1 mini Loop 2 (mL1mL2), and no loop (nL). We chose sequences from each 
class to express, purify, and characterize in order to further expand understanding of 
GUS enzyme function. These include the GUS enzymes from Eubacterium eligens 
(EeGUS, L1), Faecalibacterium prausnitizii (FpGUS, L1), Bacteroides uniformis 
(BuGUS, L2), Parabacteroides merdae (PmGUS, mL2), Bacteroides ovatus 
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(BoGUS, mL1mL2), and Bacteroides dorei (BdGUS, nL). The full sequence for each 
of these enzymes is presented in Appendix 3 in the alignment used to define their 
loop class.  
The following data confirm each of these GUS sequences as an active GUS 
enzyme and show initial characterization of the parameters under which the 
enzymes show optimal function. Because interest in this enzyme class originally 
stemmed from the ability to process SN-38G in the human intestine, we present the 
first evidence that a wide range of GUS enzymes are able to process the compound 
SN-38G. Finally, initial characterization of the GUS enzyme from Lactobacillus 
rhamnosus (LrGUS) is presented. This enzyme was not identified through analysis 
of the HMP, but rather by culturing bacteria found in a colon polyp biopsy sample. 
While this work is still ongoing, it greatly expands the current understanding of 
bacteria GUS enzymes and gives a better picture of the vast amount of chemistry 
these enzymes are responsible for in the human intestine.   
 
Materials and Methods 
Cloning of GUS Enzymes 
Clostridium perfringens GUS 
The C. perfringens β-glucuronidase (CpGUS) gene was amplified from the 
pLIC-MBP expression vector used in Wallace et al. and inserted into the pLIC-His 
vector using the primers: Forward, 5’-TACTCCAATCCAATGCGATGTTATATCCAA 
TAATTACAGAATCAAGACAATTAATAGAC-3’; Reverse, 5’-TTATCCACTTCCAATG 
CGCTATTTTTTGTATCCAAATTCCGGTATATTTGTCCATCTTTC-3’ (12).  
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Eubacterium eligens GUS 
The codon-optimized E. eligens β-glucuronidase (EeGUS) gene was 
purchases from Biobasic in the pUC57 vector. The gene was amplified and inserted 
into the pLIC-His vector using the primers: Forward, 5’-TACTTCCAATCCAATGCGA 
TGCTGTACCCTGTCCTGACTCAGTCTCG-3’; Reverse, 5’-TTATCCACTTCCAATG 
CGCTATTTGGTTTTGTAGCCAAATTCCGGAATGGTGGACCAG-3’.  
Faecalibacterium prausnitizii GUS 
The F. prausnitizii β-glucuronidase (FpGUS) gene was purchased from 
Biobasic in the pUC57 vector. The gene was amplified and inserted into the pLIC-
His vector using the primers: Forward, 5’-TACTTCCAATCCAATGCGATGAACCGTA 
GCCTGCTGTACCCTCGTG-3’; Reverse, 5’- TATCCACTTCCAATGCGCTTTTTTT 
GCGTTTTTTGAAGTCAACCG-3’.  
Bacteroides uniformis GUS 
The full-length B. uniformis β-glucuronidase (BuGUS) gene was purchased 
from Biobasic in the pUC57 vector. The gene was amplified and inserted into the 
pLIC-His vector using the primers: Forward, 5’- TACTTCCAATCCAATGCGATGG 
AGCGTGAGAAGAACACCCTGCCTCAAAAG-3’; Reverse, 5’-TTATCCACTTCCAAT 
GCGCTAATAAATGTTGCGCAGTTTAATGCCATTCAGGAAACACG-3’. The mature 
gene lacking the signal peptide was also cloned into the pLIC-His vector using the 
same reverse primer and the forward primer 5’- TACTTCCAATCCAATGCGCAACG 
TCAAACTCAAACCATCAACGACTCCTGGAAG-3’. 
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Parabacteroides merdae GUS 
The full-length P. merdae β-glucuronidase (PmGUS) gene was purchased 
from Biobasic in the pUC57 vector. The gene was amplified and inserted into the 
pLIC-His vector using the primers: Forward, 5’-TACTTCCAATCCAATGCGATGAAA 
TACCTGTTCGTCGCTTGCCTGCTGTG-3’; Reverse, 5’-TTATCCACTTCCAATGCG 
CTATTTCGGGCTTTTCAGTTCCAGAAACGCGGTC-3’. 
Bacteroides ovatus GUS 
The full-length B. ovatus β-glucuronidase (BoGUS) gene was purchased from 
Biobasic in the pUC57 vector. The gene was amplified and inserted into the pLIC-
His vector using the primers: Forward, 5’- TACTTCCAATCCAATGCGATGAAGAA 
CCGCATCATTATTCTGTGCCTGGTATGCCTGTG-3’; Reverse, 5’- TTATCCACTTC 
CAATGCGCTATTTAATGCAGTACCATTCGCAGGTGTCGG-3’. The mature gene 
lacking the signal peptide was also cloned into the pLIC-His vector using the 
primers: Forward, 5’- TACTTCCAATCCAATGCGCAGGAAACTTCTCCGCGTA 
CTATCTTCTCTCTGAAC-3’; Reverse, 5’-TTATCCACTTCCAATGCGCTATTTA 
ATGCAGTACCATTCGCAGGTGTCGGACAG-3’. 
Bacteroides dorei GUS 
The full-length B. dorei β-glucuronidase (BdGUS) gene was purchased from 
Biobasic in the pUC57 vector. The gene was amplified and inserted into the pLIC-
His vector using the primers: Forward, 5’-TACTTCCAATCCAATGCGATGAAGCGTT 
TCGCAGGTTGGCTGCTGTTCTTC-3’; Reverse, 5’-TTATCCACTTCCAATGCGCT 
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AGCGAATTTTTTTAACTTTCAGGCCGCTAATTACGCCCTG-3’. The mature gene 
lacking the signal peptide was also cloned into the pLIC-His vector using the same 
reverse primer and the forward primer 5’-TACTTCCAATCCAATGCGAGCGAGAT 
CAGCATCACTGACTCTTGGAAGTATAAG-3’. 
Lactobacillus rhamnosus GUS 
Lactobacillus rhamnosus was isolated from colon polyp biopsies and cultured 
by the Keku lab at the University of North Carolina at Chapel Hill (UNC-CH). The 
bacteria were cultured in clostridial media (Becton & Dickinson) for 48 hours in an 
anaerobic chamber at 37°C. 1 ml of bacterial culture was pelleted and the resulting 
cell pellet used for genomic DNA isolation. Genomic DNA was isolated using the 
GeneJet Genomic DNA Purification Kit (Thermo Scientific). 
The β-glucuronidase gene from L. rhamnosus (LrGUS) was amplified via 
PCR using the primers: Forward, 5’-TACTTCCAATCCAATGCGATGGAGACATC 
GTTGTTATACCCAGTGAC-3’; Reverse, 5’-TTATCCACTTCCAATGCGCTCTTT 
GCTTTATAATCCAGCGGCAGCTTATTC-3’. The gene was then inserted into the 
pLIC-His vector using ligation-independent cloning (Sondek Lab, UNC-CH). 
Expression and Purification of GUS Enzymes 
E. coli GUS 
 E. coli β-glucuronidase (EcGUS) was expressed and purified as previously 
described (12). 
Streptococcus agalactiae GUS 
 S. agalactiae β-glucuronidase (SaGUS) was expressed and purified as 
previously described (14).    
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CpGUS 
The newly cloned His-tagged protein was expressed and purified as 
described for the MBP-tagged CpGUS in Wallace et al. (14). 
BfGUS 
 The BfGUS gene in the pSGX3 plasmid was transformed into BL21 DE3 Gold 
cells for enzyme expression. Cells were grown in the presence of kanamycin in LB 
medium with vigorous shaking at 37ºC to an OD600  of 0.5, at which point the 
temperature was reduced to 18ºC. At OD600=0.8, protein expression was induced by 
the addition of 0.1 mM isopropyl-1-thio-D-galactopyranoside (IPTG) and incubation 
continued overnight. Cells were collected by centrifugation at 4500xg for 20 min at 
4ºC in a Sorvall (model RC-3B) swinging bucket centrifuge. Cell pellets were 
resuspended in 50 mL Buffer A (50 mM Tris HCl pH 7.8, 50 mM Imidazole, 10 mM 
methionine, 500 mM NaCl, 1 mM DTT, 5% glycerol), DNase, lysozyme, and a Roche 
complete-EDTA free protease inhibitor tablet. Resuspended cells were sonicated 
and clarified via centrifugation at 14,500xg for 60 min in a Sorvall (model RC-5B). 
The lysate was flowed over a Ni-NTA HP column (GE Healthcare) loaded onto the 
Aktaxpress FPLC system (Amersham Bioscience) and washed with Buffer A. Protein 
was eluted with Buffer B (50 mM Tris HCl pH 7.8, 500 mM Imidazole, 10 mM 
methionine, 500 mM NaCl, 1 mM DTT, 5% glycerol). Fractions containing the protein 
of interest were combined and passed over a HiLoad™ 16/60 Superdex™ 200 gel 
filtration column. Protein was eluted in S200 Buffer (10 mM HEPES pH 7.5, 150 mM 
NaCl, 10 mM methionine, 1mM DTT, 5% glycerol). Fractions were analyzed by SDS-
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PAGE and those with >95% purity were combined and concentrated for long-term 
storage at -80ºC.   
EeGUS, FpGUS, BuGUS, PmGUS, BoGUS, and BdGUS  
 The corresponding plasmids described above were each transformed into 
BL21-DE3 AI competent cells (Invitrogen) for enzyme expression. Cells were grown 
in LB medium to an OD600 of 0.8 in the presence of ampicillin with vigorous shaking 
at 37ºC. Transcription of the T7 RNA polymerase was induced by addition of 
arabinose to a final concentration of 0.2% (v/v) and the temperature was reduced to 
18ºC. Thirty minutes later protein expression was induced by the addition of 100 µM 
IPTG and further incubation overnight. Cells were collected, lysed, and purified as 
described above for BfGUS with the following buffers: Buffer A- 25 mM HEPES pH 
7.4, 50 mM Imidazole, 500 mM NaCl, 5% glycerol, 0.5 mM TCEP; Buffer B- 25 mM 
HEPES pH 7.4, 250 mM Imidazole, 500 mM NaCl, 5% glycerol, 0.5 mM TCEP; S200 
Buffer- 20 mM HEPES pH 7.4, 100 mM NaCl, 5% glycerol, 0.5 mM TCEP. Protein 
with >95% purity was stored at -80ºC for use in assays.   
PNPG Assay 
 Para-nitrophenyl glucuronide (PNPG) was purchased as a solid and 
suspended in water to a concentration of 50 mM. Reactions were conducted in 96-
well, black, clear-bottom assay plates (Costar, Tewksbury MA) at 37ºC with 50 µL in 
total volume. The reaction consisted of 10 µL assay buffer (100 mM HEPES, 250 
mM NaCl, pH 7.4), 10 µL enzyme, and 30 µL of substrate. The product formation 
was measured via absorbance at 405 nm using a PHERAstar Plus microplate reader 
(BMG Labtech, Ortenberg, Germany). To determine kinetic values, initial velocities 
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were determined for multiple substrate concentrations and Michaelis-Menten kinetics 
use to calculate KM, kcat, and catalytic efficiency. For pH screening, reactions were 
conducted using assay buffer at pH 4, 4.5, 5, 5.5, 6, 6.5, 7, and 7.4. At each time 
point, the reaction was quenched with 100 µL of 0.2 M sodium carbonate. When all 
reactions were quenched, product formation was measured. 
SN-38G HPLC 
Each reaction consisted of 500 nM bacterial GUS enzyme or 2 µM 
BovineGUS enzyme and 10 µM SN-38G substrate in a total volume of 250 µL. 
Reactions were incubated at room temperature and a 20 µL sample taken at each 
time point and loaded directly on to the HPLC column.  
GUS enzyme processing of SN-38G was analyzed by separation of SN-38 
and SN-38G via HPLC. Buffer was flowed at 0.5 ml/min over a Phenomenex Luna 5 
µm C18(2) reverse phase column. Buffer A consisted of 20 mM ammonium acetate 
pH 3.5 and Buffer B was 100% acetonitrile. SN38 and SN38G was visualized using 
UV detection with excitation at 368 nm and emission at 515 nm. Buffers were mixed 
as follows: 
Time	 %	B	
1	min	 10%	
3	min	 30%	
12	min	 34%	
14	min	 34	%	
15	min	 35%	
19	min	 100%		
22	min	 10%	
22.5	min	 STOP	
 
SN-38G eluted at approximately 8 minutes while SN-38 eluted at 13.3 minutes. The 
area under the curve was calculated for each peak and a rate used to calculate the 
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percent signal in the SN-38G peak. The percent SN-38G is reported for each time 
point. 
SN-38G Assay 
SN-38-glucuronide (SN-38G) was purchased as a solid from Toronto 
Research Chemicals-Canada and suspended in 100% DMSO to a concentration of 
5 mM. Reactions were conducted in 96-well, half-area, black, clear-bottom assay 
plates (Costar, Tewksbury MA) at 37°C with 50 µL in total volume. The reaction 
consisted of 10 µL assay buffer (100 mM HEPES, 250 mM NaCl, pH 7.4), 10 µL 
enzyme, and 30 µL of substrate. The disappearance of substrate as it is processed 
by GUS was measured via Ex 375 nm Em 415 nm fluorescence. Initial velocities 
(Fu/sec) were determined for multiple substrate concentrations.  
 
Results 
GUS Activity 
 Analysis of the Human Microbiome Project (HMP) sequencing repository as 
described in Chapter 6 allowed for the identification of novel GUS sequences from 
which we chose six representative proteins to characterize in addition to the four 
previously characterized enzymes. These new proteins will also allow us to explore 
the activity of each of the newly defined loop classes. The Loop 1 (L1) class is 
represented by the GUS enzymes from E. coli (EcGUS), S. agalactiae (SaGUS), C. 
perfringens (CpGUS), E. eligens (EeGUS), and F. prausnitizii (FpGUS, L1). The mini 
Loop 1 (mL1) class is represented by the previously characterized B. fragilis 
(BfGUS). The Loop 2 (L2) class is represented by B. uniformis (BuGUS) and the 
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mini Loop 2 (mL2) class by P. merdae (PmGUS). B. ovatus (BoGUS) serves as the 
representative mini Loop 1 mini Loop 2 (mL1mL2) enzyme and B. dorei (BdGUS) is 
the no loop (nL) enzyme. We first set out to confirm activity of each purified enzyme 
using the substrate p-nitrophenyl glucuronide (PNPG). PNPG is a synthetic 
substrate with no physiological relevance but provides a quick and robust assay for 
visualizing GUS activity. As the four previously characterized enzymes had 
substantial activity at pH 7.4, this reaction condition was used initial characterization 
of the new enzymes as it is unclear where in the intestines these bacteria and their 
GUS may exist and therefore what the physiologically relevant pH may be. 
 The Redinbo lab has previously characterized Loop 1 (L1) enzymes EcGUS, 
SaGUS, and the MBP-tagged version of CpGUS and the kinetic parameters of these 
enzymes is presented for comparison (12, 14). From the novel GUS sequences 
identified from the HMP sequencing repository, we identified EeGUS and FpGUS as 
sequences that are often the most abundant L1 GUS in individuals. We were able to 
confirm that these enzymes are able to process PNPG. EeGUS showed moderate 
but still substantial activity as compared to the efficient EcGUS and SaGUS 
enzymes with a kcat of 41 ± 3 s-1, KM of 0.49 ± 0.09 mM, and a catalytic efficiency of 
83.7 s-1mM-1 (Table 7.1). FpGUS showed poor activity; while an increase in PNP 
could be seen, the production was too slow to be quantified in this assay. BfGUS 
has been previously characterized and is considered the representative mL1 
enzyme (14). Representative L2 enzyme BuGUS showed a catalytic efficiency 
similar to that of BfGUS (9 s-1mM-1 and 9.5 s-1mM-1 respectably); however, this is a 
result of varying kcat and KM values. BfGUS displays a kcat of 18 ± 1 s-1 and a KM of 
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1.9 ± 0.3 mM as compared to a kcat of 4.5 ± 0.007 s-1 and a KM of 0.5 ± 0.03 mM for 
BuGUS (Table 7.1). Both mL2 enzyme PmGUS and mL1mL2 enzyme BoGUS 
showed activity that was too slow to quantify in this assay. However, we did see 
significant activity over no protein controls that indicates that these enzymes do 
function as GUS enzymes. Finally, no loop (nL) enzyme BdGUS exhibited poor but 
quantifiable activity with a kcat of 21 ± 2 s-1, KM of 2.7 ± 0.5 mM, and a catalytic 
efficiency of 7.7 s-1mM-1 (Table 7.1). This data confirms that each of these newly 
expressed GUS enzymes is able to process a glucuronidated substrate and 
validates the selection criteria used to identify GUS sequences in Chapter 6. 
However, the poor activity seen with many of these enzymes suggests that 
additional optimization of purification procedures or assay conditions may be 
beneficial.     
SN-38G Processing 
 Much of the interest in GUS enzymes has been driven by the discovery that 
they are responsible for cleaving the glucuronide sugar off inactivate SN-38G that 
excreted through the intestines. This cleavage results in active SN-38 in the 
intestines that leads to epithelial cell death and significant drug toxicity for many 
patients. With this as the focus, we set out to characterize the ability of each of the 
GUS enzymes to process SN-38G.  
 Previous quantification of SN-38G to SN-38 ratios and, indeed, the work that 
established GUS enzymes as the driver of this drug toxicity has been carried out 
using HPLC quantification of SN-38G and SN-38 presence in samples. We set out to 
use this technique to establish whether these GUS enzymes of interest are able to 
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process SN-38G. For each reaction the GUS enzyme was incubated with SN-38G 
and samples were analyzed for the SN-38G:SN-38 ratio at various time points. The 
GUS from Bos taurus (BovineGUS) was used as a negative control as it has 
previously been shown that mammalian GUS enzymes have poor activity against 
SN-38G. Indeed, we found that over 67.5 minutes, BovineGUS was able to process 
only 20% of the SN-38G into SN-38 (Figure 7.1). Alternatively, EcGUS, SaGUS, and 
BfGUS were all able to process SN-38G very efficiently with only trace amounts 
remaining after 22.5 minutes (Figure 7.1). While it had been previously established 
that EcGUS can process SN-38G, this is the first evidence that SaGUS and BfGUS 
can also process this substrate. 
 Because HPLC is a time and labor-intensive assay, we developed a 
fluorescence-based assay to more quickly quantify GUS activity against SN-38G. As 
shown in Figure 7.2A, SN-38G and SN-38 exhibit different emission spectra when 
excited at 375 nm. This allows for selective visualization of just one compound at the 
peak of their emission profile. Because SN-38 has poor solubility in the aqueous 
solutions needed to maintain enzyme activity, we chose to measure the loss of SN-
38G signal at Ex 375 nm Em 415 nm. The activity of each of the GUS enzymes was 
measured against varying concentrations of SN-38G and the rates of SN-38G 
cleavage are shown in Figure 7.2B. Here higher rates of SN-38G cleavage mean 
more efficient processing of SN-38G. With more replicates and controls, this data 
will lead to kinetic values like those established in the PNPG assay. These 
preliminary data mimic what was seen in the HPLC analysis of SN-38G: EcGUS, 
SaGUS, and BfGUS are able to efficiently process SN-38G. Because this assay 
		 167	
allows for visualization of SN-38G cleavage at much shorter time points (seconds 
versus minutes) and at varying SN-38G concentrations, we are able to tease out the 
relative activities of these enzymes. EcGUS is the most efficient at processing SN-
38G of previously characterized enzymes while SaGUS and BfGUS show similar, 
less efficient processing. Interestingly, L1 GUS EeGUS showed much more efficient 
SN-38G processing than EcGUS. This solidified the L1 class as the dominant 
processors of SN-38G. No loop GUS BdGUS showed an ability to process SN-38G 
similar to BfGUS. BoGUS, a mL1mL2 enzyme, was also able to process SN-38G but 
with low efficiency. Alternatively, no cleavage of SN-38G was seen with L2 enzyme 
BuGUS and mL2 enzyme PmGUS. While future characterization will give a much 
more complete picture of cleavage SN-38G by GUS enzymes, this analysis is the 
first evidence that enzymes within the GUS family may have substrate specificity. 
GUS Activity at Varying pH 
 The initial characterization of the GUS enzymes presented above lead us to 
realize there is much about this enzyme family that has not been previously 
explored. Upon closer analysis we saw that the attachment of an MBP-tag to the 
GUS enzyme as in the CpGUS construct impedes the activity of this enzyme even 
though the MBP tag was required for crystallization. We cloned CpGUS into the 
pLIC-His vector to eliminate the MBP-tag and moved forward with characterization of 
this construct. In addition, we found that BuGUS, PmGUS, BoGUS, and BdGUS 
each contain an approximately 20 amino acid signal sequence at the N-terminal of 
each protein sequence that is predicted to be cleaved before the protein is 
transported to the periplasmic space of these gram-negative bacteria. In order to 
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produce the form of the enzyme that is most likely to interact with substrates, we 
cloned these genes without the signal sequence portion. Finally, as mentioned 
above, it is unclear where the bacteria expressing these GUS enzymes may be 
found in the intestine and therefore what pH the enzymes are likely to function in. 
GUS enzymes purified from other environments have previously been shown to 
have optimal activity at pH values much lower than 7.4 (15, 16). Therefore, we set 
out to test the activity of these optimized enzyme constructs against PNPG at a 
range of pH values.       
 EcGUS and SaGUS show similar activity at pH values ranging from 5 to 7.4 
(Figure 7.3A, B). While both enzymes show almost no activity at pH 4, EcGUS 
exhibits moderate activity at pH 4.5 while SaGUS has poor activity at the same pH. 
The His-tagged construct of CpGUS shows high activity at pH values from 5.5 to 7.4 
and only slightly lower activity at pH 5 (Figure 7.3C). Similar to SaGUS, CpGUS has 
almost no activity at pH 4 and very poor activity at pH 4.5. EeGUS exhibits activity at 
all pH values tested but has optimal function from pH 4.5 to 6.5 (Figure 7.3D). 
Significant but lower activity is seen at pH 4, 7, and 7.4. Future characterization of 
EeGUS will be conducted at pH 6.5. FpGUS exhibits optimal activity from pH 4.5 to 
5.5 (Figure 7.3E). A moderate decrease in activity is seen at pH 4, 6, 6.5, and 7. At 
pH 7.4, activity is greatly attenuated as seen in initial kinetic activity assays. Future 
characterization of FpGUS activity will be conducted at pH 5. BuGUS shows optimal 
function at pH values 4.5 to 7 (Figure 7.3F). Activity is still strong but slightly less 
robust at pH 7.4 while activity is very poor at pH 4. A pH of 6.5 will be used for future 
BuGUS assays. These results highlight the differences between each of these GUS 
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enzymes and suggest that they may function in varying environments within the 
intestine. We predict that removal of the signal peptide and optimization of the assay 
pH will allow us to quantify activity for the PmGUS and BoGUS in addition to 
providing important information about how each of these enzymes functions.  
Lactobacillus rhamnosus GUS 
 While characterization of GUS enzymes has focused primarily on those 
identified in the HMP sequencing analysis described in Chapter 7, the GUS enzyme 
from Lactobacillus rhamnosus (LrGUS) has also been identified as an enzyme of 
interest. This enzyme was identified as an interesting target after L. rhamnosus was 
isolated from colon polyp biopsies and cultured by the Keku lab at UNC-CH. After 
observing very poor activity against PNPG and no activity against SN-38G (data not 
shown), a pH screen was conducted to find the optimal pH for activity assays. As 
shown in Figure 7.4, LrGUS is indeed inactive at pH 7.4 but shows increasing 
activity as the assay conditions become more acidic. The optimal activity of LrGUS 
is seen from pH 4.5 to 5.5 in this assay. This is congruent with a previous analysis of 
function of partially purified LrGUS that found optimal activity at pH 4.5 with similar 
activity at pH 3.5 and 5 (17). Further characterization of LrGUS will be conducted at 
pH 4.5. Characterization of LrGUS extends this catalog of GUS enzymes from 
enzymes identified from healthy individuals to enzymes from a dysbiotic 
environment.   
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Discussion 
The role of human GI microbiota-associated GUS enzymes in the drug 
toxicity of irinotecan and other drugs is well established. However, only a small 
number of these enzymes have been characterized. The data presented here shows 
the wide variety of GUS sequences identified from the HMP in Chapter 6 are 
functional GUS enzymes that are able to process the glucuronidated substrate 
PNPG with varying affinities (Table 1). While this initial activity validates the rubric 
for identifying GUS sequences, further characterization shows that we still have 
much to learn about the activity of these enzymes. Figure 7.4 shows that despite 
many similarities in sequence, especially in the active site, these enzymes have 
optimal function at varying pH ranges. L1 enzymes EcGUS, SaGUS, CpGUS, 
EeGUS, and FpGUS are expected to be cytosolic. Alternatively, BuGUS and the 
enzymes characterized from the mL1, L2, mL2, mL1mL2, and nL classes have a N-
terminal signal sequence that we predict sends these enzymes to the periplasmic 
space of gram-negative bacteria. The cytosol is expected to be buffered; however, 
the pH of the surrounding environment has been shown to have a large effect on the 
internal pH of bacteria and some bacteria such as Lactobacillus are known to 
maintain a slightly more acidic cytosol. In contrast, the pH of the periplasmic space 
is likely highly dependent on the pH of the surrounding environment. Little work has 
been done to date to characterize the distribution of various bacterial species along 
the intestine, but we hypothesize that the optimal pH range of the function of a 
bacteria’s GUS enzyme will match the pH of the locations in which that bacteria is 
found within the intestine. For instance, enzymes such as EcGUS and SaGUS have 
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optimal function at a wide range of pH values and would therefore function 
regardless of where their host bacterium was in the intestine. Alternatively, FpGUS 
has a limited range of pH values at which it shows optimal function. We know the 
host bacteria F. prausnitzii can make its way to the end of the GI as this sequence 
was identified in stool samples, but we hypothesize that the bacteria are dominate 
higher in the GI where the pH is more acidic. Further characterization of the optimal 
function of these enzymes and their host bacteria will allow us to further refine this 
hypothesis and understand the diverse ecosystems of the human GI.  
Other members of the Redinbo lab are focused on optimizing the previously 
discovered GUS inhibitors in order to eliminate GUS-mediated irinotecan drug 
toxicity. Therefore, it is important for us to understand which GUS enzymes are 
responsible for the reactivation of SN-38 in the GI. Figure 7.2 and 7.3 present the 
first in-depth analysis of this reaction with purified GUS enzymes. It had been 
previously established that purified EcGUS is able to efficiently process SN-38G, but 
this data shows that the reaction proceeds much more quickly than the 1-hour time 
point previously analyzed (12). Because of the similarity between the L1 enzymes, it 
was not surprising that SaGUS and EeGUS are also able to process SN-38G well. 
Previous characterization of the active site loop L1 had established its role in the 
efficacy of the GUS inhibitors, but it was still unclear if L1 or any variation of this 
active site loop played a role in substrate specificity. We hypothesized that L1, and 
perhaps L2, would act as a gate over the active site in order to hold in small 
substrates such as PNPG and SN-38G. Therefore, the activity of BfGUS seen in the 
HPLC analysis and refined in the fluorescence assay was a surprise that does not 
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support this hypothesis. The relatively high activity of both BfGUS and BdGUS 
against SN-38G have lead us to explore other features in the active site that may 
play an important role in substrate specificity.      
Finally, initial characterization of the LrGUS enzyme is presented. All 
sequences identified in the HMP were from the stool samples of healthy donors, 
which represents a limited snapshot of the human microbiota. We identified the 
LrGUS enzyme from cultured bacteria from a colon polyp biopsy. While stool 
samples contain primarily mobile bacteria that reside in the lumen of the intestine, 
bacteria cultured from this biopsy are more likely to be adherent to the mucus layer 
of the intestine. In addition, there is evidence that dysbiosis of the microbiota can 
lead to colon cancer, so bacteria cultured from potentially cancerous polyps may 
play a role in carcinogenesis. As we expand the current understanding of GUS 
enzymes, we would also like to expand the sources from which characterized 
sequences come and this is the first effort in this direction.  
This chapter presents the first in-depth analysis of the function of a broad 
range of GUS enzymes. While bacterial GUS enzymes including EcGUS, SaGUS, 
CpGUS, and BfGUS have been characterized previously, this focus on GUS 
sequences derived from human stool or colon biopsy samples allows closer 
characterization of the chemistry catalyzed by these enzymes in the human GI. This 
initial analysis has shown that while previously characterized enzymes are highly 
active against glucuronidated substrates including PNPG and SN-38G, there is a 
wide range of GUS enzymes that are also active against those substrates and likely 
play a significant role in the human GI.      
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Enzyme	 Loop	Class	 kcat	(s-1)	 KM	(mM)	 kcat/KM	(s-1mM-1)	
EcGUS	 L1	 120	±	12		 0.13	±	0.01	 920	±	160	
SaGUS	 L1	 80	±	2		 0.36	±	0.03	 222	±	24		
MBP-CpGUS	 L1	 2.6	±	0.6	 1.1	±	0.2	 2.4	±	1		
EeGUS	 L1	 41	±	3	 0.49	±	0.09	 83.7	±	21	
FpGUS	 L1	 unquantifiable	 	 	
BfGUS	 mL1	 18	±	1	 1.9	±	0.3	 9.5	±	2		
BuGUS	 L2	 4.5	±	0.07		 0.50	±	0.03	 9	±	0.7		
PmGUS	 mL2	 unquantifiable	 	 	
BoGUS	 mL1mL2	 unquantifiable	 	 	
BdGUS	 nL	 21	±	2	 2.7	±	0.5	 7.7	±	2	
	
Table 7.1. Catalytic Activity of β-glucuronidase Enzymes at pH 7.4 
Data are presented as the average over 3 experiments ±	SEM.	kcat,	catalytic	rate;	KM,	
Michaelis	constant;	kcat/KM,	catalytic	efficiency.	 
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Figure 7.1. Analysis of β-glucuronidase Activity Against SN-38G via HPLC  
HPLC was used to quantify the amount of SN-38G remaining after incubation with 
the β-glucuronidase from Bos taurus (BovineGUS), S. agalactiae (SaGUS), C. 
perfringens (CpGUS), and B. fragilis (BfGUS) over time.  
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Figure 7.2. β-glucuronidase Activity Against SN-38G via Fluorescence  
A. Emission wavelength scan of SN-38G and SN-38 after excitation at 375 nm.   
B. Rate of SN-38G cleavage as measured by fluorescence at varying SN-38G 
concentrations by β-glucuronidases identified from the Human Microbiome Project.  
SN-38G SN-38 
Ex	375	nm	Em	415	nm 
0
10000
20000
30000
40000
50000
60000
400 500 600 700 800
Fl
uo
re
sc
en
ce
	U
ni
ts
Wavelength	(nm)
Ex	375	nm	Em	525	nm 
0
500
1000
1500
2000
2500
400 500 600 700 800
Fl
uo
re
sc
en
ce
	U
ni
ts
Wavelength	(nm)
A. 
B. 
		 176	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
 
 
 
 
 
 
 
 
Figure 7.3. Catalytic Activity of β-glucuronidase Enzymes at Varying pH  
Activity of EcGUS (A), SaGUS (B), CpGUS (His-tagged construct, C), EeGUS (D), 
FpGUS (E), and BuGUS (F) against a single PNPG concentration over time at pH 
values 4, 4.5, 5, 5.5, 6, 6.5, 7, and 7.4. 	
EcGUS	 SaGUS	
His-CpGUS	 EeGUS	
	
FpGUS	 BuGUS	
A. B. 
C. D. 
E. F. 
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Figure 7.4. Catalytic Activity of L. rhamnosus β-glucuronidase at Varying pH 
L. rhamnosus GUS (LrGUS) shows varying function against the substrate PNPG at 
pH values ranging from 4.5 to 7.4.  
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CHAPTER 8: CONCLUSIONS AND FUTURE DIRECTIONS FOR 
CHARACTERIZATION OF β-GLUCURONIDASE AND GI DRUG REACTIVATION 
 
Conclusions 
 β-glucuronidase (GUS) enzymes encoded by the human GI microbiota are 
responsible for the severe drug toxicity associated with the chemotherapy drug 
irinotecan (CPT-11). Initial work on this process by the Redinbo lab greatly 
expanded understanding of the E. coli-type GUS proteins and characterized 
inhibitors that are effective against mice models of irinotecan-induced drug toxicity. 
The work presented here compiles a catalog of GUS sequences mined from the 
Human Microbiome Project (HMP) sequencing repository. This catalog gives a new 
appreciation of the breadth of GUS sequences found within the human microbiome 
and suggests that this enzyme class may play a larger role in the intestinal 
ecosystem than previously explored. Previous efforts to catalog GUS proteins have 
depended on gene annotations, which we have shown are often incorrect due to the 
high sequence similarity, especially in the active site, between various glycoside 
hydrolases such as β-glucuronidases and β-galactosidases (1). This approach using 
one-to-one sequence alignments to identify the presence or absence of key 
conserved residues in all identified genes in the HMP sequences repository is a 
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much more robust approach that can be used to catalog any well characterized gene 
of interest.  
 This large catalog of GUS proteins is broken into smaller classes of 
sequences based on the presence or absence and size of two similar active site 
loops. Representative enzymes from each loop class were chosen and 
characterized as presented in Chapter 7. The seven new GUS enzymes presented 
here more than double the size of the catalog of microbial GUS proteins and allows 
us to explore the diverse function of this enzyme family. While this work has given us 
unique insight into GUS enzymes, it has also opened many new avenues for further 
research, some of which are explored below.  
 
Future Directions 
Further Characterization of the HMP GUS Sequence Catalogues 
 As described in Chapter 6, the analysis of the HMP sequencing repository 
provided two datasets of GUS sequences. The first dataset from the HMGC- 
Clustered Gene Indices database is a non-redundant catalog of GUS genes. While 
initial analysis of this dataset has shown an interesting distribution of sequence 
lengths (Figure 6.2 of Chapter 6), there is still much analysis to be done with these 
sequences. The first goal is to match each sequence in this dataset to one of the 
reference genomes of bacteria cultured as part of the HMP or deposited in the NCBI 
Reference Sequence Database. This will allow us to associate each GUS sequence 
with a bacteria or closely related set of bacteria that the sequence was likely isolated 
from in the HMP fecal samples and compile a list of GUS-containing bacteria. This 
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smaller, non-redundant set also allows for better understanding of which enzymes 
contain features such as the extended C-terminal domain and signal peptide and if 
these features cluster with the active site loops.  
 The second dataset from the HMGI- Gene Indices is a redundant set of GUS 
sequences that can be grouped by which of the 139 individuals they were obtained 
from. Thus far we have analyzed the total number of GUS sequences each 
individual possessed and which loop class those sequences fell into. However, we 
have not taken into account the abundance of a sequence in each individual. It is 
likely that some bacteria and therefore their associated GUS are more abundant in 
the gut and therefore contribute more significantly to the intestinal environment. 
These abundant GUS sequences may be similar across individuals or may vary 
widely.  
Structure and Function of New GUS Enzymes 
 While we have identified the active site loops as an interesting variable region 
of this enzyme, continued functional and structural characterization of these 
enzymes will likely lead to several additional regions of interest. A quick glance at 
the sequence alignment of these enzymes presented in Appendix 3 already reveals 
small insertions and deletions; additional characterization may match those 
sequence changes to interesting functional changes. It is also likely that we will be 
able to link the variability in optimal pH conditions shown in Chapter 7 to changes in 
just a few amino acids within the active site of these enzymes.  
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SN-38G Processing 
 Chapter 7 includes the first evidence that GUS enzymes in addition to EcGUS 
can process SN-38G, including enzymes that cannot be inhibited by the well-
characterized inhibitors produced by the Redinbo lab. Despite not inhibiting GUS 
enzymes that process SN-38G, these inhibitors are effective in reducing the 
irinotecan-induced diarrhea in mice. This suggests we still have much to learn about 
GUS activity in vivo and which enzymes encounter SN-38G. Continued 
characterization of the bacteria that encode GUS sequences from the HMP analysis, 
will lead to better understanding of the regulatory mechanisms that may impact GUS 
expression and transport of glucuronidated compounds. The Redinbo lab is currently 
characterizing the GUS gene repressor (GusR) found in E. coli and a small number 
of related bacteria that allows for increased GUS expression when glucuronidated 
compounds bind GusR. There is also a known glucuronide transporter in the same 
operon in E. coli, but this transporter as well as the transporters that are likely 
present in other bacteria have not been characterized. It is possible that these 
transporters show substrate selectivity such that many of these GUS enzymes rarely 
come in contact with SN-38G. In addition to these molecular-level details, members 
of the Redinbo lab are also conducting mice experiments to measure the effect of 
irinotecan and inhibitor treatment on the microbiota. A better understanding of the 
complex environment in which GUS enzymes interact with SN-38G will allow for 
further optimization of previously characterized inhibitors and improve the efficacy 
against drug toxicity.  
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 A related area of exploration is characterization of why some patients 
experience severe diarrhea after irinotecan treatment while other patients have 
minimal side effects. We hypothesize that patients that experience severe diarrhea 
possess significantly more of the bacteria and GUS enzymes that are able to 
process SN-38G. We are interested in comparing microbiome samples from patients 
treated with irinotecan but with varying degrees of drug toxicity severity in order to 
correlate variation in the microbiota with severity of drug toxicity. If high-processing 
SN-38G bacteria are identified through molecular approaches, mouse studies, or 
patient data, it may be possible to design a screening tool to determine which 
patients are likely to react poorly to irinotecan treatment and would be ideal 
candidates for GUS inhibitor treatment.  
Other Glucuronidated Compounds 
 Both drugs and endogenous compounds are glucuronidated by UGT 
enzymes in liver. Although this work focuses on SN-38G, many other glucuronidated 
compounds are also processed by GUS enzymes in the GI. In fact, the Redinbo lab 
and collaborators have shown that GUS inhibitors are effective in reducing the size 
and number of small intestinal ulcers caused by non-steroidal anti-inflammatory 
drugs (NSAIDs) (2, 3). Many NSAIDs including ketoprofen, indomethacin, and 
diclofenac are inactivated and eliminated through glucuronidation as described for 
SN-38G in Chapter 5 (4). Two thirds of patients show drug-induced small intestine 
lesions after both chronic (>3 months) and short-term (<1 week) NSAID use (4). 
While the mechanism of small intestinal damage is unclear, the efficacy of GUS 
inhibitors confirms that the damage is GUS mediated (2, 3). Because of the success 
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of these inhibitors in these mouse studies, we are interested in characterizing 
NSAID-glucuronide processing with purified GUS enzymes. While characterization 
can and has been conducted using HPLC, that is a time- and effort-intensive 
approach that could be replaced by an absorbance or fluorescence based assay that 
could be conducted quickly in a plate reader. While some compounds can be 
analyzed directly as described for SN-38G in Chapter 7, not all compounds will show 
varying absorbance for fluorescence profiles with and without the glucuronide sugar. 
Therefore, an additional requirement for this assay is that it will function with a 
variety of glucuronidated compounds.  
In order to satisfy these two requirements, we have designed a coupled assay 
during which the free glucuronide sugar generated by the GUS enzyme is utilized in 
a second reaction that generates a convenient read-out. Uronate dehydrogenase 
(Udh) is an enzyme that processes glucuronic acid using NAD+ as a cofactor that 
can be used as a read-out. The basic assay scheme is shown in Figure 8.1. 
Because Udh uses NAD+ as a cofactor and produces one molecule of NADH for 
each molecule of glucuronic acid, an observed increase in NADH signal via 
absorption at 340 nm correlates to the increase in glucuronic acid produced by the 
GUS enzyme included in the assay. As long as the catalytic activity and 
concentration of Udh in the assay is sufficiently high, the glucuronic acid produced 
by GUS enzyme(s) should be the limiting reagent. Therefore, the Udh kinetics 
observed via NADH production should mimic the kinetics of glucuronic acid 
production by the GUS enzyme. Initial work in the Redinbo lab has shown this assay 
scheme to be an effective way to measure glucuronic acid production using both 
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purified Agrobacterium tumefaciens Udh and the D-Glucuronic/D-Galacturonic Acid 
Assay Kit from Megazyme. This assay will allow us to explore a much wider variety 
of glucuronidated compounds ranging from drugs such as NSAIDs to endogenous 
compounds such as steroid hormones. Further understanding of GUS function will 
allow us to identify the native substrates of this enzyme family as well as explore the 
ways in which bacteria have adapted to the environment of the human gut. We also 
hope that we will be able to optimize the initial GUS inhibitors to be effective against 
a wide range of GUS mediated intestinal damage. 
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Figure 8.1 Uronate dehydrogenase Coupled Assay Scheme 
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APPENDIX 1: pWBG749 OR pSK41 ORIGIN-OF-TRANSFER MIMC 
SEQUENCE CONTENT 
	
pWBG749	or	pSK41	origin-of-transfer	mimc	sequence	content	of	Staphylococcal	plasmids	as	
determined	by	BLASTN.	Adapted	from	O'Brien	et	al	2015	(Nucleic	Acids	Research	43:7971-
7983).	
Species	 Plasmid	name	 Accession	
pWBG749	
OriT?	
pSK41	
OriT?	
aureus	 pSA1308	 NC_007928.1	 TRUE	 TRUE	
aureus	 pWBG1773	 NC_010616.1	 TRUE	 FALSE	
aureus	 pKH3	 NC_005020.1	 TRUE	 FALSE	
aureus	 pLGA251	 NC_017348.1	 TRUE	 FALSE	
aureus	 pKH12	 NC_010687.1	 TRUE	 FALSE	
aureus	 pTW20_2	 FN433598.1	 TRUE	 FALSE	
aureus	 SAP070A	 GQ900423.1	 TRUE	 FALSE	
aureus	 SAP104A	 GQ900450.2	 TRUE	 FALSE	
aureus	 pKH14	 NC_010428.1	 TRUE	 FALSE	
aureus	 p18807-P01	 CP002136.1	 TRUE	 FALSE	
aureus	 p18808-P01	 CP002138.1	 TRUE	 FALSE	
aureus	 p18811-P01	 CP002144.1	 TRUE	 FALSE	
aureus	 pUSA01	 NC_007790.1	 TRUE	 FALSE	
aureus	 SAP046B	 GQ900404.1	 TRUE	 FALSE	
aureus	 SAP049B	 GQ900408.1	 TRUE	 FALSE	
aureus	 SAP051B	 GQ900411.1	 TRUE	 FALSE	
aureus	 pKH18	 NC_010231.1	 TRUE	 TRUE	
aureus	 pC55s	 AY048756.1	 TRUE	 TRUE	
aureus	 pNewBould305	 NZ_AKYW01000028.1	 TRUE	 TRUE	
aureus	 pWBG760	 GQ900473.1	 TRUE	 FALSE	
aureus	 USA300_TCH959	 NZ_AASB02000125.1	 TRUE	 TRUE	
aureus	 ATCC	51811	 NZ_ADVP01000034.1	 TRUE	 TRUE	
aureus	 SAP105B	 NC_013378.1	 TRUE	 FALSE	
aureus	 pBORa53	 NC_013550.1	 TRUE	 TRUE	
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aureus	 A8796	 NZ_ADJJ01000025.1	 TRUE	 TRUE	
aureus	 TCH70_2	 NZ_ACHH02000018.1	 TRUE	 FALSE	
aureus	 pSA268	 NC_023278.1	 TRUE	 TRUE	
aureus	 pUSA300HOUMS	 NC_010066.1	 TRUE	 FALSE	
aureus	 55/2053	 NC_022126.1	 TRUE	 FALSE	
aureus	 SAP055A	 GQ900414.1	 TRUE	 FALSE	
aureus	 pSAS	 BX571858.1	 TRUE	 TRUE	
aureus	 pWBG750	 GQ900392.1	 TRUE	 TRUE	
aureus	 SAP072A	 GQ900424.1	 TRUE	 TRUE	
aureus	 pMW2	 NC_005011.1	 TRUE	 TRUE	
aureus	 SAP053A	 GQ900413.1	 TRUE	 TRUE	
aureus	 p21	 NC_002517.1	 TRUE	 TRUE	
aureus	 SAP073A	 GQ900425.1	 TRUE	 TRUE	
aureus	 pSaa6159	 CP002115.1	 TRUE	 TRUE	
aureus	 pWBG757	 GQ900397.1	 TRUE	 TRUE	
aureus	 pWBG763	 GQ900467.1	 TRUE	 TRUE	
aureus	 65-1322	 NZ_GG700565.1	 TRUE	 FALSE	
aureus	 SAP058A	 GQ900479.1	 TRUE	 FALSE	
aureus	 pSK62	 GQ900446.1	 TRUE	 FALSE	
aureus	 pSA1379	 NC_007931.1	 TRUE	 TRUE	
aureus	 SAP060A	 GQ900416.1	 TRUE	 FALSE	
aureus	 A8115_con_1.21	 NZ_ACKG01000021.1	 TRUE	 FALSE	
aureus	 SAP051A	 GQ900410.1	 TRUE	 TRUE	
aureus	 M876	 NZ_GG700623.1	 TRUE	 FALSE	
aureus	 E1410	 NZ_GG700609.1	 TRUE	 FALSE	
aureus	 A8117	 NZ_ACYO01000019.1	 TRUE	 FALSE	
aureus	 M1015	 NZ_GG749015.1	 TRUE	 FALSE	
aureus	 M809	 NZ_GG749324.1	 TRUE	 FALSE	
aureus	 pSK76	 GQ900444.1	 TRUE	 FALSE	
aureus	 C101_1.21	 NZ_GG730140.1	 TRUE	 FALSE	
aureus	 WBG10049	 NZ_GG730219.1	 TRUE	 FALSE	
aureus	 pWBG756	 GQ900472.1	 TRUE	 FALSE	
aureus	 TCH60_unnamed	 NC_017345.1	 TRUE	 FALSE	
aureus	 58-424_3	 NZ_GG749073.1	 TRUE	 FALSE	
aureus	 A9635	 NZ_ACKI01000002.1	 TRUE	 TRUE	
aureus	 pCA347	 NC_021552.1	 TRUE	 TRUE	
aureus	 pN315	 NC_003140.1	 TRUE	 TRUE	
aureus	 pWBG752	 GQ900394.1	 TRUE	 TRUE	
aureus	 pST75	 NC_016942.1	 TRUE	 FALSE	
aureus	 SAP049A	 GQ900407.1	 TRUE	 FALSE	
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pSK41	
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aureus	 pWBG755	 GQ900471.1	 TRUE	 FALSE	
aureus	 pPM1	 NC_019148.1	 TRUE	 TRUE	
aureus	 SAP063A	 GQ900418.1	 TRUE	 FALSE	
aureus	 SAP059A	 GQ900480.1	 TRUE	 FALSE	
aureus	 SAP065B	 GQ900481.1	 TRUE	 FALSE	
aureus	 pWBG761	 GQ900474.1	 TRUE	 FALSE	
aureus	 SAP071A	 GQ900485.1	 TRUE	 FALSE	
aureus	 p18807-P03	 CP002135.1	 TRUE	 TRUE	
aureus	 pUSA300HOUMR	 NC_010063.1	 TRUE	 TRUE	
aureus	 p18808-P03	 CP002137.1	 TRUE	 TRUE	
aureus	 p18810-P03	 NC_018963.1	 TRUE	 TRUE	
aureus	 SAP050A	 GQ900409.1	 TRUE	 TRUE	
aureus	 p18806-P03	 CP002134.1	 TRUE	 TRUE	
aureus	 pLAC-P03	 CP002149.1	 TRUE	 TRUE	
aureus	 SAP015A	 GQ900380.1	 TRUE	 TRUE	
aureus	 SAP046A	 GQ900403.1	 TRUE	 TRUE	
aureus	 p18805-03	 CP002132.1	 TRUE	 TRUE	
aureus	 p18811-03	 CP002143.1	 TRUE	 TRUE	
aureus	 SAP056A	 GQ900478.1	 TRUE	 TRUE	
aureus	 M0408_conjugative	 AIWO01000029	 TRUE	 FALSE	
aureus	 SAP012A	 GQ900377.1	 TRUE	 FALSE	
aureus	 A9781	 NZ_ACKL01000034.1	 TRUE	 FALSE	
aureus	 pWBG744	 GQ900398.1	 TRUE	 FALSE	
aureus	 SAP048A	 GQ900406.1	 TRUE	 FALSE	
aureus	 SAP074A	 GQ900426.1	 TRUE	 FALSE	
aureus	 pLUH02	 FR714929.1	 TRUE	 FALSE	
aureus	 pZ172_1	 NC_022610.1	 TRUE	 FALSE	
aureus	 p19231-P03	 CP002147.1	 TRUE	 FALSE	
aureus	 SAP019A	 GQ900385.1	 TRUE	 FALSE	
aureus	 pSK67	 NC_019010.1	 TRUE	 FALSE	
aureus	 A8819	 NZ_ADJK01000020.1	 TRUE	 FALSE	
aureus	 pWBG759	 GQ900401.1	 TRUE	 TRUE	
aureus	 p18809-P04	 CP002146.1	 TRUE	 TRUE	
aureus	 SAP047A	 NC_013331.1	 TRUE	 TRUE	
aureus	 pI258	 GQ900378.1	 TRUE	 FALSE	
aureus	 SAP104C	 GQ900498.1	 TRUE	 FALSE	
aureus	 SAP070B	 GQ900484.1	 TRUE	 FALSE	
aureus	 pSK59	 GQ900488.1	 TRUE	 FALSE	
aureus	 pTW20_1	 FN433597.1	 TRUE	 FALSE	
aureus	 SAP027A	 GQ900388.1	 TRUE	 TRUE	
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aureus	 pSJH101	 NC_009619.1	 TRUE	 TRUE	
aureus	 pSJH901	 NC_009477.1	 TRUE	 TRUE	
aureus	 SAP064A	 GQ900419.1	 TRUE	 FALSE	
aureus	 pSK57	 GQ900493.1	 TRUE	 FALSE	
aureus	 pSK80	 GQ900492.1	 TRUE	 FALSE	
aureus	 SAP066A	 GQ900482.1	 TRUE	 FALSE	
aureus	 SAP101A	 GQ900495.1	 TRUE	 FALSE	
aureus	 pI3T3	 NC_020565.1	 TRUE	 FALSE	
aureus	 SAP052A	 GQ900412.1	 TRUE	 TRUE	
aureus	 SAP017A	 GQ900382.1	 TRUE	 TRUE	
aureus	 pI6T6	 NC_020567.1	 TRUE	 FALSE	
aureus	 pCM05	 GQ900387.1	 TRUE	 FALSE	
aureus	 pWBG747	 GQ900399.1	 TRUE	 TRUE	
aureus	 pWBG746	 GQ900390.1	 TRUE	 TRUE	
aureus	 D139	 GG730186.1	 TRUE	 FALSE	
aureus	 pSK64	 GQ915268.1	 TRUE	 FALSE	
aureus	 pEDINA	 NC_010077.1	 TRUE	 TRUE	
aureus	 SAP076A	 GQ900427.1	 TRUE	 FALSE	
aureus	 pSK60	 GQ915267.1	 TRUE	 FALSE	
aureus	 pSK74	 GQ915266.1	 TRUE	 FALSE	
aureus	 pTZ2162	 NC_010419.1	 TRUE	 TRUE	
aureus	 SAP078A	 GQ900430.1	 TRUE	 FALSE	
aureus	 SAP077A	 GQ900428.1	 TRUE	 FALSE	
aureus	 pSK79	 GQ900489.1	 TRUE	 FALSE	
aureus	 SAP102A	 GQ900496.1	 TRUE	 FALSE	
aureus	 pSK21	 GQ900490.1	 TRUE	 FALSE	
aureus	 SAP075A	 GQ900486.1	 TRUE	 FALSE	
aureus	 SAP067A	 GQ900483.1	 TRUE	 FALSE	
aureus	 SAP054A	 GQ900477.1	 TRUE	 FALSE	
aureus	 pWBG749	 GQ900391.1	 TRUE	 FALSE	
aureus	 pWBG745	 NC_013325.1	 TRUE	 FALSE	
aureus	 pETB	 NC_003265.1	 TRUE	 FALSE	
aureus	 pSK53	 GQ915270.1	 TRUE	 FALSE	
aureus	 pV030-8	 NC_010279.1	 TRUE	 TRUE	
aureus	 SAP057A	 GQ900415.1	 TRUE	 FALSE	
aureus	 pSK23	 GQ900491.1	 TRUE	 FALSE	
aureus	 SAP082A	 GQ900434.1	 TRUE	 TRUE	
aureus	 pWBG748	 GQ915265.1	 TRUE	 FALSE	
aureus	 pSK156	 GQ900448.1	 TRUE	 TRUE	
aureus	 SAP079A	 GQ900432.1	 TRUE	 TRUE	
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aureus	 pGO1	 NC_012547.1	 TRUE	 TRUE	
aureus	 pWBG762	 GQ900475.1	 TRUE	 TRUE	
aureus	 pLW043	 NC_005054.1	 TRUE	 TRUE	
epidermis	 SAP045A	 NC_013374.1	 TRUE	 FALSE	
epidermis	 SAP106A	 NC_013379.2	 TRUE	 FALSE	
epidermis	 SAP016A	 NC_013372.1	 TRUE	 FALSE	
epidermis	 Epidermis_conjugative	 AHLC01000011.1	 TRUE	 FALSE	
simulans	 pACK5	 NC_015176.1	 TRUE	 FALSE	
simulans	 pACK2	 NC_015173.2	 TRUE	 FALSE	
warneri	 pPI-2	 NC_005208.1	 TRUE	 FALSE	
arlettae	 pSS-03	 NC_016054.1	 FALSE	 FALSE	
aureus	 pSN2	 NC_005565.1	 FALSE	 FALSE	
aureus	 SAP093B	 NC_013310.1	 FALSE	 FALSE	
aureus	 pDLK3	 NC_013969.1	 FALSE	 FALSE	
aureus	 pAVY	 NC_013451.1	 FALSE	 FALSE	
aureus	 pSK6	 NC_001995.1	 FALSE	 FALSE	
aureus	 SAP104B	 GQ900451.2	 FALSE	 FALSE	
aureus	 pSK3	 NC_001994.1	 FALSE	 FALSE	
aureus	 pNVH99	 AJ296103.1	 FALSE	 FALSE	
aureus	 pLUH01	 NC_017346.1	 FALSE	 FALSE	
aureus	 pWBG754	 GQ900396.1	 FALSE	 FALSE	
aureus	 TCH70_1	 NZ_ACHH02000015.1	 FALSE	 FALSE	
aureus	 pS1e	 NZ_AUPS01000034.1	 FALSE	 FALSE	
aureus	 A6300	 NZ_ACKF01000018.1	 FALSE	 FALSE	
aureus	 p9b	 NC_019143.1	 FALSE	 FALSE	
aureus	 SAP087A	 GQ900439.1	 FALSE	 FALSE	
aureus	 pWBG764	 GQ900468.1	 FALSE	 FALSE	
aureus	 A9765	 NZ_ACSN01000068.1	 FALSE	 FALSE	
aureus	 A9719	 NZ_ACKJ01000014.1	 FALSE	 FALSE	
aureus	 pDLK1	 NC_019139.1	 FALSE	 FALSE	
aureus	 pKH20	 NC_010686.1	 FALSE	 FALSE	
aureus	 SAP078B	 GQ900431.1	 FALSE	 FALSE	
aureus	 pKH8	 U50077.1	 FALSE	 FALSE	
aureus	 Cn1	 NC_022228.1	 FALSE	 FALSE	
aureus	 CF-Marseille	 NZ_CABA01000093.1	 FALSE	 FALSE	
aureus	 p19321-P01	 NC_018969.1	 FALSE	 FALSE	
aureus	 pE5	 M17990.1	 FALSE	 FALSE	
aureus	 pKH19	 NC_010685.1	 FALSE	 FALSE	
aureus	 pWBG738	 NC_007209.1	 FALSE	 FALSE	
aureus	 pWBG751	 GQ900393.1	 FALSE	 FALSE	
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aureus	 pT48	 NC_001395.1	 FALSE	 FALSE	
aureus	 TCH130	 NZ_ACHD01000266.1	 FALSE	 FALSE	
aureus	 TCH959	 NZ_AASB02000192.1	 FALSE	 FALSE	
aureus	 pKH4	 U81980.1	 FALSE	 FALSE	
aureus	 pKH21	 NC_010684.1	 FALSE	 TRUE	
aureus	 A5948_3	 NZ_ACKD01000027.1	 FALSE	 FALSE	
aureus	 pS1d	 NZ_AUPS01000033.1	 FALSE	 TRUE	
aureus	 pNVH01	 NC_004562.1	 FALSE	 TRUE	
aureus	 pUR5425	 NC_019146.1	 FALSE	 TRUE	
aureus	 pBMSa1	 AY541446.1	 FALSE	 TRUE	
aureus	 pKH15	 NC_010427.1	 FALSE	 FALSE	
aureus	 pBMb9393	 NC_021657.1	 FALSE	 FALSE	
aureus	 pDLK2	 GU562625.1	 FALSE	 FALSE	
aureus	 SAP065A	 GQ900420.1	 FALSE	 FALSE	
aureus	 pKH13	 NC_010426.1	 FALSE	 FALSE	
aureus	 pC194	 NC_002013.1	 FALSE	 FALSE	
aureus	 pS0385-3	 AM990995.1	 FALSE	 TRUE	
aureus	 pE194	 NC_005908.1	 FALSE	 FALSE	
aureus	 pSBK203	 U35036.1	 FALSE	 FALSE	
aureus	 pNS1	 M16217.1	 FALSE	 FALSE	
aureus	 pS1c	 NZ_AUPS01000031.1	 FALSE	 FALSE	
aureus	 SAP085B	 GQ900438.1	 FALSE	 FALSE	
aureus	 pKH7	 NC_002096.1	 FALSE	 FALSE	
aureus	 C101_1.1	 NZ_GG730120.1	 FALSE	 FALSE	
aureus	 M899	 NZ_GG730190.1	 FALSE	 FALSE	
aureus	 pS0385-2	 AM990994.1	 FALSE	 FALSE	
aureus	 pS123b	 NZ_AUPU01000024.1	 FALSE	 FALSE	
aureus	 pS194	 NC_005564.1	 FALSE	 FALSE	
aureus	 pKH6	 U38428.1	 FALSE	 FALSE	
aureus	 pUSA02	 NC_007791.1	 FALSE	 FALSE	
aureus	 SAP085A	 GQ900437.1	 FALSE	 FALSE	
aureus	 SAP093A	 GQ900441.1	 FALSE	 FALSE	
aureus	 SAP094A	 GQ900443.1	 FALSE	 FALSE	
aureus	 SAP095A	 GQ900445.1	 FALSE	 FALSE	
aureus	 pT181	 NC_006629.2	 FALSE	 FALSE	
aureus	 pKH17	 NC_010284.1	 FALSE	 FALSE	
aureus	 pKH16	 NC_010262.1	 FALSE	 FALSE	
aureus	 ATCC	BAA-39	 NZ_AEEK01000040.1	 FALSE	 FALSE	
aureus	 A8115_con_1.2	 NZ_ACKG01000002.1	 FALSE	 FALSE	
aureus	 SAP060B	 GQ900417.1	 FALSE	 FALSE	
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aureus	 MR1_139	 NZ_ACZQ01000139.1	 FALSE	 FALSE	
aureus	 JKD6009	 NZ_ABSA01000025.1	 FALSE	 FALSE	
aureus	 pUB110	 NC_001384.1	 FALSE	 FALSE	
aureus	 A10102	 NZ_ACSO01000036.1	 FALSE	 FALSE	
aureus	 A6300_2	 NZ_ACKF01000048.1	 FALSE	 FALSE	
aureus	 A6244	 NZ_ACKE01000028.1	 FALSE	 FALSE	
aureus	 A9763	 NZ_ACKK01000035.1	 FALSE	 FALSE	
aureus	 pC221	 NC_006977.1	 FALSE	 FALSE	
aureus	 pTZ4	 NC_010111.1	 FALSE	 FALSE	
aureus	 A5937	 NZ_ACKC01000002.1	 FALSE	 FALSE	
aureus	 CF-Marseille_2	 NZ_CABA01000045.1	 FALSE	 FALSE	
aureus	 SAP084A	 GQ900436.1	 FALSE	 FALSE	
aureus	 SAP089A	 NC_013308.1	 FALSE	 FALSE	
aureus	 MR1_138	 NZ_ACZQ01000138.1	 FALSE	 FALSE	
aureus	 pC223	 AY355285.1	 FALSE	 FALSE	
aureus	 pKKS49	 NC_019149.1	 FALSE	 FALSE	
aureus	 pS1b	 NZ_AUPS01000028.1	 FALSE	 FALSE	
aureus	 A9754	 NZ_ADJI01000035.1	 FALSE	 FALSE	
aureus	 58-424_1	 NZ_GG749054.1	 FALSE	 FALSE	
aureus	 pS0385-1	 AM990993.1	 FALSE	 FALSE	
aureus	 pCPS49	 NC_019142.1	 FALSE	 FALSE	
aureus	 pS1a	 NZ_AUPS01000027.1	 FALSE	 FALSE	
aureus	 pS94a	 NZ_AUPW01000021.1	 FALSE	 FALSE	
aureus	 pVGA	 NC_011605.1	 FALSE	 FALSE	
aureus	 pCPS32	 NC_019141.1	 FALSE	 FALSE	
aureus	 pJ3358	 NC_001763.1	 FALSE	 FALSE	
aureus	 pUR3912	 NC_020183.2	 FALSE	 FALSE	
aureus	 pKKS627	 NC_014156.1	 FALSE	 FALSE	
aureus	 pSA8589	 NC_021230.1	 FALSE	 FALSE	
aureus	 pMSA16	 NC_019144.1	 FALSE	 FALSE	
aureus	 pUR4128	 NC_019147.1	 FALSE	 FALSE	
aureus	 pUR2355	 NC_019145.1	 FALSE	 FALSE	
aureus	 pRJ6	 NC_011522.1	 FALSE	 FALSE	
aureus	 pS130a	 NZ_AUPT01000023.1	 FALSE	 FALSE	
aureus	 pSK17	 GQ900513.1	 FALSE	 FALSE	
aureus	 pRJ9	 AF447813.1	 FALSE	 FALSE	
aureus	 SAP077B	 NC_013341.1	 FALSE	 FALSE	
aureus	 pKKS832	 FN377602.2	 FALSE	 FALSE	
aureus	 pS123a	 NZ_AUPU01000021.1	 FALSE	 FALSE	
aureus	 SAP099B	 GQ900449.1	 FALSE	 FALSE	
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aureus	 pAVX	 NC_013453.1	 FALSE	 FALSE	
aureus	 pCH91	 NC_020227.1	 FALSE	 FALSE	
aureus	 pUB101	 NC_005127.1	 FALSE	 FALSE	
aureus	 SAP015B	 GQ900500.1	 FALSE	 FALSE	
aureus	 p11819-97	 NC_017350.1	 FALSE	 FALSE	
aureus	 VRSAp	 NC_002774.1	 FALSE	 FALSE	
aureus	 SAP105A	 NC_013377.1	 FALSE	 TRUE	
aureus	 68-397	 NZ_GG700590.1	 FALSE	 FALSE	
aureus	 pSK77	 GQ900494.1	 FALSE	 FALSE	
aureus	 pSK1	 NC_014369.1	 FALSE	 FALSE	
aureus	 SAP103A	 GQ900497.1	 FALSE	 FALSE	
aureus	 pWBG753	 GQ900395.1	 FALSE	 FALSE	
aureus	 p18813-P03	 NC_018967.1	 FALSE	 TRUE	
aureus	 pUSA03	 NC_007792.1	 FALSE	 TRUE	
aureus	 pI5S5	 NC_020535.1	 FALSE	 TRUE	
aureus	 pWBG758	 NC_013329.1	 FALSE	 FALSE	
aureus	 pSA737	 NC_021076.1	 FALSE	 FALSE	
aureus	 pPR9	 NC_013653.1	 FALSE	 TRUE	
aureus	 SAP069A	 GQ900422.1	 FALSE	 TRUE	
aureus	 SAP080A	 GQ900433.1	 FALSE	 TRUE	
aureus	 pSK41	 AF051917.1	 FALSE	 TRUE	
aureus	 SAP014A	 GQ900379.1	 FALSE	 TRUE	
aureus	 SAP068A	 GQ900421.1	 FALSE	 TRUE	
aureus	 pETB	 NC_022598.1	 FALSE	 TRUE	
chromogenes	 pLNU8	 NC_008352.1	 FALSE	 FALSE	
chromogenes	 pLNU4	 NC_007771.1	 FALSE	 TRUE	
chromogenes	 pLNU9	 NC_008354.1	 FALSE	 FALSE	
epidermis	 pBE131	 NC_001390.1	 FALSE	 FALSE	
epidermis	 pSepCH	 NC_003969.1	 FALSE	 FALSE	
epidermis	 pSK108	 NC_013395.1	 FALSE	 FALSE	
epidermis	 SAP108D	 NC_013392.2	 FALSE	 FALSE	
epidermis	 pLNU6	 NC_008356.1	 FALSE	 TRUE	
epidermis	 pSE-12228-01	 NC_005008.1	 FALSE	 FALSE	
epidermis	 SAP108C	 NC_013391.1	 FALSE	 FALSE	
epidermis	 pSK103	 NC_013394.1	 FALSE	 FALSE	
epidermis	 pSE-12228-02	 NC_005007.1	 FALSE	 FALSE	
epidermis	 SAP108B	 NC_013390.1	 FALSE	 FALSE	
epidermis	 pSE-12228-06	 NC_005003.1	 FALSE	 FALSE	
epidermis	 SAP110B	 NC_013384.1	 FALSE	 FALSE	
epidermis	 pUR3937	 NC_019304.1	 FALSE	 FALSE	
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epidermis	 pUR3036	 NC_019303.1	 FALSE	 FALSE	
epidermis	 pSE-12228-03	 NC_005006.1	 FALSE	 FALSE	
epidermis	 pSK639	 NC_005566.1	 FALSE	 FALSE	
epidermis	 SAP106B	 NC_013380.1	 FALSE	 FALSE	
epidermis	 SAP107B	 NC_013382.1	 FALSE	 FALSE	
epidermis	 pSE-12228-04	 NC_005005.1	 FALSE	 FALSE	
epidermis	 pSK105	 NC_013393.1	 FALSE	 FALSE	
epidermis	 pSE-12228-05	 NC_005004.1	 FALSE	 FALSE	
epidermis	 SAP108A	 NC_013389.1	 FALSE	 TRUE	
epidermis	 SAP110A	 NC_013383.1	 FALSE	 FALSE	
epidermis	 pSERP	 NC_006663.1	 FALSE	 FALSE	
epidermis	 pSWS47	 NC_022618.1	 FALSE	 FALSE	
epidermis	 SAP107A	 NC_013381.1	 FALSE	 FALSE	
equorum	 pSEQU3	 NZ_AVBD01000026.1	 FALSE	 FALSE	
equorum	 pSEQU2	 NZ_AVBD01000024.1	 FALSE	 FALSE	
equorum	 pSEQU1	 NZ_AVBD01000023.1	 FALSE	 FALSE	
haemolyticus	 pSHaeA	 NC_007169.1	 FALSE	 FALSE	
haemolyticus	 pSHaeB	 NC_007170.1	 FALSE	 FALSE	
haemolyticus	 pLNU3	 NC_007770.1	 FALSE	 TRUE	
haemolyticus	 pLNU7	 NC_008353.1	 FALSE	 TRUE	
haemolyticus	 pSHaeC	 NC_007171.1	 FALSE	 FALSE	
hyicus	 hyicus_unnamed	 NC_016137.1	 FALSE	 FALSE	
hyicus	 p7313178-1	 NC_016140.1	 FALSE	 FALSE	
hyicus	 p9811071-1	 NC_016139.1	 FALSE	 FALSE	
hyicus	 pKKS966	 NC_015171.1	 FALSE	 FALSE	
hyicus	 pSTE1	 NC_020237.1	 FALSE	 FALSE	
lentus	 pSTE2	 NC_006871.1	 FALSE	 FALSE	
lugdunensis	 pLUG10	 NC_002093.1	 FALSE	 FALSE	
pasteuri	 pSP187	 NC_007167.1	 FALSE	 FALSE	
saprophyticus	 pSES22	 NC_007621.1	 FALSE	 FALSE	
saprophyticus	 pSSP2	 NC_007352.1	 FALSE	 TRUE	
saprophyticus	 pSSAP2	 NC_016643.1	 FALSE	 FALSE	
saprophyticus	 pSSP1	 NC_007351.1	 FALSE	 TRUE	
saprophyticus	 pSSAP1	 NC_015432.1	 FALSE	 FALSE	
sciuri	 pC194-like	 NC_010626.1	 FALSE	 FALSE	
sciuri	 pACK6	 NC_006974.1	 FALSE	 FALSE	
sciuri	 pSCFS1	 NC_005076.1	 FALSE	 FALSE	
simulans	 pLNU5	 NC_008351.1	 FALSE	 TRUE	
simulans	 pLNU2	 NC_007769.1	 FALSE	 TRUE	
simulans	 pACK4	 NC_013033.1	 FALSE	 FALSE	
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simulans	 pACK3	 NC_013945.1	 FALSE	 FALSE	
simulans	 pACK1	 NC_013944.1	 FALSE	 FALSE	
sp.	693-2	 SAP008A	 NC_013371.1	 FALSE	 FALSE	
sp.	693-2	 pLEW6932	 NC_009130.1	 FALSE	 FALSE	
sp.	CDC25	 SAP018B	 NC_013388.1	 FALSE	 FALSE	
sp.	CDC25	 SAP018A	 NC_013387.1	 FALSE	 FALSE	
sp.	CDC3	 SAP020A	 NC_013373.1	 FALSE	 FALSE	
warneri	 pvSw7	 NC_020269.1	 FALSE	 FALSE	
warneri	 pvSw3	 NC_020265.1	 FALSE	 FALSE	
warneri	 pSZ4	 NC_020165.1	 FALSE	 FALSE	
warneri	 pvSw6	 NC_020268.1	 FALSE	 FALSE	
warneri	 pvSw2	 NC_020264.1	 FALSE	 FALSE	
warneri	 pvSw1	 NC_020274.1	 FALSE	 FALSE	
warneri	 pvSw5	 NC_020267.1	 FALSE	 FALSE	
warneri	 pvSw4	 NC_020266.1	 FALSE	 FALSE	
warneri	 pPI-1	 NC_005207.3	 FALSE	 FALSE	
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APPENDIX 2: PLASMIDS CONTAINING pSK41 ORIGIN-OF-TRANSFER 
MIMIC SEQUENCES 
	
Details	on	plasmids	containing	pSK41	origin-of-transfer	mimic	sequences	as	noted	in	
Appendix	1.	
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Species Ref Updated Ref 
Plasmid_ 
name 
OriT_ 
type 
Sequence
_variant 
Complete 
Seq? 
NES-
type 
gene? 
Multiple 
41 
OriTs? Strand Sequence 
aureus NC_007928.1  pSA1308 pSA1308 A  TRUE FALSE FALSE PLUS 
GCGTTCTTTTAGAACGCAT
AAGTGCGCCCTTACGGGA
TTTAAC 
aureus NC_010231.1 EU333812.1 pKH18 pSA1308 A TRUE FALSE FALSE PLUS 
GCGTTCTTTTAGAACGCAT
AAGTGCGCCCTTACGGGA
TTTAAC 
aureus AY048756.1  pC55s pSA1308 A TRUE FALSE FALSE PLUS 
GCGTTCTTTTAGAACGCAT
AAGTGCGCCCTTACGGGA
TTTAAC 
aureus NZ_AKYW01000028.1 
pNewBould
305 pSA1308 A Genome FALSE FALSE MINUS 
GCGTTCTTTTAGAACGCAT
AAGTGCGCCCTTACGGGA
TTTAAC 
aureus NC_013550.1  pBORa53 pSA1308 A TRUE FALSE FALSE PLUS 
GCGTTCTTTTAGAACGCAT
AAGTGCGCCCTTACGGGA
TTTAAC 
aureus NC_013331.1  SAP047A pSA1308 A TRUE FALSE FALSE PLUS 
GCGTTCTTTTAGAACGCAT
AAGTGCGCCCTTACGGGA
TTTAAC 
aureus NC_019146.1  pUR5425 pSA1308 A TRUE FALSE FALSE PLUS 
GCGTTCTTTTAGAACGCAT
AAGTGCGCCCTTACGGGA
TTTAAC 
haemo-
lyticus NC_007770.1  pLNU3 pSA1308 A TRUE FALSE FALSE PLUS 
GCGTTCTTTTAGAACGCAT
AAGTGCGCCCTTACGGGA
TTTAAC 
sapro-
phyticus NC_007351.1  pSSP1 pSA1308 A TRUE FALSE FALSE MINUS 
GCGTTCTTTTAGAACGCAT
AAGTGCGCCCTTACGGGA
TTTAAC 
aureus GQ900412.1  SAP052A pSA1308 B TRUE FALSE TRUE MINUS 
GCGTTCTTTTTAGAACGCA
TAAGTGCGCCCTTACGGG
ATTTAAC 
aureus AM990995.1  pS0385-3 pSA1308 B TRUE FALSE FALSE MINUS 
GCGTTCTTTTTAGAACGCA
TAAGTGCGCCCTTACGGG
ATTTAAC 
epi-
dermis NC_013389.1  SAP108A pSA1308 B TRUE FALSE FALSE MINUS 
GCGTTCTTTTTAGAACGCA
TAAGTGCGCCCTTACGGG
ATTTAAC 
haemo-
lyticus NC_008353.1 pLNU7 pSA1308 B TRUE FALSE FALSE PLUS 
GCGTTCTTTTTAGAACGCA
TAAGTGCGCCCTTACGGG
ATTTAAC 
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Plasmid_ 
name 
OriT_ 
type 
Sequence
_variant 
Complete 
Seq? 
NES-
type 
gene? 
Multiple 
41 
OriTs? Strand Sequence 
aureus AY541446.1  pBMSa1 pSA1308 C TRUE FALSE FALSE PLUS 
GCGTTCTTTTTAGAACGTA
TAAGTGCGCCCTTACGGG
ATTTAAC 
chromo-
genes NC_007771.1  pLNU4 pSA1308 D TRUE FALSE FALSE PLUS 
GCGTTCTTTTAGAACGCAT
AAGTGCGCCCTTACGGGA
ATTAAC 
simulans NC_007769.1  pLNU2 pSA1308 CD TRUE FALSE FALSE PLUS 
GCGTTCTTTTAGAACGTAT
AAGTGCGCCCTTACGGGA
ATTAAC 
aureus 
NZ_AASB0200
0125.1 Unknown 
USA300_ 
TCH959 
pCA347/
pSK156 A Genome FALSE FALSE MINUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus 
NZ_ADVP0100
0034.1 Unknown 
ATCC 
51811 
pCA347/
pSK156 A Genome FALSE FALSE MINUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus NZ_ADJJ01000025.1 A8796 
pCA347/
pSK156 A Genome FALSE FALSE PLUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus BX571858.1  pSAS 
pCA347/
pSK156 A Genome FALSE FALSE PLUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus GQ900392.1  pWBG750 
pCA347/
pSK156 A TRUE FALSE FALSE MINUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus GQ900424.1  SAP072A 
pCA347/
pSK156 A TRUE FALSE FALSE PLUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus NC_005011.1  pMW2 
pCA347/
pSK156 A TRUE FALSE FALSE PLUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus GQ900413.1  SAP053A 
pCA347/
pSK156 A TRUE FALSE FALSE MINUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus NC_002517.1  p21 
pCA347/
pSK156 A TRUE FALSE FALSE MINUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus GQ900425.1  SAP073A 
pCA347/
pSK156 A TRUE FALSE FALSE PLUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus CP002115.1  pSaa6159 
pCA347/
pSK156 A TRUE FALSE FALSE PLUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
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type 
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Multiple 
41 
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aureus GQ900397.1  pWBG757 
pCA347/
pSK156 A TRUE FALSE FALSE MINUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus GQ900467.1  pWBG763 
pCA347/
pSK156 A TRUE FALSE FALSE MINUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus NC_007931.1  pSA1379 
pCA347/
pSK156 A TRUE FALSE FALSE PLUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus GQ900410.1  SAP051A 
pCA347/
pSK156 A TRUE FALSE FALSE MINUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus NZ_ACKI01000002.1 A9635 
pCA347/
pSK156 A Genome FALSE FALSE MINUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus NC_021552.1  pCA347 
pCA347/
pSK156 A TRUE FALSE FALSE PLUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus NC_003140.1  pN315 
pCA347/
pSK156 A TRUE FALSE FALSE PLUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus GQ900394.1  pWBG752 
pCA347/
pSK156 A TRUE FALSE FALSE PLUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus CP002135.1  
p18807-
P03 
pCA347/
pSK156 A TRUE FALSE FALSE PLUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus NC_010063.1  
pUSA300 
HOUMR 
pCA347/
pSK156 A TRUE FALSE FALSE PLUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus CP002137.1  
p18808-
P03 
pCA347/
pSK156 A TRUE FALSE FALSE PLUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus NC_018963.1  
p18810-
P03 
pCA347/
pSK156 A TRUE FALSE FALSE PLUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus GQ900409.1  SAP050A 
pCA347/
pSK156 A TRUE FALSE FALSE MINUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus CP002134.1  
p18806-
P03 
pCA347/
pSK156 A TRUE FALSE FALSE PLUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
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NES-
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41 
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aureus CP002149.1  pLAC-P03 
pCA347/
pSK156 A TRUE FALSE FALSE PLUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus GQ900380.1  SAP015A 
pCA347/
pSK156 A TRUE FALSE FALSE MINUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus GQ900403.1  SAP046A 
pCA347/
pSK156 A TRUE FALSE FALSE MINUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus CP002132.1  p18805-03 
pCA347/
pSK156 A TRUE FALSE FALSE PLUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus CP002143.1  p18811-03 
pCA347/
pSK156 A TRUE FALSE FALSE PLUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus CP002146.1  
p18809-
P04 
pCA347/
pSK156 A TRUE FALSE FALSE PLUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus GQ900388.1  SAP027A 
pCA347/
pSK156 A TRUE FALSE FALSE PLUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus NC_009619.1  pSJH101 
pCA347/
pSK156 A TRUE FALSE FALSE MINUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus NC_009477.1  pSJH901 
pCA347/
pSK156 A TRUE FALSE FALSE MINUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus GQ900412.1  SAP052A 
pCA347/
pSK156 A TRUE FALSE TRUE MINUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus NC_010419.1  pTZ2162 
pCA347/
pSK156 A TRUE FALSE FALSE MINUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus GQ900475.1  pWBG762 
pCA347/
pSK156 A FALSE FALSE FALSE MINUS 
ATGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus NC_023278.1  pSA268 
pCA347/
pSK156 B TRUE FALSE FALSE MINUS 
ACGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus NC_019148.1  pPM1 
pCA347/
pSK156 B TRUE FALSE FALSE MINUS 
ACGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
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NES-
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Multiple 
41 
OriTs? Strand Sequence 
aureus GQ900478.1  SAP056A 
pCA347/
pSK156 B FALSE FALSE FALSE PLUS 
ACGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus GQ900401.1  pWBG759 
pCA347/
pSK156 B TRUE FALSE FALSE MINUS 
ACGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus GQ900382.1  SAP017A 
pCA347/
pSK156 B TRUE FALSE FALSE MINUS 
ACGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus GQ900399.1  pWBG747 
pCA347/
pSK156 B TRUE FALSE FALSE PLUS 
ACGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus GQ900390.1  pWBG746 
pCA347/
pSK156 B TRUE FALSE FALSE PLUS 
ACGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus NC_010077.1  pEDINA 
pCA347/
pSK156 B TRUE FALSE FALSE MINUS 
ACGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus GQ900448.1  pSK156 
pCA347/
pSK156 B TRUE FALSE FALSE MINUS 
ACGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus NC_010684.1  pKH21 
pCA347/
pSK156 B TRUE FALSE FALSE PLUS 
ACGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus NC_013377.1  SAP105A 
pCA347/
pSK156 B TRUE FALSE FALSE MINUS 
ACGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
epi-
dermis NC_008356.1  pLNU6 
pCA347/
pSK156 B TRUE FALSE FALSE PLUS 
ACGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
pLNU5 NC_008351.1  pLNU5 
pCA347/
pSK156 B TRUE FALSE FALSE PLUS 
ACGTCGATTTATCCGACGT
ATAAGTGCGCCCTTACGG
GATTTAAC 
aureus NZ_AUPS01000033.1 pS1d 
pCA347/
pSK156 C Genome FALSE FALSE MINUS 
CACGTCGATTTATCCGACG
TGTAAGTGCGCCCTTACG
GGATTTAAC 
aureus NC_004562.1  pNVH01 
pCA347/
pSK156 C TRUE FALSE FALSE MINUS 
CACGTCGATTTATCCGACG
TGTAAGTGCGCCCTTACG
GGATTTAAC 
aureus NC_022598.1  pETB pETB A TRUE FALSE TRUE MINUS 
ACCGTTTGGAACAAACGTA
TAAGTGCGCCCTTACGGG
ATTTAAC 
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aureus NC_022598.1  pETB pETB B TRUE FALSE TRUE PLUS 
AGCGTTTGGAACAAACGTA
TAAGTGCGCCCTTACGGG
AGTTAA 
sapro-
phyticus NC_007352.1  pSSP2 pETB C TRUE FALSE FALSE PLUS 
CGTTTGGAGCAAACGTGTA
AGTGCGCCCTTACGGGAT
TTAAC 
aureus NC_010279.1  pV030-8 pV030-8 A TRUE TRUE FALSE PLUS 
TACGTTTGGAACAAACGTG
TAAGTGCGCCCTTACGGG
ATTTAAC 
aureus NC_018967.1  
p18813-
P03 pV030-8 A TRUE TRUE FALSE PLUS 
TACGTTTGGAACAAACGTG
TAAGTGCGCCCTTACGGG
ATTTAAC 
aureus GQ900434.1  SAP082A pSK41 A TRUE TRUE FALSE MINUS 
GCGAACGGAACGTTCGCA
TAAGTGCGCCCTTACGGG
ATTTAAC 
aureus GQ900432.1  SAP079A pSK41 A TRUE TRUE FALSE PLUS 
GCGAACGGAACGTTCGCA
TAAGTGCGCCCTTACGGG
ATTTAAC 
aureus NC_012547.1  pGO1 pSK41 A TRUE TRUE FALSE PLUS 
GCGAACGGAACGTTCGCA
TAAGTGCGCCCTTACGGG
ATTTAAC 
aureus NC_005054.1  pLW043 pSK41 A TRUE TRUE FALSE PLUS 
GCGAACGGAACGTTCGCA
TAAGTGCGCCCTTACGGG
ATTTAAC 
aureus NC_007792.1  pUSA03 pSK41 A TRUE TRUE FALSE PLUS 
GCGAACGGAACGTTCGCA
TAAGTGCGCCCTTACGGG
ATTTAAC 
aureus NC_020535.1  pI5S5 pSK41 B TRUE TRUE FALSE PLUS 
GCGAACGTAACGTTCGCAT
AAGTGCGCCCTTACGGGA
TTTAAC 
aureus NC_013653.1  pPR9 pSK41 A TRUE TRUE FALSE PLUS 
GCGAACGGAACGTTCGCA
TAAGTGCGCCCTTACGGG
ATTTAAC 
aureus GQ900422.1  SAP069A pSK41 A TRUE TRUE FALSE MINUS 
GCGAACGGAACGTTCGCA
TAAGTGCGCCCTTACGGG
ATTTAAC 
aureus GQ900433.1  SAP080A pSK41 A TRUE TRUE FALSE PLUS 
GCGAACGGAACGTTCGCA
TAAGTGCGCCCTTACGGG
ATTTAAC 
aureus AF051917.1  pSK41 pSK41 A TRUE TRUE FALSE PLUS 
GCGAACGGAACGTTCGCA
TAAGTGCGCCCTTACGGG
ATTTAAC 
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aureus GQ900379.1  SAP014A pSK41 A TRUE TRUE FALSE PLUS 
GCGAACGGAACGTTCGCA
TAAGTGCGCCCTTACGGG
ATTTAAC 
aureus GQ900421.1  SAP068A pSK41 A TRUE TRUE FALSE MINUS 
GCGAACGGAACGTTCGCA
TAAGTGCGCCCTTACGGG
ATTTAAC 
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APPENDIX 3: MULTIPLE-SEQUENCE ALIGNMENT OF β-GLUCURONIDASE 
SEQUENCES OF INTEREST 
 The following multiple sequence alignment was used to define the loop 
class of each GUS sequence according to the location and length parameters 
described in Table 6.2. 
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CLUSTAL O(1.2.1) multiple sequence alignment 
 
H_sapiens          MARGS---AVAWAALGPLLWGCALGLQGGMLYPQESPSRECKELDGLWSFRADFSDNRRR 
F_prausnitzii      -------------------------MNRSLLYPRATTTRRLIGLDGMWRFSFD---PESK 
E_coli             -----------------------------MLRPVETPTREIKKLDGLWAFSLD---RENC 
S_agalactiae       -----------------------------MLYPLLTKTRNTYDLGGIWNFKLG---EH-N 
C_perfringens      -----------------------------MLYPIITESRQLIDLSGIWKFKLN---EG-N 
E_eligens          -----------------------------MLYPVLTQSRLLSDLSGVWDFKLD---NG-K 
P_merdae           ---------MKYLFVACLL--CLSV---LSAVAKV-PAMNKIRLTNNWEYLKG---DLGG 
H11G11-BG          -------------------------------------MREVININKNWLFSKK---EQPV 
B_Fragilis         -----------------------------------MSLRQDILLNNNWNFRFS---HQVQ 
B_ovatus           --------MKNRIIILCLVCLCLVN---IGLFAQETSPRTIFSLNEGWECRPI---TTVN 
B_uniformis        MEREKNTLPQKACHWMAAVIISLFV------LPPVHAQRQTQTINDSWKFLKG---ECTA 
B_dorei            --------MKRFAGWLLFFWGC-----------ICCICASEISITDSWKYKAE---NDER 
 
H_sapiens          GFEEQWYRRP-------LWESGPTVDMPVPSSFNDI-SQDWRLRHFVGWVWYEREVILPE 
F_prausnitzii      GVEAGWA-LD-------LPS---SLSMPVPASFCDL-FTDKASREYCGDFWYETSFFVPA 
E_coli             GIDQRWWESA-------LQE---SRAIAVPGSFNDQ-FADADIRNYAGNVWYQREVFIPK 
S_agalactiae       PN------EL-------LPS---DEVMVIPTSFNDL-MVSKEKRDYIGDFWYEKVIEVPK 
C_perfringens      GLTEELSKAP-------LED---TIEMAVPSSYNDL-VESQEVRDHVGWVWYERNFTIPK 
E_eligens          GFEEKWYEKP-------LKD---ADTMPVPASYNDL-KEGTDFRDHYGWVFYQRNISVPE 
P_merdae           -----IWEAVRPAAPGSSEAVPIWQPVTLPHCFNAEDAVDPDVNYYEGPGWYKTLLAIDN 
H11G11-BG          -------------P---KTLPEDWESVNLPHTWNGTDGQDGGNDYYRGKCCYVKLLKKAD 
B_Fragilis         ---------------------GDTRRVDLPHTWNAQDALAGKIDYKRGIGNYEKALYIRP 
B_ovatus           -------------------RKAPFTPVTIPHTWNTS-YIEGTTLYERKMMVYQRPLVVTK 
B_uniformis        -------------AADSAFDDSKWTSIHLPHTWNTDAYT--EKDYYRGTGWYRRQLTLPQ 
B_dorei            -------------FSSMDWNDSDWVTVDLPHTWNAGDVIDEQRGYRRGISWYRKKLFIPS 
 
H_sapiens          RWTQDLRTRVVLRIGSAHSYAIVWVNGVDTLEHEGGYLPFEADISNLVQV---------- 
F_prausnitzii      EWSG---WDIVLRFGSVTHRARVFVNGVEVAQHEGGFLPFDATVTNIVRY---------- 
E_coli             GWAG---QRIVLRFDAVTHYGKVWVNNQEVMEHQGGYTPFEADVTPYVIA---------- 
S_agalactiae       VSED---EEMVLRFGSVTHQAKIYVDGVLVGEHKGGFTPFEVLVPECKYN---------- 
C_perfringens      TLLN---ERIVLRFGSATHEAKVYLNGELLVEHKGGFTPFEAEINDLLVS---------- 
E_eligens          YVKS---QRIVLRCAAVTHYAMIYLNGKLICEHKGGFLPFEVELNDDLQD---------- 
P_merdae           PYRN---GRIVLDFDGAGQKTDVYVYTTHVGSHVGGYDSWNVDITDAVKAFLGSKDAERF 
H11G11-BG          LGEK---PVHYIQFDGVNSSAEVWWNGEKIGSHDGGYSAFRVRIPEISD----------- 
B_Fragilis         EWKG---KRLFLRFDGVNSIADVFINRKHIGEHRGGYGAFIFEITDLVKY---------- 
B_ovatus           AMKN---KRLFLYFEGVNSAAQVFMNRRTVGEHLGGYTAFCIEITDEVKE---------- 
B_uniformis        GWKE---KQIILRLDAAGKSATIYINGKNVGEHAGGYTACSFNITPFLSF---------- 
B_dorei            EARD---KKITLRFDGVASKADVYLNGKLLKTHLGAYTAFGVDITDICEV---------- 
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H_sapiens          GPLPSRLRITIAINNTLTP-TTLPPGTIQYLTDT-----SKYPKGYFVQNTYFDFFNYAG 
F_prausnitzii      NQ---FNKLSVLANNELSE-TMLPAGTTCTLA-----------DGRKIAAPYFDFYNYAG 
E_coli             GK---SVRITVCVNNELNW-QTIPPGMVIT-----------DENGKKKQSYFHDFFNYAG 
S_agalactiae       NE---KIKVSICANNVLDY-TTLPVGNYSEII-------QEDGSIKKKVRENFDFFNYAG 
C_perfringens      G----DNRLTVAVNNIIDE-TTLPVGLVKEV--------EVDGKKVIKNSVNFDFFNYAG 
E_eligens          G----DNLLTIAVNNVIDY-TTLPVGGKANMMSGMMGGMGAGASDKPQNNPNFDFFNYCG 
P_merdae           KG---KVPLSIRCDNSRDL-EMIPS-------------------------DLADFNIYGG 
H11G11-BG          -----ENILTVYADNSPN--DTVYP-------------------------QVADFTFYGG 
B_Fragilis         GE---KNSVLVRANNGEQ--LDIMP-------------------------LVGDFNFYGG 
B_ovatus           GE---NL-LEVWASNAYR--TDILP-------------------------VSGDFNVNGG 
B_uniformis        DT---PNTLAVCVDNAR---QDIAP-------------------------ISGDFTFFGG 
B_dorei            GK---ENLLAVKVDNSSSLGEILPP-------------------------VSGDFSIFGG 
 
H_sapiens          LQRSVLLYTTPTTYIDDITVTTSVEQ----DS----GLVNYQIS--VKGSN--LFKLEVR 
F_prausnitzii      IHRPVWLMALPKERVLDYSTRYRLTE----TG----AEIDYTVS--TNGP----HPVTVE 
E_coli             IHRSVMLYTTPNTWVDDITVVTHVAQDCN--H----ASVDWQVV--ANG------DVSVE 
S_agalactiae       VHRPLKLMIRPKNHIFDITITSRLSDDLQ--S----ADLHFLVE--TNQK---VDEVRIS 
C_perfringens      IHRPVKIYTTPKSYIEDITIVTDFKE----NN----GYVNYEVQ--AVGK----CNIKVT 
E_eligens          ITRPVKIYTTPETYINDITVTADIDFTKEEPS----AVLNYNVE--IKGKDYNNITCKVE 
P_merdae           LYRYLNLVYLPEVSFEQIHLESSLSSNL------KEGILKVKTSFYNP-EDIRKADVTVS 
H11G11-BG          IYRDVTVIGVDESHFDLEFYGSSGIMITPKVSG-----LSAAVNITARVTNPQDCSVRFV 
B_Fragilis         IYRDVHLLITDETCISPLDYASPGVYLVQEVVSPQEAKVCAKVNLSNRA-ADGTAELQVL 
B_ovatus           IHRPCHLIVTGQDCISPLFYASPGVFIHQENISKTVADVNVETHLSLKN-KKQGLRLKTT 
B_uniformis        IYRDVWLTAVPNQHFNLTNHGSDGLFISTPQVSEEQATLSIRGEVKNDAPEKATLELTHT 
B_dorei            IYRRVFLQWTEKVHFVTEPYAAVPVRIQTPEVSVSEASMQIVAFLKNDFTDTKHVHVNVF 
 
H_sapiens          LLDAENKVVANGT-------G-----TQGQLKVPGVSLWWPYLMHERPAYLYSLEVQLTA 
F_prausnitzii      LYDGT-TRVAESS-------G-----TTGTLVVKNARLWNVH-----AAYLYDLVIRIHE 
E_coli             LRDADQQVVATGQ-------G-----TSGTLQVVNPHLWQPG-----EGYLYELCVTAKS 
S_agalactiae       VFDEDNKLVGE---------T-----KDSRLFLSDVHLWEVL-----NAYLYTARVEIFV 
C_perfringens      IIDEENNIVAEGE-------G-----KEGKLTINNVHLWEPM-----NAYLYKLKVELLD 
E_eligens          LFDEEGTKLSETE-------G-----SEGTFEISNVRLWQPL-----NAYLYKIKVTAGQ 
P_merdae           VYDVDRKPVFSKTLEGILPLG-DQ--LLAKMKIKNPVLWDV-----DVPQLYTCELTVKT 
H11G11-BG          VTDADKKPVGEK-------NV-DASDGKTVIEIENAHLWNGT----QDPYLYSLTAELL- 
B_Fragilis         VTDGTKVICKESRNVS-LKQG-ADILEQLPLLIQKPRLWNGC----EDPFMYQVSISLH- 
B_ovatus           VADADNKTV----ASN-EVEV-SDVIVKQPMKIHRPILWDGK----KNPYLYTVTVELY- 
B_uniformis        IYRPDGTLLQTLKKNIQLKAGETYAFSNEATPVLKPELWTP-----ETPRLYRVETTLRN 
B_dorei            LCDEMNRIVKEKQLKLKLIPGRKYPISTSVGRIENPHLWSP-----ELPYLYTVKVQVCD 
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H_sapiens          QTSLGPVSDFYTLPVGIRTVAVT-KSQFLINGKPFYFHGVNKHEDADIRGKGFDWPLLVK 
F_prausnitzii      GS---AVVDEYLDRIGIRTFEIR-HGRFLLNGSPVYLRGFGRHEDADIRGRGLDLPTVKR 
E_coli             QT----ECDIYPLRVGIRSVAVK-GEQFLINHKPFYFTGFGRHEDADLRGKGFDNVLMVH 
S_agalactiae       DN---QLQDVYEENFGLREIEVT-NGQFLLNRKPIYFKGFGKHEDTFINGRGLNEAANLM 
C_perfringens      DE---EIIDTYFEEFGVRTVEVK-DGKFLINNKPFYFKGFGKHEDSYVNGRGINEAINIK 
E_eligens          --------DVYTLPYGVRSVRVD-GTKFLINEKPFYFKGYGKHEDTFPNGRGINLPMNTK 
P_merdae           ----PDQTFTTEERFGFRHTEFKDKGPFFLNGKRLLLRGTHRHEDHAGVAQAMTEDMMRR 
H11G11-BG          -K-DGEKTDEISVRFGCRSFSIDPQKGFILNGKPCPLRGVSRHQDRPGIGNALTEKEHRE 
B_Fragilis         -K-DGKQIDSVTQPLGLRYYHTDPDKGFFLNGKHLPLHGVCRHQDRAEVGNALRPQHHEE 
B_ovatus           -D-GNLLKDRMVQRTGFRYFSVDHEKGFFLNGEYLNLYGFCRHEDAVGRASALLPEDYRM 
B_uniformis        RK-TKTLLDQSNHYTAFRWFRFDGDEGFFLNGKPYKLRGICRHQDQKPIGPALTDEMHRR 
B_dorei            AK-NGEMYQEVISPVGFRWFSVD-KTGFYLNGKYLKLRGAARHQDYAGLGTAIPVEMNRR 
 
H_sapiens          DFNLLRWLGANAFRTSHYPYAEEVMQMCDRYGIVVIDECPGVGLALPQF----------- 
F_prausnitzii      DFELMKWIGANCFRTSHYPYAEEIYQMADEEGFLIIDEVPAVGFMQSTANFLAANQGNGR 
E_coli             DHALMDWIGANSYRTSHYPYAEEMLDWADEHGIVVIDETAAVGFNLSLGIGF--EAGN-K 
S_agalactiae       DLNLLKDMGANSFRTSHYPYSEEMMRLADRMGVLVIDEVPAVGLFQNFNASL--DLSP-- 
C_perfringens      DFNLMKWIGANSFRTSHYPYSEEIMRLADREGIVVIDETPAVGLHLNFMAT---GFGG-D 
E_eligens          DISIMKWQHANSFRTSHYPYSEEMMRLCDEEGIVVIDETTAVGVNLQFGGGA--NFGG-E 
P_merdae           EMRMMKDMGVNFIRLGHYQQSEIILDLCDELGILVWEEIPWCRGG--------------- 
H11G11-BG          DMDLICELGANTIRLAHYQHSRVFYDLCDECGMAVWAEIPYISRH--------------- 
B_Fragilis         DVALMREMGVNAIRLAHYPQATYMYDLMDKHGIVTWAEIPFVGPGGYADKGF-------- 
B_ovatus           DMELIKESGATAMRLAHYPHAEPMYDLSDENGIILWTEIPMCGPGGQAFTGF-------- 
B_uniformis        DFLLMKEMGANFIRISHYPQDDALLEMCDKLGMLAWEEIPIIDIV--------------- 
B_dorei            DMRLLKEMGANFVRISHYPQDPEIYRACDELGLIVWSEICVVNEV--------------- 
 
H_sapiens          ----F-----NNVSLHHHMQVMEEVVRRDKNHPAVVMWSVANEPASHLE----------- 
F_prausnitzii      QQGFFEK-ETTPALLKNHKAALTDMIDRDKNHPSVIAWSLLNEPQCTSA----------- 
E_coli             PKELYSEEAVNGETQQAHLQAIKELIARDKNHPSVVMWSIANEPDTRPQ----------- 
S_agalactiae       --KDNGT-WNLMQTKAAHEQAIQELVKRDKNHPSVVMWVVANEPASHEA----------- 
C_perfringens      AP-KRDT-WKEIGTKEAHERILRELVSRDKNHPCVVMWSVANEPDSDSE----------- 
E_eligens          RIGTFDK-EHGVQTQEHHKDVIRDLISRDKNHACVVMWSIANEPDSAAE----------- 
P_merdae           --------LGGDVYKKQARRMLANMIVQHHNHPAVIIWGLGNENDWPNDFNTFDKS---- 
H11G11-BG          ----------MPGGRENTVSQMKELIYQNINHPSIIVWGLSNEITMNGASD----S---- 
B_Fragilis         --------VDQASFRENGKQQLIELIRQHYNHPSICFWGLFNELKEV-------GD---- 
B_ovatus           --------VDTEGYKDNARLAVKELVYQKFNHPSICFWGICNEILVSDGKRFVEYD---- 
B_uniformis        --------PNTPGYGDNCERNLREMIRQHYNHPSIITWGYMNEILLVTQRKYKTEAELKP 
B_dorei            --------RKNTAFAHNCKEMLKEMILQNYNHPSVVLWGAMNELWDYHKQ---------- 
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H_sapiens          ---SAGYYLKMVIAHTKSLDPS-RPVTFVSNS-------NYAADKGAPYVDVICLNSYYS 
F_prausnitzii      ---GTEEYFKPLFELARRLDPQKRPRTYTVLMTS-----LPDTSKGQRFADFVSLNRYYG 
E_coli             ---GAREYFAPLAEATRKLDPT-RPITCVNVMFC-----DAHTDTISDLFDVLCLNRYYG 
S_agalactiae       ---GAHDYFEPLVKLYKDLDPQKRPVTLVNILMA-----TPDRDQVMDLVDVVCLNRYYG 
C_perfringens      ---GAKEYFEPLIKLTKELDPQKRPVTVVTYLMS-----TPDRCKVGDIVDVLCLNRYYG 
E_eligens          ---GAYDYFKPLYDLARELDPQKRPCTLVSVQGT-----TADTDCSSQLSDVICLNRYYG 
P_merdae           ---AIRAFMKELHDMAHRLDDT-RMTAIRRCEFC------------NDIVDVYSPSIWAG 
H11G11-BG          ---SLIENHRMLNDLVHKIDPT-RPTTIAVLSMC------DPGEEYVRIPDVLSYNHYFG 
B_Fragilis         ---NPVEYVKELNALAKQEDPT-RPTTS---ASN------QDGNL-NFITENIAWNRYDG 
B_ovatus           ---NPIPFIKELNGIYKSIDSS-RLTAL---ATC------VDQSYYLGCSDLIAWNKYFG 
B_uniformis        VLERTLALANRLERVLKEEDST-RISTMAFHGSN-----SYNETGLSKITDIVGWNLYQG 
B_dorei            ----AIALARELEALKKELDPY-RLSCVAFHAFTWEKPYTQSSKEMFSISDVNGVNVYES 
 
H_sapiens          WYHDYG-HLELIQLQLATQFENWYKKY-QKPIIQSEYGAETIAGFHQDPPL--------- 
F_prausnitzii      WYVLGGAGLADAEAAFHHEMDGWAKVLHGRPLIFTEYGTDNLSGAHKLPSV--------- 
E_coli             WYVQSG-DLETAEKVLEKELLAWQEKL-HQPIIITEYGVDTLAGLHSMYTD--------- 
S_agalactiae       WYVDHG-DLTNAEVGIRKELLEWQDKFPDKPIIITEYGADTLPGLHSTWNI--------- 
C_perfringens      WYVAGG-DLEEAKRMLEDELKGWEERCPKTPIMFTEYGADTVAGLHDTVPV--------- 
E_eligens          WYFGGP-DLEVSEIGLRKELSDWGKL--GKPVMFTEYGADTVSGLHDTTSV--------- 
P_merdae           WYRGVFT-------DYKSISEQEMQKV--KHFLHVEWGGDSHARRHSEDAFYNLKNIEAG 
H11G11-BG          WYGGKTD-------MYGPWFDKFHKKYPDRAVGMSEYGCEALNWHTS-DPQ--------- 
B_Fragilis         WYGSTPK-------TLATFLDRTHKKHPELRIGISEYGAGASIYHQQ-DSL--------- 
B_ovatus           WYKDAAP-------SASKFFDDCRDSSKGIPVGVSEYGGGASINHHQ-WPL--------- 
B_uniformis        WYGGDLT-------GFEKFLAQQHQNHPTHPMIVSEYGAGSDKRLHSLHPR--------- 
B_dorei            WYQGDSA-------TIAPMFDKFCSYSTAKPRFLSEFGAGSDERIHSYTPR--------- 
 
H_sapiens          ------------------------MFTEEYQKSLLEQYHLGLDQKRRKYVVGELIWNFAD 
F_prausnitzii      ------------------------MWSAEYQNEYLEMTHAVFDH--YDFVQGELVWNFAD 
E_coli             ------------------------MWSEEYQCAWLDMYHRVFDR--VSAVVGEQVWNFAD 
S_agalactiae       ------------------------PYTEEFQCDFYEMSHRVFDG--IPNLVGEQVWNFAD 
C_perfringens      ------------------------MFTEEYQVEYYKANHEVMDK--CKNFVGEQVWNFAD 
E_eligens          ------------------------MYTEEYQVEYYEMNNKVFDE--FDFVVGEQAWNFAD 
P_merdae           KGGDERAGDASLYGGVPRASRDGD-WSESYVVRLIDWHLKEQET--MPWLTGTAYWPFKD 
H11G11-BG          ------QGD----------------YTEEYQAKYHEDVIRQIAV--RPWLWSTHVWNMFD 
B_Fragilis         ------KQP----------SASGWWHPENWQTYYHMENWKIIAE--RPFVWGTFVWNMFD 
B_ovatus           ------AME---------DRSDSHFHPEEAQTFCHEGNWESFAK--RPYLWAKFIWVFAD 
B_uniformis        ------AFD----------------FSIEYQQKYLEHYLPVLED--TPYICGGTHWNFID 
B_dorei            ------TFD----------------FTPEFQLDFNRRYINEMEK--RPDYIGYSIWNLVD 
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H_sapiens          FMTEQSPT--RVLGNKKGIFTRQRQ-PKSAAFLLRERYWK-IANETRYPHSVAKS----- 
F_prausnitzii      FQTTEGIL--RVDGNKKGIFTRQRQ-PKDAAYLFRKRWTT-LPVDFKKRKK--------- 
E_coli             FATSQGIL--RVGGNKKGIFTRDRK-PKSAAFLLQKRWTG-MN-FGEKPQQGGKQ----- 
S_agalactiae       FETNLMIL--RVQGNHKGLFSRNRQ-PKQVVKEFKKRWMT-IPHYHNKKNSVK------- 
C_perfringens      FATSQGII--RVQGNKKGIFTRERK-PKMIAHSLRERWTN-IPEFGYKK----------- 
E_eligens          FATSQSLL--RVQGNKKGLFTRDRK-PKMVAHYFRNRWST-IPEFGYKTK---------- 
P_merdae           FSTPVRPDNPVPYVNQKGVVERDFT-PKESYYVFQSYWT-EKPMIHIYGHTWPVRWGGKD 
H11G11-BG          FAADARSEGGENGMNHKGLVTFDRKYKKDSFYAYKA-WLSDEPFVHICGKRYIDRPESM- 
B_Fragilis         FGAAHRTEGDRPGINDKGLVTFDRKVRKDAFYFYKANWNKQEPMIYLAEKRCRLRYQPE- 
B_ovatus           FPSYMRQEGEKDGYNDKGLVTHDRKTKKDAFYFYKANWNP-EPMIYITSRRFTKRDNPK- 
B_uniformis        FSSALRDES-MPRINNKGLVYADRT-PKDVYHYYQAAWRKDIPVLHIASRDWTDRAGVQQ 
B_dorei            FQVDGRGDS-KPNLNQKGMLTEDRR-KKEIYYYCQARWS-DIPMIHIAGADWTKRVEICD 
 
H_sapiens          -------------QCLENSLFT-------------------------------------- 
F_prausnitzii      ------------------------------------------------------------ 
E_coli             ------------------------------------------------------------ 
S_agalactiae       ------------------------------------------------------------ 
C_perfringens      ------------------------------------------------------------ 
E_eligens          ------------------------------------------------------------ 
P_merdae           DR----KEILVYSNCDEVELFVNGVSQGVKRRNSQDYPAAGLRWNCV-YQEGMNEIRAVG 
H11G11-BG          ------TSVTVYTNEPSVELFANGKSLGVQKRGEFPF----FYFSVP--NEGETVLTAKA 
B_Fragilis         ------QTFMAFTTAPEAELFVNGVSCGKQKADTYST----VVWKNVKLTSGENIIRVT- 
B_ovatus           ------TDIKVFTNLKEATLYINNRKIGTMKPDEMNR----VIWKDIRLNDGRNIICVE- 
B_uniformis        GNAPVYLPVKIYTNLSEVELFIDGISLGKQKTENYTA----TF-EVP-FSNRNPFLFAQG 
B_dorei            DSINV-RKISVFSNQKTVELIHNGKSLGVREVVNGEA----VF-AVP-FINGENLLDARS 
 
H_sapiens          ------------------------------------------------------------ 
F_prausnitzii      ------------------------------------------------------------ 
E_coli             ------------------------------------------------------------ 
S_agalactiae       ------------------------------------------------------------ 
C_perfringens      ------------------------------------------------------------ 
E_eligens          ------------------------------------------------------------ 
P_merdae           VKKKEKKEVSDVIRQE-------------------------------------------- 
H11G11-BG          GDC------TDESRIRKVDKANPDY----------VLQEEG-AVI--------------- 
B_Fragilis         -------------------TPGKKP----------LT---D-EVT--------------- 
B_ovatus           -------------------GKNGKG----------LL---S-DTC--------------- 
B_uniformis        NYQ--GKTVQDGLRINF--TPIPACLDANNLKGLELAVNVG-SQCFFTSDESQLTWLPDQ 
B_dorei            GA------LSDRLKIQM--KLLSSRLTDSDVLLDGLCINLGQEHCYFIDPQLQEIWIPDK 
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H_sapiens          ------------------------------------------------------------ 
F_prausnitzii      ------------------------------------------------------------ 
E_coli             ------------------------------------------------------------ 
S_agalactiae       ------------------------------------------------------------ 
C_perfringens      ------------------------------------------------------------ 
E_eligens          ------------------------------------------------------------ 
P_merdae           -YQTAKWDKEAACQVSL-------------LSE---EGDTALVQVQLIDKNGIRCLSSKK 
H11G11-BG          -----NWFEIETPPGYMS---VND-----TIGDILATAKGKLLALKI---LKMVRANMKK 
B_Fragilis         -----VEYKEDREGHHHH---HH------------------------------------- 
B_ovatus           -----EWYCIK------------------------------------------------- 
B_uniformis        PYAAGSWGYIGGKEGT-------------AQTEIQNTADGPLFQTLR---NEIEGY---- 
B_dorei            PYTKGSWGYMDGKPFNSWPGSSHDGVRYGVGADIKNTFLEPLFQTFL---IGTTCY---- 
 
H_sapiens          ------------------------------------------------------------ 
F_prausnitzii      ------------------------------------------------------------ 
E_coli             ------------------------------------------------------------ 
S_agalactiae       ------------------------------------------------------------ 
C_perfringens      ------------------------------------------------------------ 
E_eligens          ------------------------------------------------------------ 
P_merdae           QITFEIAGDG---------SLICNLGTSTGSRKVQAYNGRALI-------RIKR----NE 
H11G11-BG          NKGKSTGGMADMAKGMKINKSIIEMGKGFSVKRVCMMAGGLFTKEQILEINA-------- 
B_Fragilis         ------------------------------------------------------------ 
B_ovatus           ------------------------------------------------------------ 
B_uniformis        --------RFDAP------QGVYEIE---------LLFTDIFRRNAGIAYQLDRNGQQEN 
B_dorei            --------RLDVP------DGVYEIG---------FYFTEPFSKDERK--NIVRTGVSAE 
 
H_sapiens          ------------------------------------------------------------ 
F_prausnitzii      ------------------------------------------------------------ 
E_coli             ------------------------------------------------------------ 
S_agalactiae       ------------------------------------------------------------ 
C_perfringens      ------------------------------------------------------------ 
E_eligens          ------------------------------------------------------------ 
P_merdae           GNSVVA--------------VKSEGLPTAFLELKS--------------PK--------- 
H11G11-BG          ----------------SLNKIKKK------------------------------------ 
B_Fragilis         ------------------------------------------------------------ 
B_ovatus           ------------------------------------------------------------ 
B_uniformis        RESTFGISINGEVVEESLSPCKESGYFRALRKKYYI-TNDKEYIDIRFHSTSGTCFLNGI 
B_dorei            GQRVFDVSVNGEKLIDSLNLADSYGEQTAVVKTLVVNVRNHEGLEILLSPQKGQGVISGL 
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H_sapiens          ------ 
F_prausnitzii      ------ 
E_coli             ------ 
S_agalactiae       ------ 
C_perfringens      ------ 
E_eligens          ------ 
P_merdae           ------ 
H11G11-BG          ---QK- 
B_Fragilis         ------ 
B_ovatus           ------ 
B_uniformis        KLRNIY 
B_dorei            KVKKIR 
 
